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This proposal had three interrelated aims. The first aim was to examine the lifetime 
prevalence and comorbidity of selected mental disorders in a group of 847subjects sampled 
from the Epidemiologic Catchment Area (ECA). The second aim was to examine the association 
of the Serotonin Reuptake (SERT) gene polymorphism with the prevalence, comorbidity burden 
of psychopathology in this sample. The final and third aim, born out of the need to fulfill the first 
two goals, was to develop instruments to quantitatively and comprehensively measure the 
comorbidity burden in a sample. 
We found extensive comorbidity between the individual anxiety disorders, between the 
anxiety and mood disorders, and between mood disorders and Alcohol Dependence.  
Agoraphobia, Social Phobia, Obsessive Compulsive Disorder (OCD), Generalized Anxiety 
Disorder (GAD) were highly comorbid with each other. Comorbidities between Major Depressive 
Disorder (MDD) and Panic Disorder (OR: 3.20), Agoraphobia (OR: 2.79), Social Phobia (OR: 
2.46), and, OCD (OR: 4.74) were highly significant. 
Using Poisson Regression models, we found an increased risk for lifetime prevalence of 
Panic Disorder in participants who were carriers of the short (s) allele of the SERT 
polymorphism (Prevalence Ratio: 2.61). We found a significant association between SERT (s) 
allele carrier status and a decreased risk to be diagnosed with Obsessive-Compulsive Disorder 
in the time-to-event analysis (Hazard Ratio: 0.11). In addition, the carriers of the SERT (s) allele 
had a significant increased risk for two comorbidity pairs, MDD and Social Phobia, and 
Agoraphobia and MDD.  
When comparing the overall number of diagnoses, we were unable to find an increase in 
the burden for psychopathology in the carriers of the (s) allele. In summary, the SERT 
polymorphism seems to confer a modest vulnerability to psychopathology. 
iii 
 
We explored the relationship between the number of individuals diagnosed, the number 
of diagnoses and the number of comorbidities, both for the individual mental disorders, as well 
as for the whole sample. Using simple probability concepts, based on discrete random 
variables, we developed a series of instruments to measure the comorbidity burden in our study 
sample. These instruments could be useful in the comparison of the diagnostic information 
between samples. 
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CHAPTER 01: INTRODUCTION 
C01.P01 Overall Aims:  
In the study, we investigated the association between the serotonin transporter gene 
(SERT) polymorphism and the prevalence, comorbidity burden, time to diagnosis, age of onset, 
and treatment patterns of Alcohol Dependence, Alcohol Abuse, Opioid Dependence, 
Schizophrenia and other Psychotic Disorders, Major Depressive Disorder, Bipolar Disorder, 
Panic Disorder, Agoraphobia, Social Phobia, Obsessive Compulsive Disorder, Generalized 
Anxiety Disorder, Simple Phobia, Dysthymic Disorder, and Anxiety Disorder Not Otherwise 
Specified. These conditions were the most frequently diagnosed mental disorders in a group of 
847subjects sampled from the Epidemiologic Catchment Area (ECA) in Baltimore, Maryland.  
The primary goal of our study was to examine the phenomenon of comorbidity between 
the mental disorders. Extensive comorbidity between mental disorders presents a major 
challenge to our current psychiatric nomenclature as well as a hindrance to the advancement of 
research in the etiology and treatment of mental disorders. 
Our approach was innovative and comprehensive. We proposed indicators of the 
comorbidity burden that allow us to characterize and quantify this phenomenon both for the 
whole sample, as well as for the individual mental disorders included in the analysis.   
We explored the association between a specific polymorphism in the serotonin 
transporter gene (SERT) and the increase in the prevalence and co-occurrence (comorbidity) of 




studied for potential associations with a variety of mental disorders. The findings have been, so 
far, inconclusive. 
In addition, we analyzed the age- at-onset of the individual mental disorders, and we -
investigated whether the carriers of the SERT short (s) allele had a significant difference in the 
time to attain full criteria for the selected disorders as compared to the non-carrier subjects. 
Lastly, we analyzed the use of medications in the study participants. We explored 
whether the carriers of the SERT (s) allele had an increase in the use of psychotropic agents, as 
compared to the non-carrier subjects. 
 
C01P02. Summary  
We examined the burden of comorbidity in our study sample using novel techniques. We 
determined whether there is an association of the SERT (s) gene polymorphism with an 
increased prevalence and comorbidity, a shortened time to attain a diagnosis, and an increase 
in the use of psychotropic medications  
The value and novelty of this work was that we were able to evaluate the comorbidity of 
several mental disorders in a comprehensive way in a study sample that was obtained from the 
community using probabilistic methods. The study participants were assessed by board certified 
psychiatrists, trained in the use of the Schedules for Clinical Assessment in Neuropsychiatry. 
The use of this rich population based sample that has been comprehensively examined and 
genotyped afford us this unique opportunity to assess the patterns of psychiatric comorbidity, as  






CHAPTER 02: REVIEW OF COMORBIDITY IN MENTAL DISORDERS 
 
C02.S01 Background and Significance of Comorbidity in General Medicine  
Comorbidity has become an important area of study in medicine. Over the past decades, 
there has been an increased interest in the phenomenon of comorbidity. This interest is fueled 
by the awareness that individuals are frequently affected by more than one disease or condition. 
It is safe to say that, in most clinical settings, the management of patients with multiple 
coexisting conditions is more the norm rather than the exception. (C2R01-02).    
Comorbidity cannot be reduced to a mere issue of frequency or prevalence in a clinical 
sample or group of individuals under examination. It is well recognized that the presence of 
multiple medical conditions in an individual could greatly impact clinical symptoms, the 
diagnostic process, the overall prognosis, and the clinical management of the conditions under 
treatment. Comorbidity has a strong impact on mortality, health-related quality of life, and overall 
daily functioning (C2R03-07). In addition, comorbidity has a substantial effect on health care 
expenditures. As an example, it is estimated that 80% of Medicare expenditures in the United 
States are devoted to patients with four or more chronic conditions (C2R08).  
 
 
C02.S02. Concept of Comorbidity in Medical Literature  
In spite of the strong impact that comorbidity imparts on virtually all aspects of public 
health, it is a surprisingly recent and poorly defined concept in the medical literature. Alvan 




clinical entity that has existed or that may occur during the clinical course of a patient who has 
the index disease under study"  
 
C02.S03. Classification of Comorbidity  
In 1974, Kaplan and Feinstein further formulated and clarified the concept of comorbidity 
(C2R10). These authors described four different types of comorbidity that they branded: 
diagnostic comorbidity, pathogenic comorbidity, prognostic comorbidity and cogent comorbidity.  
Diagnostic comorbidity applies when a particular symptom of a disease occurs in a 
patient with two coexisting conditions that independently could cause said symptom. The 
authors give the example of polyuria in a patient that suffers from both diabetes mellitus (the 
index condition) and a co-existing renal disease (the comorbid condition). As the index condition 
(diabetes) and the comorbid condition (renal disease) produce polyuria, it is expected that the 
prevalence of polyuria will be higher in patients affected both with diabetes and renal disease 
when compared to the ones affected solely with diabetes. Thus, diagnostic comorbidity can aid 
with the disease definition and symptom prevalence by examining how symptoms of a disease 
are impacted by the presence of additional diseases to the index condition under study. 
Pathogenic comorbidity describes the presence in a patient of a second disease that is 
considered “related” to the index condition. The authors state that certain cardiovascular or 
renal disorders can be regarded as “related” to diabetes (index disease), while other 
cardiovascular diseases can be regarded as “unrelated”. Thus, pathogenic comorbidity can 
serve as a framework to investigate or to describe how one index disease can be the etiological 
risk factor for a second disease. It is important to note that the authors believed that not all 




high co-occurrence of two conditions could be seen as an indicator of a potential common 
etiologic link, but not as a proof of one. 
Prognostic comorbid applies when “an ailment predisposes, either by itself or in 
combination with the main disease, to the future development of adverse target events”. As an 
example, the authors state that “a patient with diabetes and hypertension may be more likely to 
develop retinopathy than a patient with diabetes alone”. Similarly, “a diabetic patient with 
chronic obstructive pulmonary disease may be more likely to develop cardiac decompensation 
than if the lungs were normal”. This concept seems similar to the concept of pathogenic 
comorbidity, as it postulates the etiological risk factor involved in comorbidity. The difference is 
that is stresses the importance of temporality, that is that the third condition develops later in 
time as the consequence of the first two conditions. 
Kaplan and Feinstein coined the term cogent comorbidity to describe a scenario where 
the additional ailment “might be expected to impair a patient’s long-term survival”. Cogent 
comorbidity is present in this definition if the added conditions “involved vital body systems or 
were associated with anatomic, functional, or behavioral effects that might either threaten life 
directly or make the patient particularly susceptible to fatal ailments”. Non-cogent comorbidity 
would describe other scenarios where additional ailments have no impact on survival, 
specifically “the term non-cogent was applied to chronic conditions that could be well controlled 
with or without medication and that had no direct effects on vital organs. Another type of non-
cogent comorbidity consisted of episodic events that had occurred once in the past, without 
involvement of heart or brain, and without residua in the affected structures”.  
 




In 1999, Angold et al. (C2R11) proposed several additions to the classification of the 
comorbidity phenomena that are relevant to the field of mental illness. The most important 
additions were the concept of homotypic comorbidity and concurrent or successive comorbidity. 
Homotypic comorbidity describes the case of co- occurrence of two or more disorders within the 
same diagnostic grouping. Heterotypic comorbidity defines the presence of two disorders that 
do not belong to the same diagnostic grouping. The term grouping used by these authors stems 
from the classification in psychopathology, where mental disorder are placed in groups due to 
their shared symptoms (e.g., anxiety disorders, psychotic disorders).  The authors gave the 
example of major depression and dysthymia as an illustration of homotypic comorbidity and, 
major depression and conduct disorder as an example of heterotypic comorbidity, respectively. 
The authors suggested that homotypic comorbidity may be a possible indicator of the lack of 
validity of individual diagnostic categories. In the example given, the homotypic comorbidity 
between major depression and dysthymia might suggest that the diagnostic criteria for these 
disorders are poorly defined at a symptom level. Thus, the current classification system could 
be splitting one disorder into two distinct conditions. An alternative explanation would be that 
homotypic comorbidity is an indicator of how the diagnostic criteria of a particular disorder could 
fail to capture the continuity of a single disease process over time with its natural waxing and 
waning (primary dysthymia that over time can worsen to major depression, or major depression 
that can, over time, improve to a milder, albeit chronic form).  
In addition, Angold et al. (C2R11) also posited the concept of concurrent versus 
successive comorbidity. Concurrent comorbidity applies to the existence of a co-occurrence of 
two or more diseases at the same time, whereas successive comorbidity describes the case 
where one person is affected first by one disease, and later on by a second disease, but the two 





C02.S05. Primary versus Secondary Disorder Distinction 
The concept of concurrent versus successive comorbidity is analogous to the distinction 
of primary versus secondary disorder (C2R14). If an individual is diagnosed with two disorders, 
the diagnosis that came first in time is considered the primary disorder. In this case, the primary-
secondary disorder distinction is used in a pure chronological approach. The primary vs. 
secondary distinction can also be used in an etiological framework. In this case, the primary 
condition is considered the cause of the secondary diagnosis. This etiologic distinction between 
primary and secondary is used in the DSM-III organic disorders (due to medical condition), and 
substance induced disorders (C2R12). The third use of the primary versus secondary disorder 
distinction applies to the case of symptom or diagnostic hierarchy (C2R14). In this use, the 
subject presents with multiple symptoms that could fit into two diagnoses, and the condition that 
has a hierarchical precedence gets diagnosed at the cost of the second. As an example, a 
patient might present with severe delusions, auditory hallucinations, panic attacks, and 
insomnia. The clinical judgment and hierarchical rules of the psychiatric classification points out 
to one diagnoses as primary (psychosis). A secondary diagnosis of anxiety or sleep disorder 
might be withheld as these “secondary” symptoms might subside once the psychosis is 
managed. 
 
C02.S06. Comorbidity and Longitudinal Course of Psychopathology 
The concurrent versus successive or the primary versus secondary paradigms are 
connected to the longitudinal study of psychopathology. The study of the course of 
psychopathology over time is an important concept when analyzing the phenomenon of 
comorbidity. The study of the “natural history of psychopathology” as postulated by Eaton 




assessed based on their lifetime prevalence. An examination of the onset, course and outcome 
of the mental disorders in a population-base sample is necessary to avoid the Berkson bias 
(C2R16) observed more in treatment samples, especially if the analysis is done in a cross-
sectional approach. The relevance of the presence of two conditions in a lifetime prevalence 
measurement cannot be fully understood without an analysis of the dynamics between these 
two conditions over time.  
 
C02.S07. Discussion and Summary 
All the described definitions of comorbidity are largely theoretical and difficult to apply 
empirically. They reveal in an implicit way, several distinctive perspectives from where to 
examine the concept of comorbidity. The first vantage point addresses the identification of 
common casual factors, and mechanisms of action between the two comorbid conditions. The 
second perspective focuses on the level on which the assessment of the comorbidity is 
implemented: specifically, whether comorbidity is considered only as the co-occurrence of 
diseases in an individual, or as the presence in a person of a particular symptom that could be 
better explained as the effect of more than one disease.  
In summary, the concept of comorbidity in medicine presents a challenge in an era of 
aging populations and increased use of technologies. In a narrow use, it is a descriptive term 
that defines the co-occurrence of multiple symptoms or diseases in the same individual. In a 









C02.S08. Introduction to Comorbidity in Mental Health 
The concept and study of comorbidity in mental disorders takes a dimension that is 
different from the rest of the medical field. There are many reasons that conspire to create this 
unique phenomenon (C2R14). One of these factors stems from the complex relationship 
between the mental and the physical or also called “medical” disorders.  
 
C02.S09. Medical Comorbidity and the Diagnostic and Statistical Manual of Mental Disorders 
The multiaxial diagnostic system represented a concerted effort from the DSM system in 
recording any possible medical condition that could cause or influence the course of the 
psychiatric disorder under study. The inclusion of medical conditions in the psychiatric 
diagnoses created numerous challenges. There was a lack of clear guidelines about the 
relevance of the medical conditions that should be included in the multiaxial diagnoses. In 
addition, there was a scarcity of specifiers in the system to document whether the medical 
conditions included in the multiaxial diagnosis played any role in the comorbid psychiatric 
disorders (except for the limited listing of mental disorders that were deemed completely due to 
a general medical condition). Nevertheless, this effort in detecting and recording medical 
comorbidities increased the awareness of the importance of the co-occurrence of psychiatric 
and medical conditions  
 




Another rationale for this complexity stems from the challenges in the classification of 
mental disorders: in particular, the relationship between primary mental, also known as “clinical” 
disorders (e.g. schizophrenia, depression), substance use disorders, and personality disorders. 
A modern classification of mental disorders needs to provide coverage for all these conditions. 
Unfortunately, including heterogeneous dimensions in one single classification translates into a 
major challenge for its internal consistency.   
When a psychiatric classification that contains heterogeneous concepts of mental illness 
is used to diagnose a patient, these heterogeneous concepts act as different perspectives from 
where to evaluate the diagnosed subject. The presence of different perspectives increases the 
likelihood that an individual can receive more than one diagnosis. Thus, the presence of 
heterogeneous concepts within a classification system constitutes a de facto source of 
comorbidity that is built into the classification. 
The phenomenon of comorbidity in mental disorders is intimately linked to the 
development of the classification of mental disorders. It is therefore, necessary to review the 
historical development of the current classification of mental disorders to understand how this 
connection between comorbidity and classification developed over time. 
  
C02S11. Comorbidity and Classification of Mental Disorders 
The introduction of the third edition of the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-III) (C2R12) in 1980 was a landmark as it inaugurated a new era in psychiatry. 
The DSM-III had three main areas of innovation. It established explicit diagnostic criteria, a 
multiaxial diagnostic assessment system, and an approach that attempted to be neutral with 





C02S12. Historical Development of the DSM  
The implementation of explicit diagnostic criteria was the result of a movement in 
psychiatry that started in the late 1960’s.This movement, described by Klerman as neo- 
Kraepelinian (C2R13, 14), was fueled by a growing discontent of clinicians and researchers 
regarding the absence of objective, and empirically based methods for describing 
psychopathology. This neo-Kraepelinian group lead by Robins, Guze and their colleagues at 
Washington University in St. Louis, promoted a descriptive approach to psychopathology that 
was a refinement and extension of a categorical diagnoses model for major mental disorders 
advocated by Emil von Kraepelin. (C2R13, 14, 17).  
 
C02S13. The Feighner Criteria 
This group carried out extensive work on constructing and validating the diagnostic 
criteria and developing psychiatric interviews for research and clinical uses. The result of this 
work was the creation of the first diagnostic system with explicit criteria attached to every 
diagnosis. This criteria set was called “Feighner Criteria” (FC), for the first author of its 
publication (C2R18).These diagnostic criteria were largely based on the principles established 
by Robins and Guze, in their seminal paper discussing the establishment of diagnostic criteria 
for schizophrenia (C2R19). The basic tenet behind this classification was that, ultimately, each 
particular clinical syndrome would be validated by its clear separation from other disorders, 
would have a particular clinical course, as well as a specific genetic aggregation found in family 
studies.  
The purpose of the use of explicit diagnostic criteria was to improve the reliability of the 




stepping stone in the process of investigating the causes and clinical management of mental 
disorders.  
The FC included 15 specific diagnostic groups: neuroses (anxiety, phobic, obsessional, 
hysterical disorders), affective disorders (depressive or bipolar disorders), schizophrenia, 
organic brain syndromes, substance abuse disorders (alcoholism, other drugs), sexual 
disorders (homosexuality, transsexuality), eating disorders (anorexia, bulimia), and one 
personality disorder (antisocial personality) (C2R17). Eli Robins, Samuel Guze and their 
colleagues expected that their newly created diagnostic criteria would allow assignment of about 
80% of all psychiatric patients to one diagnosis (C2R17). Eli Robins frequently emphasized that 
the aim of their approach was to diagnose an individual with only one mental disorder. If one 
subject met criteria for more than one disorder, the subject should be considered as 
undiagnosed, or as having an uncertain diagnosis. The expectation for this 20% of undiagnosed 
subjects was to develop new diagnostic categories that would eventually diagnose these 
subjects in a valid fashion (C2R17). 
 
C02.S14. Research Diagnostic Criteria and DSM  
Based upon the success of the FC, Spitzer et al. elaborated the “Research Diagnostic 
Criteria” (RDC) at Columbia University, New York (C2R20). The RDC continued the use of 
explicit diagnostic criteria, providing coverage to an increased number of mental disorders.  
Robert Spitzer later became the chair of the American Psychiatric Association's task 
force in charge of the development of the third edition of the DSM (DSM-III). The concepts that 
shaped the FC and RDC became the blueprint for the development of the DSM-III. The DSM-III 
extended the explicit diagnostic criteria to several additional diagnoses, and added a multiaxial 





C02.S15. The Multiaxial Diagnostic Assessment 
The multiaxial diagnostic assessment was designed to separate the so-called “clinical 
disorders”, such as schizophrenia or depression, from the effect of personality disorder traits or 
mental retardation when examining an individual’s behavior. The distinction, largely influenced 
by political motivations, aimed at the importance of the evaluation of character and personality 
in the overall psychiatric assessment. However, the multiaxial diagnostic system had the 
unintended effect of promoting multiple diagnoses by default (C2R14, 17). 
 
C02.S16. Elimination of Hierarchical Rules  
Although the original FC had some hierarchical rules between disorders that prevented 
multiple diagnoses. The DSM-III purported a “cause-neutral” paradigm. This approach would 
lead to the removal of hierarchical barriers between the clinical disorders that were present in 
previous diagnostic instruments. There was a further elimination of additional exclusion criteria 
in the newer revisions of the DSM after the realization that mental disorders that were 
considered not etiologically related could be largely comorbid (C2R21).  
 
C02.S17. The New Era of Comorbidity in Mental Disorders 
The overall effect of the increase in the number of diagnostic categories, and the 
elimination of the exclusion criteria transformed the practice of psychiatric diagnosis over the 
following decades. Diagnosing a patient with multiple diagnostic labels became the norm rather 
than exception. However, not all psychiatric comorbidities should have the same consequence 




Since the introduction of the DSM-III, and until the recent removal of the multiaxial 
classification in the fifth edition of the DSM, patients could be diagnosed on the Axis I with a 
clinical diagnosis (e.g. depression or anxiety). In addition, patients could be diagnosed in Axis I 
with a substance abuse disorder. Alternatively (or additionally), the same subject could be 
diagnosed with a personality disorder in the Axis II. These three diagnoses might be considered 
as three different mental disorders, or complementary perspectives from where to label the 
manifestations of a single ailment.   
 
C02.S18. Heterogeneity of the Comorbidity in the Diagnostic Assessment   
 While the presence of a comorbidity between a mental disorder in Axis I and a medical 
condition in Axis III could be a desired phenomenon, the presence of a comorbidity between a 
“clinical disorder” and a substance abuse disorder or a personality disorder could be seen as 
the indicative of the heterogeneity of the concept of what constitute a mental disorder in the 
classification. The inclusion of these heterogeneous concepts translated into the existence of 
different approaches or viewpoints from where to diagnose a patient.  
In contrast, the presence of strong patterns of comorbidity between the Axis I “clinical 
disorders’, especially those that we could described as heterotypic, or belonging to different 
diagnostic classes like anxiety and depression, presents as a challenge to the underlying 
validity of the DSM categorical diagnostic system as a whole.  
In practical use, when patients present both symptoms of depression and anxiety, a 
clinician might be inclined to diagnose the patient only with the former, in the belief that 
depression has a superior hierarchical position. Another clinician might be inclined to diagnose 
the patient only with an anxiety disorder, and a third with both. When a patient receives multiple 




depending on their current assessment, or whether they intend to provide different treatment 
approaches (psychotherapy vs. pharmacologic treatment).  
The presence of a high degree of comorbidity between heterotypic clinical disorders 
collides with the main goal of the classification of mental disorders. This goal is to provide a 
common language or “frame of reference”. A reliable diagnostic system should increase 
agreement, facilitate communication between physicians and with the users of mental services 
(C2R17). Additionally, it contradicts the theoretical basis of the DSM classification of mental 
disorders. The DSM is a categorical system that assumes that categorical diagnoses reflected 
underlying discrete and diverse disease entities (C2R14, 17, 22). 
 
C02.S19. Prevalence of Comorbidity between Mental Disorders: Introduction 
Early epidemiologic surveys in treatment-based samples have shown a widespread 
comorbidity between mental disorders. Ross et al. reported (C2R23) that in a sample of 
treatment-seeking patients suffering from alcohol dependence, 78% met criteria for a lifetime 
comorbidity for other mental disorder. Wolf et al. (C2R24) reported that half of the patients 
admitted to psychiatric unit in a major academic center, received more than one psychiatric 
diagnosis. They also reported a high correlation between substance abuse disorders and 
antisocial personality disorder, while affective disorders were highly correlated with each other 
in this population. 
 
C02.S20. Comorbidity in Community Epidemiologic Surveys 
With the advent of the large-scale psychiatric epidemiologic surveys, it was possible to 




respective comorbidity. The advantage of using population-based surveys and structured 
interviews reduced the bias from the results of previous treatment-based samples.  
 
C02.S21. Comorbidity in the Epidemiologic Catchment Area Program 
The Epidemiologic Catchment Area Program (ECA) (C2R25, 26, 27, 28) investigators 
reported that about 32% of adults in the US met criteria for one or more psychiatric or substance 
abuse disorder in their lifetime. In addition, comorbidity was widespread among most of the 
measured mental disorders included in the survey. When exclusion rules that prevented giving a 
second diagnosis were lifted, the authors reported that 18% of the total population had had at 
least two psychiatric disorders in their lifetime: namely, that 60% of those with at least one 
disorder, had at least one additional disorder. Investigators reported that somatization had the 
highest rate of comorbidity (100%), followed by antisocial personality, panic and schizophrenia 
(all with comorbidity rates over 90%).   
 
C02.S22. Comorbidity in the National Comorbidity Study 
The National Comorbidity Study (NCS) (C2R29), conducted a decade later than the 
ECA, showed similar results in a national based sample. The lifetime prevalence for any 
psychiatric or substance abuse disorder for adults was 48%. Stratifying the subjects by the 
number of lifetime prevalence diagnoses received, 52.0% of the sample met no criteria for 
lifetime disorder, 21.0% met criteria for only 1 disorder, 13.0% of the sample met criteria for only 
two disorders, and the remaining 14.0% of the sample met criteria for three or more disorders in 
their lifetime. When examining the total number of diagnoses by subject, 20.6% of the disorders 
were diagnosed in subjects that met criteria for only one psychiatric disorder, 25.5% of the 




53.9% of the lifetime disorders diagnosed in a sample were diagnosed in subjects that met 
criteria for three or more lifetime disorders.  
In summary, the results of the NCS pointed out that comorbidity amongst mental 
disorders should be considered the norm more than the exception, as 56.25% of all the subjects 
that received a DSM diagnoses met criteria for more than one disorder. Notably, 79.4% of the 
lifetime diagnoses of psychiatric and substance abuse disorders diagnosed in the NCS sample 
were comorbid conditions (C2R29).  
 These findings from the NCS are remarkable, as they clearly highlight that the vast 
majority of the psychopathology found in the community is comorbid, and that a single 
psychiatric diagnosis is the exception to the rule. 
 
C02.S23. Comorbidity and Debate about Classification   
Considerable debate grew in the psychiatric literature about the concept of comorbidity 
and its implications for the classification of psychiatric disorders (C2R30). Some authors posited 
against the use of the concept of comorbidity in psychiatry (C2R31). Maj’s main argument was 
that some psychiatric disorders did not meet the criteria of “disease or condition” that the 
Feinstein definition of comorbidity required. Maj posited that some anxiety and “neurotic” 
conditions were more dimensional in nature as they lacked a clear definition with each other and 
with normality.  
Robert Spitzer (C2R32), and Lee Robins (C2R33) clearly supported the use of the 
concept of comorbidity in the classification. Spitzer saw no reason to abandon the use of the 






C02.S24. Research Domain Criteria and DSM-5  
In view of the challenges to the current diagnostic classification, the National Institute of 
Mental Health launched the Research Domain Criteria (RDoC) project to create a new research 
framework to be implemented in pathophysiology (C2R34, 35). The RDoC project is intended to 
be a “next step”, as it intends to shift the classification from the current clinically based system 
proposed by the third edition of the DSM to a new classification based on pathophysiology. The 
overarching goal of the RDoC project is to incorporate the findings of genomics and 
neuroscience into the classification of psychiatric disorders with the goal to identify new targets 
for treatment development, detect subgroups for treatment selection, and provide a foundation 
for future research findings. Thus, the RDoC is based on a cross-diagnostic or “tans-diagnostic” 
approach to overcome the challenges to validity of the categorical system posed by comorbidity.  
(C2R34, 35).  
White the RDoC project is still underway, the fifth edition of the DSM was launched in 
2013 (C2R36).  During the process of drafting the DSM-5, widespread debate existed on 
whether the new classification of mental disorders should abandon the categorical model and 
substitute it for a dimensional perspective (C2R37). Despite the debate and the inclusion of 
dimensional instruments, the DSM-5 was still based on a categorical disorder model. 
 
C02.S25. Comorbidity of Depression and Anxiety: Introduction  
Depressive and anxiety disorders are amongst the most prevalent group of mental 
illnesses. The NCS investigators reported a lifetime prevalence of Major Depressive Disorder of 
17.1% and of Dysthymia of 6.4% for adult men and women. The lifetime prevalence estimate for 




Disorder: 3.5%, Agoraphobia without Panic Disorder: 5.3%, Social Phobia: 13.3%, Simple 
Phobia: 11.3%, Generalized Anxiety Disorder: 5.1%) (C2R29).  
 
C02.S26. Clinical Implications of the Comorbidity between Anxiety and Depression 
A high rate of comorbidity between anxiety and depressive disorders can have a 
particular significance, not only due to the possible strength of the comorbid association, but 
also due to the high prevalence of these two conditions. In addition, anxiety and depressive 
disorders are usually treated by general practitioners in non-mental health settings. These 
practitioners are not extensively trained to understand the complexities and caveats of the 
diagnosis and the management of mental disorders. One set of symptoms could be ignored 
over the other, and patients might not receive an appropriate treatment that could address their 
condition. A busy clinician in a general medical clinic might not feel the need or have the 
expertise to inquire about possible comorbid symptoms of anxiety once the diagnosis of 
depression is given. Thus, comorbidity is not only a theoretical challenge for those interested in 
psychiatric diagnosis, but is also a practical issue, as the lack of appropriate diagnosis is often 
followed by inappropriate treatment. 
 
C02.S27. NCS Findings on Comorbidity in MDD  
Studies of diagnostic patterns in community samples have shown that mood disorders 
are widely comorbid with other psychiatric conditions, including anxiety disorders. NCS 
respondents had a 17.1% a lifetime prevalence of Major Depressive Disorder (MDD). Only 26% 
of the subjects with MDD had this condition as sole or “pure” disorder. This meant that 74% of 
all NCS respondents with a lifetime history of MDD had an additional disorder (C2R29). Kessler 




cases, was categorized as primary MDD, in which MDD preceded the comorbid condition, and 
the second subgroup, that included the extant 61.8% of total MDD cases, in which the condition 
could be considered “secondary”. In this secondary group, the respondents had at least one of 
the other DSM disorders assessed in the NCS before or in the same year as their first onset of 
depression.  
Of these 74% of the NCS respondents with lifetime MDD that had more than lifetime 
diagnoses condition, 24.7% met criteria for only one additional psychiatric disorder in their 
lifetime, 17.4% met criteria for only two additional conditions, and, finally, 31.9% met criteria for 
three or more additional mental disorders in their lifetime (C2R38, 39). 
 
C02.S28.Prevalence of the Comorbidity between Anxiety and Depression 
Focusing on the comorbidity between Major Depressive Disorder and all anxiety 
disorders, 58.0% of NCS respondents that met criteria for MDD in their lifetime, also met criteria 
for at least one anxiety disorder: namely, the NCS respondents diagnosed with MDD had 4 
times the risk of meeting criteria for one anxiety disorder in their lifetime as compared to the 
total sample (OR= 4.2 (95% CI= 3.4 - 5.2)) (C2R38, 39).  
C02.S29.Findings of the National Comorbidity Survey on Anxiety Disorders 
The NCS findings for the comorbidity between Major Depressive Disorder and the 
anxiety disorders were as follows (percentage MDD respondents with the specified anxiety 
condition, odds ratio (OR) for the comorbidity between MDD and the specified anxiety disorder 
with 95% Confidence Interval). Generalized Anxiety Disorder: 17.2%, OR: 6.0 (95% CI:4.2, 8.6), 
Agoraphobia: 16.3%, OR: 3.4 (95% CI: 2.5, 4.6), Simple Phobia: 24.3%, OR: 3.1 (95% CI: 2.5, 




2.7, 6.1), Posttraumatic Stress Disorder: 19.5%, OR: 4.0 (95% CI: 3.1, 5.2), respectively 
(C2R38, 39).  
 
C02.S30.Findings of the National Comorbidity Survey Replication 
The National Comorbidity Survey Replication (NCS-R) (C2R40) is a nationally 
representative face-to-face household survey of 9090 noninstitutionalized respondents aged 18 
years or older. It was conducted between February 2001 and December 2002. Prevalence and 
correlates of MDD were obtained using the World Health Organization's (WHO) Interview (CIDI) 
(C2R41). The lifetime prevalence estimate for MDD was 16.2% for adult men and women. The 
majority of respondents (72.1%) with lifetime MDD reported at least one other lifetime DSM-IV 
disorder. Of the respondents with lifetime MDD, 59.2% also met criteria for lifetime anxiety 
disorder, 24.0% met criteria for a substance use disorder, and 30.0% met criteria for an impulse 
control disorder (C2R40).   
When MDD is found in a comorbidity pair with any other mental disorder, MDD was 
considered the primary condition in only 12.35 % of the respondents. Of those respondents that 
met criteria for both MDD and an anxiety disorder, only 13.7% had MDD as the primary 
disorder. Of the respondents that met criteria for both MDD and a substance abuse disorder, 
41.3% had MDD as the primary mental disorder.  Finally, of the respondents that met criteria for 
both MDD and an impulse control disorder, 20.8% had MDD as the primary disorder (C2R40).  
In the summary, the NCS-R findings confirm that MDD seems to be a highly comorbid 
condition, and appears later in the subject’s life. Over half of the respondents that met criteria 
for depression, also met lifetime criteria for an anxiety condition. Anxiety disorders appear 
earlier in time in the vast majority of cases (87.3%). 




The NCS investigators estimated the effect of the anxiety disorders in predicting a 
subsequent onset of lifetime MDD by using survival models in a sample of 1,769 adolescents 
and young adults who participated in the National Comorbidity Survey (C2R42).  The survival 
coefficients were exponentiated to yield odd ratios (OR). For Any Anxiety Disorder, the OR to 
develop a subsequent MDD was 3.4 (95%CI: 2.8, 4.2). The results suggest that those who 
suffered from a previous anxiety disorder were 3.4 times more likely to develop a Major 
Depressive Disorder than the rest of the sample. Discriminated by disorder (OR (95% CI)); 
Panic Disorder: 3.3 (1.7, 6.3), Generalized Anxiety Disorder: 5.1 (2.8, 9.3), Posttraumatic stress 
Disorder: 2.8 (2.1, 3.8), Simple Phobia: 3.1 (2.4, 4.0), Social Phobia: 2.9 (2.2, 3.7), and, 
Agoraphobia: 2.7 (1.7, 4.2). Results were significant for all anxiety Disorders (p < 0.05) 
(C2R40). 
 
C02.S32. Comorbidity from the Anxiety Disorders Perspective 
Kaufman and Charney (C2R43) pooled data from several epidemiological and treatment 
samples to analyze the comorbidity of some selected anxiety disorders with other non-anxiety 
mental disorders, as well as the comorbidity between the individual anxiety disorders 
              For Panic Disorder, the authors reported a prevalence in the sample of 1.4%-2.9% of 
cases. Panic Disorder was found to be comorbid with any psychiatric disorder: 74%-90% of 
cases, with MDD: 56%-73%, with any other anxiety disorder: 10% of cases (C2R43). 
             For Social Phobia, the authors reported a prevalence in the sample of 1.4%-3.8% of 
cases. Social Phobia was found to be comorbid with any psychiatric disorder: 67%-92% of 




For Generalized Anxiety Disorder (GAD), the authors reported a prevalence in the 
sample of 1.9%-6.6% of cases. GAD was found to be comorbid with any psychiatric disorder: 
80-90% of cases, with MDD: 62%-67%, with any other anxiety disorder: 17% of cases (C2R43).   
For Post-traumatic Stress Disorder (PTSD), the authors reported a prevalence in the 
sample of 1%-13.8% of cases. PTSD was found to be comorbid with any psychiatric disorder: 
73-83% of cases, with MDD: 37%-48%, with any other anxiety disorder: 20% of cases (C2R43).  
 
C02.S33. Longitudinal Course of the Comorbidity between Depression and Anxiety disorders 
Coryell at al. (C2R44) reported that patients who suffered from MDD comorbid with 
panic attacks had more severe depressive symptoms and were less likely to recover in a 2 year 
follow up period when compared to individuals who suffered from MDD without panic attacks 
(C2R44). 
Roy-Byrne et al. (C2R45) posited that, in the participants of the National Comorbidity 
Survey (NCS), there was a strong association between panic disorder and depression. Patients 
with this comorbidity had more severe symptoms, and increase need for clinical treatment as 
compared to those without comorbid depression and panic. The authors also reported that there 
was an increase in functional impairment, a higher number of lost work days, and a higher 
number of episodes of depression or panic in those individuals affected with this comorbidity 
(C2R45). 
Based on findings from the Zurich Cohort Study, a prospective community study that has 
followed subjects with depression and anxiety over two decades, Merikangas et al. (C2R46) 
reported a high stability of depression and anxiety symptoms over time. Previous anxiety was a 
strong predictor of a subsequent onset of depression. The presence of both depressive and 




authors challenged the idea that comorbid depression and anxiety should be considered as two 
different conditions based on their findings (C2R46). 
 
C02.S34. Comorbidity and Response to Treatment 
Fava et al. (C2R47) reported findings from the Sequenced Treatment Alternatives to 
Relieve Depression (STAR*D) project. The STAR*D aimed to determine the effectiveness of 
several treatments for outpatients with nonpsychotic major depressive disorder. The authors 
compared the effectiveness of antidepressant therapy (citalopram) in 1,530 subjects with 
anxious depression (depression comorbid with anxiety symptoms) with the effectiveness of 
citalopram in treating 1,346 subjects suffering from non-anxious depression (depression without 
comorbid anxiety symptoms). The results of the STAR*D clearly indicated that anxious 
depression subjects had significantly lower rates of remission  and needed longer follow-up time 
to achieve remission than the non-anxious depression subjects. In addition, subjects with 
anxious depression had more frequent and severe side effects than the patients with non-
anxious depression. Lastly, subjects with anxious depression fared significantly worse than the 
subjects with non-anxious depression, when they were given an alternative or an additional 
antidepressant agent to address their symptoms (C2R47). 
 
C02.S35. Conclusion 
In summary, comorbidity is a recent concept in medical literature that addresses a 
common occurrence that was overlooked in the past. The increase in the interest in the area 
stems from the realization that the majority of individuals are affected by more than one disease 




In the general medicine field, the study of comorbidity is linked to the challenges that 
patients with multiple conditions can present in their diagnosis and clinical management. 
Another important challenge is the cost that the health services endure from the treatment of 
patients with multiple and severe conditions. In addition, there are no assurances that these 
enormous and increasing costs will translate into the improvement of health outcomes in this 
vulnerable population 
In psychiatry, comorbidity has taken a different direction than the one described in 
general medicine. This difference is mostly due to our difficulties in accurately classifying mental 
disorders. The reliance on a categorical classification that provides coverage for a wide number 
of heterogeneous conditions, as well as the removal of hierarchies or barriers that could 
obstruct the practice of multiple diagnoses were also instrumental to the generation of 
comorbidity in the classification of mental disorders. The creation of the multiaxial diagnostic 
system also stimulated the adjudication of multiple diagnoses in the psychiatric patients.  
While some comorbidities in psychiatry are expected as the natural consequence of our 
diagnostic schemes, others challenge the very validity of the classification system, as they 
provide clear evidence of the flaws in the premises of our classification system. Anxiety and 
depression are not two taxa or families of mental disorders that are categorically dissimilar. The 
evidence gathered from different large-scale, population based studies, shows that they anxiety 
and depression are intimately related, and they share a longitudinal “natural” course in the vast 
majority of cases.  
The study of the relationship between the diagnoses of depression and anxiety in a 
population base sample, and the examination of its association with genetic markers appears to 
be a worthy task. We believe that this could shed some light into this complex issue and may 




          
 CHAPTER 03: LITERATURE REVIEW OF THE SEROTONIN TRANSPORTER GENE 
POLYMORPHISM AND ITS ASSOCATION WITH PSYCHOPATHOLOGY 
C03.S01. Serotonin. Historical Introduction and Function  
Serotonin (5-hydroxytryptamine, 5-HT), is a monoamine neurotransmitter that regulates 
several key physiological processes. First isolated by Rapport et al., serotonin received its name 
as a result of its vaso-constricting activity (C3R01). At the same time, serotonin was being 
studied in the digestive system, where it was found to play a key role in the intestinal motility 
and in the digestive process. (C3R02).  
It was later discovered that serotonin was also present in the central nervous system 
(C3R03-4). Serotonin-producing neurons are localized in cell clusters centrally located, 
surrounding the reticular formation. Due to their central location they receive the name raphe 
nuclei. The dorsal raphe, the largest brain stem serotonin nucleus, contains approximately 50% 
of the total serotonin neurons in the mammalian CNS. From the raphe nuclei, serotonergic 
neurons project widely throughout the CNS, including the nigrostriatal and limbic systems and 
cortex (C3R05) where they play a regulatory function. Serotonin modulates noradrenergic and 
dopaminergic release in hippocampus and prefrontal cortex. The serotoninergic system can 
reduce or increase anxiety and impulsivity, either directly or by altering functions of other 
neurotransmitter systems (C3R06). In addition, serotonin modulates arousal and prevents 
uncontrolled anxiety or panic through its effect on the locus coeruleus, (C3R07).  
Early psychopharmacologic studies evidenced that the monoamine neurotransmitters 
play a role in the development of depression. These investigations led to the catecholamine 
theory of depression. This theory postulates that a depletion of catecholamines, particularly 




(C3R08). Pharmacologic studies revealed that antidepressant agents also interacted with the 
serotoninergic system. Thus, investigators postulated a role for serotonin similar to the one of 
the catecholamines: namely, that at a deficiency in serotoninergic neuronal function was at the 
core of the pathophysiology of some depressive states (C3R09-11). 
 
C03.S02. The Serotonin Transporter (SERT) 
The serotonin pathways configure a highly complex system, regulated by 14 different 
receptors and transporter sites (C3R06).  Presynaptic receptors are auto-receptors that 
decrease activity of serotonergic neurons and have mostly anxiolytic effects, while postsynaptic 
receptors cause anxiety-like behaviors in animals (C3R12). 
The serotonin transporter (SERT) is a pre-synaptic plasma membrane transporter. It 
belongs to the subclass SL6 gene family of the sodium/chloride- coupled transporters that also 
includes transporters for the monoamines norepinephrine and dopamine, as well as for the 
neurotransmitter GABA (gamma-aminobutyric acid) and the amino acid glycine. The SERT 
plays a key role in the modulation of the serotonergic neurotransmission. It regulates the 
magnitude and duration of serotonergic responses, by capturing the 5-HT from the synaptic 
cleft. The SERT has been an important focus of research, as it has been established that both 
the tricyclic antidepressants (TCAs) as well as the newest serotonin reuptake inhibitors (SRIs) 
exert their initial pharmacological effect by binding to the SERT. The blockade of the SERT 
function increases the levels of serotonin in the synaptic cleft. This increase in serotonin 
promotes secondary changes in the serotoninergic transmission both at the presynaptic and 






C03.S03. The Serotonin Transporter Gene Polymorphism 
The human serotonin transporter (SERT) is encoded by a single gene (SLC6A4) located 
on the long arm of chromosome 17 (17q111-17q12). The SLC6A4 gene is organized into 14 
exons spanning approximately 31kb.  The most investigated area of the SLC6A4 is the 
serotonin transporter gene promoter region (5-HTTLPR), located 1kb upstream of the SERT 
gene transcription initiation site. The 5-HTTLPR has been the object of great attention due to a 
functional polymorphism. This polymorphism is constituted by a 44 base pair deletion /insertion 
in the 5’ regulatory region. The polymorphic variant that includes this 44 base pair is referred as 
the long (L) allele, the variant without the 44 base pair is called the short (S) allele (C3R14, 
C3R15). Lesch et al. reported that the 5-HTTLPR genotypes were distributed according to 
Hardy-Weinberg equilibrium: 32% l/l, 49% l/s, and 19% s/s (C3R15). 
The short (S) variant of the 5-HTTLPR was associated with lower levels of gene 
transcription (C3R16, C3R17). This decreased level of transcriptional efficacy of the SERT by 
the short (S) allele has been associated with several psychiatric disorders. The primary focus of 
several studies has been the link of the short (s) allele to major depression, and suicidal 
behavior (C3R18, C3R20).  
 
C03.S04. Beyond Bi-Allelic SERT Polymorphism   
Hu et al. reported an additional single nucleotide polymorphism in the long allele. This 
site, identified as rs25531, has two variants one with adenine designated as LA, and the second 
one with guanine, designated as LG (C3R21-23). The LG allele has been associated with a 
reduced gene transcription of SERT mRNA and protein compared to the LA allele (C3R24-25).  
Nakamura M et al. (C3R26) identified ten novel sequence variants for the 5-HTTLPR. 




into four and six kinds of allelic variant, respectively. The investigators also reported a significant 
ethnic difference between Japanese and Caucasian populations in the distributions of alleles 
and genotypes  
 
C03.S05. The Variable Number of Tandem Repeat (VNTR) Polymorphism in Intron 2 
A variable number of tandem repeat (VNTR) in intron 2 (STin2 VNTR) is the third 
polymorphism that was described in the SLC6A4 gene. It consists of a variable number (9, 10, 
or 12) of nearly identical 16/17bp segments. The 10-repeat and 12-repeat alleles of a 16/17 bp 
are present in all ethnicities, and the rare 9-repeat allele appears only in people of European or 
African descent (C3R55-56). The 9-repeat allele (STin2.9) has been associated with an 
increased risk for major depression and bipolar disorder (C3R57-58). The 12-repeat allele 
(STin2.12) has been associated with bipolar disorder and schizophrenia (C3R59-61).  
 
C03.S06.Association of 5-HTLLPR with Psychiatric Disorders and Antidepressant Response 
The potential association of the SERT gene polymorphism with clinical psychiatric 
disorders and antidepressant response has been the target of multiple investigations. A full 
review of the whole literature in the area is beyond the scope of this review. The main areas of 
this research have been the association of 5-HTLLPR with: 1) depression (both primary and in 
response to stressful events), 2) suicidal behavior, 3) non-affective mental disorders, and 4) 
response to antidepressant treatment.  
 




Several studies examined the association of 5-HTTLPR with Depression. Findings have 
been so far, contradictory. Lesch et al. (C3R15) were the first in reporting the association 
between S allele (S/S or S/L) and a neuroticism factor (anxiety and depressive symptoms and 
traits). Caspi et al. (C3R26) reported that individuals who were carriers and homozygous for the 
S allele exhibited more depressive symptoms, diagnosable depression, and suicidality in 
relation to stressful life events than individuals homozygous for the long allele This was 
considered an influential study that postulated a gene-by-environment interaction role for the 
SERT, in which an individual's response to environmental insults is moderated by the 5-
HTTLPR. The association between SERT polymorphism and an increase risk of depression in 
an interaction with stressful life events was challenged by a meta-analysis conducted by Risch 
et al. (C2R66), only to be later confirmed by a more recent meta-analysis conducted by Karg et 
al. (C2R67). 
Eaton et al. (C3R28) reported that individuals from the Epidemiologic Catchment Area 
Follow-Up Study (C3R29) who were heterozygous and homozygous of the S allele had a higher 
risk of an initial episode of depression, and, paradoxically experienced episodes of shorter 
duration as compared to non-carriers. This study is particularly relevant as it examines the 
incidence of depression and its association with the 5-HTLPLPR in a population based sample.  
Several studies (C3R30-37) confirmed the association of 5-HTTPLR with depression, 
while others failed to find any significant association (C3R38-40). In a recent collaborative meta-
analysis, Cluverhouse et al. (C3R41) examined the association between the allele of the 5-
HTTLPR serotonin transporter promoter region and the increased risk of depression in 
individuals exposed to stressful situations.  This massive undertaking involved the collaboration 
of multiple researchers in multiple academic centers. The analysis included 31 datasets 
containing 38 802 European-ancestry subjects. The investigators were unable to find a 





C03.S08. Association of 5-HTLLPR with Depression with Suicidal Behavior  
The evidence regarding the association between the 5-HTTLPR polymorphism and 
suicidal behavior is conflicting. While three separate meta-analyses done by Anguelova et al. 
(C3R42), Lin et al. (C3R43), and by Li et al. (C3R44) reported a positive association of the S 
allele and suicidal behavior, several studies (C3R45-47) contradict these findings, reporting 
negative findings 
 
C03.S09. Association of 5-HTLLPR with Antidepressant Response 
The SERT is one of the main modulators of serotonin transmission, and the primary site 
of action for several antidepressant agents, especially the serotonin reuptake inhibitors (SRIs).  
Several reports have demonstrated that the L/L allele polymorphism in 5-HTTLPR is associated 
with an increased effectiveness in antidepressant response. Yu et al. (C3R48) reported that 
patients with the L/L genotype had a significantly better response to fluoxetine (20-60 mg/day) 
than the S/S carriers.  Zanardi et al. (C3R49), as well as Smeraldi et al. (C3R50) posited that L 
allele carriers (S/L and L/L) had a better response to fluvoxamine when compared to S 
homozygous. 
 
C03.S10. Association of 5-HTLLPR with Non-Affective Mental Disorders  
In addition to the literature linking the SERT polymorphism to the affective disorders, 
several studies have reported its association with several non-affective mental disorders.  Calati 
et al. (C3R51) reported an increased risk for eating disorders, in particular Anorexia Nervosa in 




Disorders had a higher frequency of the low expression (s/s) genotype than normal controls. 
These results were contradicted by Grabe et al. (C3R53), who reported a strong additive gene-
environment interaction with the high expression L(A) allele of 5-HTTLPR and frequent trauma 
in PTSD 
A meta-analysis conducted by Feinn et al. (C3R62) reported that the S allele was 
significantly associated with Alcohol Dependence, as well as with an increased risk to suffer 




C03.S11. Association of 5-HTLLPR with Obsessive Compulsive Disorder (OCD) 
The SERT gene promoter region polymorphism has been associated with OCD in case 
controls and family based studies. In a case control study that included 75 cases of Caucasian 
OCD patients, Bengel et al. reported that the OCD subjects were more likely to carry two copies 
of the long SERT long (l) allele as compared to the 397 matching controls (C363). Bloch at al 
reported a significant association between the (l) allele and OCD in children and Caucasians 
(C3R54) 
C03.S12. Association of 5-HTLLPR with Panic Disorder 
The association between the SERT gene promoter region and Panic Disorder has been 
investigated with mixed results. Lesch et al. reported that in a sample of 505 individuals, the 
SERT gene promoter polymorphism accounted for 3 to 4 % of the total variation and 7 to 9 % of 
the inherited variance for anxiety-related personality traits in individuals as well as sibships 




5% of the population variation in anxiety related behavioral traits (Cc3R24). Strug et al. reported 
no association of the SERT promoter gene polymorphism with an increased risk for Panic 
Disorder in a sample of N=179 subjects sampled from the NIMH Human Genetic Initiative 
(C3R64). In addition, Blaya et al. reported no association of the SERT promoter gene 
polymorphism in a case-control candidate gene association study with 107 patients with Panic 
Disorder (C3R65) 
C03.S13. Summary and Conclusions 
There is a vast body of literature on the potential association of the 5-HTTLPR with an 
extensive list of psychiatric conditions. The results of these investigations have been, so far, 
inconclusive. 
Considering the role of serotonin transmission in the central nervous system, and the 
role of the SERT in the regulation of serotonin transmission, the existence of a polymorphism in 
the gene that codes the SERT should continue to be an area of active interest in research. 
Especially if this polymorphism impacts on the SERT function, and therefore, on the serotonin 
transmission. 
The aim of this investigation was to study the potential impact of the 5-HTTLPR in 
psychopathology. We explored the potential role of the 5-HTTLPR beyond its association with 
the prevalence of individual mental disorders. We examined the association of the 5-HTTLPR 
with the presence of an increase burden of comorbidity of mental disorders. This approach 






CHAPTER 04. PART 01.  
METHODS: STUDY PARTICIPANTS SELECTION PROCESS 
S04. P01.S01. Introduction to Participant Selection 
The sample population for this study was the result of a three-phase selection process. 
The first phase involved the development of the original cohort for the Baltimore site of the 
Epidemiologic Catchment Area in the early 1980’s (C4R01). The second phase consisted in a 
series of waves that, during the 1990’s, re-sampled the cohort obtained in the first phase. These 
waves are generically called the Baltimore Epidemiologic Catchment Area Follow-up (EFU) 
(C4R02- C4R04). The third phase entailed the development of a sub-sample of the EFU for this 
investigation, the Comorbidity and Serotonin Transporter Gene (C4R06- C4R07). (Figure 
C4AF01) 
 
S04. P01.S02. First Phase: The Epidemiologic Catchment Area Program (ECA) 
The Epidemiologic Catchment Area Program (ECA) was a collaborative research project 
designed to assess the prevalence of mental and addictive disorders and to estimate the use 
made of different sectors of the mental health system. It was designed by the National Institute 
of Mental Health (NIMH) and five research groups in five different cities in the US. These included 
Yale University in New Haven, Connecticut; Johns Hopkins University in Baltimore, Maryland; 
Washington University in St Louis, Missouri; Duke University in Durham, North Carolina; and 
University of California in Los Angeles, California (C4R01). 
 
The ECA was designed as a response to some of the major epidemiological and 
research gaps identified by the 1978 report of the President’s Commission on Mental Health 
(C4R01). It represented the first coordinated multi-site, large scale, community based 




criteria, standardized diagnostic interviews and survey methods. (C4R01). 
Over 20,000 subjects were examined in two series of interviews between 1980 and 1983 
in the five sites in the US. Subjects were aged 18 and older living in regular households, as 
well as in nursing homes, prisons and institutions. Participants were selected by the five 
research groups. The groups used probabilistic sampling to select subjects who were 
representative of their respective catchment area. At the first encounter, respondents gave 
informed consent and permission to be interviewed again. Respondents at all sites were re-
interviewed 12 months later (C4R01-04). 
The target population for the Baltimore ECA site consisted of the household residents of 
East Baltimore (an area with 175,211 adult inhabitants in 1981). Out of the 4238 individuals 
that were probabilistically designated for interview, 3,481 subjects completed the interviews. 
This represented an 82% completion rate of the original 4,238 that were designated (C4R01-
04). 
 
S04. P01.S03.Diagnostic Interview Schedule Interview in the ECA 
Subjects of the ECA were interviewed using the Diagnostic Interview Schedule (DIS) 
(C4R07). The DIS is a structured clinical interview that was developed for the ECA. The DIS 
was designed to provide a standardized and reliable psychiatric diagnosis while administered 
by lay interviewers as the large-scale dimension of the ECA study precluded the use of 
trained professionals as interviewers. (C4R07). 
 
S04. P01.S04. Second Phase: Baltimore Epidemiologic Catchment Area Follow-Up Study 
During the 1990’s, the subjects of the original Baltimore ECA Study cohort were contacted 




(C4R02-06). During the period of time between the ECA (1980-3) and the first wave of the EFU 
(1993-4), several subjects were lost to follow-up. Out of the 3,481 respondents of the original ECA, 
848 people had died, 415 individuals could not be located, and 298 refused to participate. 
Ultimately, 1920 subjects of the original 3,481 Baltimore ECA participants (approximately 73% 
of the 2633 survivors), were re-interviewed for the EFU (C4R02). The first wave of EFU 
respondents did not differ from the non-respondents in terms of age, sex, and rates of 
depression and other psychiatric disorders (C4R02) 
 
S04. P01.S05. Diagnostic Interview Schedule Interview in the EFU 
Following the protocol of the original ECA, the subjects of the EFU were interviewed 
using the Diagnostic Interview Schedule (DIS) (C4R07). For the EFU, the DIS version III, 
revised was used. This version of the DIS provided diagnostic algorithms for DSM-III-R. DIS 
interviews were designed to be as similar as possible as to the ones conducted for the ECA. 
Interviews were done by lay interviewers in the respondents’ household (C4R02-05). 
 
S04.P01.S06. Third Phase: Comorbidity and Serotonin Transporter (SERT) Gene Polymorphism  
The sample for this study, the Comorbidity and Serotonin Transporter (SERT) Gene 
Polymorphism, was obtained from the EFU cohort. The selection process intended to 
oversample subjects that had “filtered positive” (RE06), on the ECA or the EFU on selected 
DSM-IIIR psychiatric disorders in the DIS. The seven psychiatric disorders of interest were: 
Major Depressive Disorder, Panic Disorder, Agoraphobia, Social Phobia, Obsessive-
Compulsive Disorder, Alcohol Use Disorders, and Cognitive Impairment. The sample for this 
phase also randomly selected subjects that had not endorsed the aforementioned disorders in 





S04. P01.S07. Schedule for Clinical Assessment in Neuropsychiatry Interview 
Eligible subjects were invited to the Johns Hopkins Hospital for an interview with a 
psychiatrist. The subjects were invited to complete an assessment using the Schedules for 
Clinical Assessment in Neuropsychiatry (SCAN) (C4R08-09). The SCAN was administered by 
board-certified psychiatrists who had undergone a SCAN training course at an official World 
Health Organization SCAN training center. The findings of the DIS were concealed to the 
examining psychiatrists until the SCAN assessment was completed. After the interview was 
concluded, the psychiatrist dictated a 2- or 3-page summary for each subject in a standard 
format that described the subject’s clinical picture, ensured inclusion of important idiosyncratic 
details, and explained possible disagreements with the DIS as well as overall diagnostic 
impressions and decisions that, in the view of the psychiatrist, were not clearly supported by 
the SCAN. The first 20 interviews of each rater were discussed in detail in a conference 
attended by the other interviewing psychiatrists. The rest of the interviews were discussed with 
at least one other interviewing psychiatrist. In the event of a challenging case, a full conference 
was scheduled to review the findings (C4R05-06). 
For the Baltimore ECA follow-up, several items were added to the SCAN, version 1.0. 
Some of these additions were incorporated into the second edition of the SCAN. The following 
items were added in the section of depression: social withdrawal, increase in appetite, age at 
first onset of dysphoria or anhedonia, age at first onset of depressive delusions, organic cause 
of symptoms about thinking and concentration, and age at first onset of sleep problems 
(C4R06). A computer algorithm was written in order to achieve a DSM-III-R diagnosis. This 
algorithm was based on the World Health Organization SCAN algorithm previously written for 
the International Classification of Diseases, 10th Revision (C4R05-06). 
The Schedules for Clinical Assessment in Neuropsychiatry (SCAN) (C4R08-09) was 
developed with the encouragement and support of the Task Force on Psychiatric Assessment 




the accuracy and reliability of measurement and classification of psychiatric disorders. The 
core part of SCAN is the tenth version of the Present State Examination (PSE-10), a semi-
structured interview (C4R08-09). 
The interview is based on clinical "cross-examination" with the aim of discovering whether 
each of a comprehensive list of symptoms is present in the subject and, if so, with what degree 
of severity. This decision is made by the examiner, not by the respondent. For most symptoms, 
a form of questioning is suggested, although the interviewer is free to depart from this and from 
the order of questioning, if necessary, with the goal to obtain clarity (C4R08-09). 
The Present State Examination had its origins in studies conducted in the late 1950s. 
Updated versions were used for large scale international studies as the United States-United 
Kingdom Diagnostic Project, and the International Pilot Study of Schizophrenia. It is important 
to note that, the PSE was originally not a "diagnostic" scale, but an instrument aimed at 
describing psychopathological phenomena comprehensively, precisely, and accurately 
(C4R08-09). 
The PSE-10 is divided into two parts. Part I contains the sections concerned with neurotic 
symptoms, eating, and substance abuse disorders. The second part deals with psychotic 
experiences and affect, speech, and behavior. All these symptoms are rated during the 
examination. In the SCAN, the course of a clinical disorder, for purposes of classification, is 
either regarded as a single "primary" period or divided into two kinds of period, primary and 
secondary. If a single primary period is clinically appropriate (as decided by the examiner), it is 
fairly simple to accumulate the relevant database and apply the nosological algorithms. The 
primary period is further classified into three subtypes: 1) present state, 2) present episode, and 
3) lifetime ever. (C4R08-09). 
In summary, the SCAN enables the collection of symptoms, diagnoses (both current and 
past), as well as treatment history and socioeconomic information, in a way that is both 




data (bottom-up approach), instead of evaluating the presence or absence of pre-determined 
DSM diagnostic criteria (top-down approach). This feature of the SCAN allowed for the collection 
of symptom level and diagnostic information on a wide variety of symptoms and diagnoses on 
a population that was sampled probabilistically from the community. 
 
S04. P01.S08. Genetic Sampling of Study Participants 
Subjects provided a venous blood sample. In the event of refusing to provide a blood 
sample, a swab buccal mucosa swab was obtained. Blood samples collected were placed onto 
a specially formulated “Isocode” Card. DNA was isolated from peripheral blood leukocytes using 
Puregene Blood Kit chemistry on an Autopure LS automated DNA purification instrument 
(Qiagen, Valencia, Calif). Following manufacturer’s protocols, blood collected on Isocode Cards 
was isolated by heating hole punches in distilled water at 95 degrees centigrade for 30min. 
Buccal cell swabs were manually isolated using Puregene DNA isolation kit (Qiagen). 
Manufacturer’s protocols were used in this procedure. DNA concentrations were established 
by spectrophotometry using a DU 530 Life Science UV/Vis Spectrophotometer (Beckman 
Coulter, Brea, California). The serotonin transporter genotype was determined by polymerase 
chain reaction amplification (C4R10). 
 
A total of 602 (74.1%) of the 847 participants provided a DNA sample and were 
genotyped for SERT. The 219 non-genotyped subjects had similar distributions of gender, 
race, and educational level (Table C4AT01). The genotyped sample was slightly younger than 
the non-genotyped sample. Mean age of genotyped sample was 47.19 years old (95% CI: 






The frequencies of SERT polymorphism in the sample was: “l/l”, 280 (44.6%); “l/s”, 274 
(43.6%); and “s/s”, 74 (11.8%). The distribution of the alleles followed the Hardy-Weinberg 
Equilibrium Chi2 (1df): 0.38 (p>0.5).  For the analysis, we combined the “s/s” and “l/s” alleles 
into a carrier group and compared these groups to the non-carrier group that only included 
those with “l/l” genotype (Table C4AT02). This was done following previous literature that had 








CHAPTER 04. PART 02. ANALYTICAL APPROACH 
 
C04.P02. S01. Introduction 
In this section, we will detail the analytical approaches used in the study. Similar 
information is included in each individual chapter. We will list the different aims of each chapter, 
followed by the analytical approaches used  
 
C04. P02. S02. Analytical Approach for Chapter 04. Aim 01: Missing Genetic Information for 
Covariates  
We used univariate Statistics (Chi Square Tests and Fischer’s Exact Test for count data, 
Student’s T-Test for and Wilcoxon rank-sum test for continuous data) to determine whether the 
study participants who provided no sample for genetic testing (non-genotyped sample) were 
significantly different from the subjects who have a sample for genetic testing (genotyped). We 
tested the differences with the following variables that could be a potential confounder. These 
variables included: 1) Age in years, 2) Gender, 3) Race (Dichotomized as Whites vs Non-
Whites), 4) Educational Level (Dichotomous: High School Diploma, No High School Diploma), 
5) Educational Level (Categorical: High School Incomplete, HS Complete, College Incomplete, 
College Complete), 6) Marital Status (Dichotomous: Married versus ingle/ Divorced/ Separated/ 
Widowed)  




 We determined the frequency distribution of Serotonin Transporter Gene (SERT) short 
“s” allele in the sample. We examined whether the allele frequency follows the Hardy-Weinberg 
Equilibrium.  
 
C04. P02. S04. Analytical Approach for Chapter 05. Aim 01. Determine the Lifetime Prevalence 
of the Selected Mental Disorders 
 Using Chi Square Tests and Poisson Regression Analyses, we calculated the lifetime 
prevalence (LP) of selected psychiatric disorders with their corresponding 95% Confidence 
Interval (95%CI) 
 
C04. P02. S05. Chapter 05 Aim 02. Determine the Association of the Individual Mental 
Disorders with the SERT (S) Polymorphism  
 Using Chi Square Tests and Poisson Regression Analyses, we calculated the LP of the 
each mental disorder for the genotyped and non-genotyped sub-samples. Using Poisson 
Regression, we later calculated a Prevalence Rate Ratio for each disorder with their 
corresponding 95% Confidence Interval (95%CI). These Prevalence Ratios measured the 
association of the SERT status with the risk for LP for each condition. 
 
C04. P02. S06. Chapter 05 Aim 03. Determine the Comorbidity of the Individual Mental 
Disorders for the Whole Sample (Genotyped+ Non-Genotyped; n= 847)  
 We first explored the patterns of comorbidity between the individual mental disorders for 




calculated the Odds Ratios for each comorbid pair. This yielded an estimate of the strength of 
the association between the all pair of conditions included in the study sample 
 
C04. P02. S07. Chapter 05 Aim 04. Determine the Association of the SERT (s) Allele with 
Comorbidity of the Individual Mental Disorders  
 We first explored the patterns of comorbidity between the individual mental disorders for 
the SERT (s) allele carrier and the non-carrier subgroups using tetrachoric correlations. Using 
Logistic Regression Analysis stratified by the patients affected by the first selected condition, we 
calculated the odds of comorbidity for the carriers and non-carriers. Thus, for those affected with 
a given condition, we obtained an odds ratio that measured the odds of comorbidity of the 
carriers to be diagnosed with a selected second condition divided by the odds of the non-
carriers to be diagnosed with the same second condition. Using this approach, we were able to 
determine whether the SERT (s) allele carrier status was associated with an increased risk for 
any given comorbidity between the selected conditions. 
 
C04. P02. S08. Chapter 05 Aim 05. Determine the Distribution of Subjects with Multiple 
Diagnoses in the Sample 
We used univariate statistics (Chi Square Test and Fischer’s Exact Test) to determine 
the distribution of participants with multiple LP diagnoses in the sample. We examined the 
association of gender, and age in this distribution 
 
C04. P02. S09. Chapter 05 Aim 06. 5. Determine the Association of the SERT (s) Allele Carrier 




We used Chi Square and Fisher’s Exact Test to we examine the association of the 
SERT (s) allele carrier status with distribution of affected subjects.  
We subsequently grouped the subjects into dichotomous categories according to the 
number of lifetime diagnoses received in order to perform a logistic regression analysis that 
could allow us to adjust for possible confounding variables. In the first analysis, we divided the 
sample into a first group that included the subjects with one or more diagnoses, and a second 
group that included the subjects with no diagnoses. For the second analysis, we divided the 
subjects into a first group that included the subjects who had received two or more diagnoses, 
and a second group that included the subjects who had received one or no diagnoses. We 
performed a Logistic Regression Analysis to determine the risk for the SERT (s) carrier subjects 
to belong to the category that presented with the higher number of diagnoses as compared to 
the risk for the non-carrier subjects. We adjusted the regression models for the effect of gender, 
age, marital status, and ethnicity.  
 
C04. P02. S10. Analytical Approach for Chapter 06: Comorbidity: Methodological Approaches 
In this section, we evaluated the comorbidity burden in the sample using different and 
complementary analytical approaches.  
In the first approach, we examined the ratio between the number of comorbidities and 
the number of diagnoses in each individual mental disorder, as in the sample as a whole.  
In the second approach, we examined the importance or impact of each comorbidity pair 
or dyad. We examined this impact using three different vantage points or perspectives. In the 
first perspective, we analyzed the importance of each comorbidity dyad as measured by their 
overall sample prevalence. In the second vantage point, we analyzed the impact or weight of all 




point, we obtained a measure of the strength of each comorbidity pair with respect to both of its 
integrating mental disorders.  
Lastly, in the third approach, we examined the association between each individual 
disorder and the presence of individuals in the sample that received multiple diagnoses. For this 
last approach, we stratified the individuals in the sample according to the number of diagnoses 
received (0, 1, 2 or more conditions) and we then examined the association of the prevalence of 
the individual conditions in each diagnostic stratum with the number of affected individuals in 
each diagnostic stratum.  
Chapter 06 includes detailed information on all the analytical approaches used for the 
analysis of the burden of comorbidity in the study sample. A mathematical appendix that 
provides further background is also included. 
C04. P02. S11. Analytical Approach for Chapter 07. Part 1. Aim 01; Examine the Time to 
Diagnoses for Selected Disorders in the Whole Sample  
We used the Kaplan-Meier (Product Limit) Approach. Subjects started to accrue 
exposure time at the moment of their birth. The follow-up time ended at the time the respondent 
had the “event” or “failure” of interest: namely, the reported age when they met criteria for the 
selected disorder. Subjects who never met criteria for the selected disorder at the moment of 
the study, were censored at the age of the interview. We used this technique for each selected 
disorder in which we had information of the age of onset in the sample. By calculating the 
quotient between the number of events (first time occurrence of the disorders) and the total 






C04. P02. S12. Analytical Approach for Chapter 07. Part 1. Aim 02: Determine the Association 
of the SERT (s) allele carrier with the Time to Diagnoses for Selected Disorders  
Using Kaplan-Meier Approach, we calculated the events and exposure time both for the 
carriers of the SERT (S) allele and for the non-carrier subjects. We obtained separate Incidence 
Rates for both groups in each condition included in the study. The ratio between the Incidence 
Rates of carriers and non-carries for each condition is a measure of the association of the 
carrier state with the onset of the examined mental disorder.   
We later calculated Log-Rank tests for each condition to estimate whether the survival 
curves (in our case the time to diagnosis) were different between groups: namely, whether the 
carriers had a different time trajectory in attaining each diagnoses under examination 
Finally, we performed a Cox Proportional Hazards Regression Analysis for each 
condition in the study. This approach enabled us to examine the association the SERT (s) allele 
carrier to the survival time (in our case, time to attain diagnosis). The Cox Proportional Hazard 
Regression model also allowed us to adjust the hazard estimates by potential confounding 
variables: namely, gender, ethnicity, and marital status. Thus, using this technique we were able 
to obtain a Hazard Ratio between the carrier and non-carrier participants for each condition 
examined, both unadjusted and adjusted for the aforementioned variables. Lastly, we examined 
whether our analysis for each condition met the proportional-hazards assumption required in the 
Cox Regression Model. 
 
C04. P02. S13. Analytical Approach for Chapter 07. Part 02. Use of Psychotropic Agents and Its 
Association with the Serotonin Transporter Gene Polymorphism 
Using Pearson’s Chi-Square and Fisher Exact Tests, we explored the association of the 




antidepressant medications, anti-anxiety agents, hypnotic agents, antipsychotic agents, and, 
anti-manic agents at the moment of the interview. In addition, we created cumulative categories 
to improve the power of the analyses. We combined anti-anxiety and antidepressant agents into 
one category. Finally, we combined all psychotropic agents that were included in the interview 
into one category to explore if there was any association between the use of any individual 









CHAPTER 05: LIFETIME PREVALENCE AND COMORBIDITY OF PSYCHIATRIC 





C05. S01. Lifetime Prevalence of Selected Disorders 
We examined the lifetime prevalence (LP) of Alcohol Dependence, Alcohol Abuse, Opioid 
Dependence, Schizophrenia and other Psychotic Disorders, Major Depressive Disorders (MDD), 
Bipolar Disorder, Panic Disorder, Agoraphobia, Social Phobia, Obsessive Compulsive Disorder 
(OCD) , Generalized Anxiety Disorder (GAD), Simple Phobia, Dysthymic Disorder, Anxiety 
Disorder Not Otherwise Specified, Depressive Disorder Not Otherwise Specified, and Adjustment 
Disorder with Depressed Mood in the study population using Poisson regression models and Chi 
Square Tests. Table C5T01 summarizes the un-weighted LP prevalence estimates with 95% 
confidence intervals (CI) of the 16 Axis I disorders examined. Column 01 summarizes the 
estimates for the whole sample (N=847), column 02 for the genotyped sub-sample (N=628). The 
disorders with the highest prevalence were: Alcohol Dependence (20.90 (95% CI: 18.32; 23.82)), 
followed by Major Depressive Disorder (17.95 (95% CI: 15.54; 20.73), Simple Phobia (12.51 
(95% CI: 10.47; 14.95)), and Social Phobia (11.81 (95% CI: 9.82; 14.91), respectively. 
 
  
C05. S02 Association of Lifetime Prevalence estimates of the examined disorders with 




We examined the association of the lifetime prevalence of the 16 disorders included in 
this investigation and the SERT polymorphism using logistic regression models. In other words, 
we evaluated whether the carriers of the short (S) allele of the SERT polymorphism had an 
increased risk for receiving a lifetime diagnoses of the 16 disorders examined in this 
investigation  
Table C5T01 summarizes in column 03 the LP estimates of each individual mental 
disorder in the serotonin transporter gene (S) allele (SERT) carrier sub-sample (N=348), and, 
column 04 summarizes the estimates in the SERT non-carrier sub-sample (N=280). Column 05 
summarizes the LP estimates of SERT carriers divided by the LP estimates of the SERT non-
carrier for each disorder. Column 06 summarizes significance estimates (p-values) for each of 
the ratios compiled in column 5. Panic Disorder was the only condition examined in the study 
sample that had a significant ratio (2.61 (95% CI: 1.20; 5.69), p=0.02). Thus, we can state the 
carriers of the (s) in this study sample have a risk of diagnosis with Panic Disorder in their lifetime 
that is 2.61 higher than those who are non-carries of the (s) allele. Lastly, we examined the 
association between the (s) carrier status and the LP estimates of the conditions examined in this 
study stratified by gender (Table C5T02). The association between the (s) carrier status was 
similar for both male (2.1) and female participants (2.79) affected by Panic Disorder. Due to 
difference in sample size for both genders, the ratio was only significant in women.   
In addition, the (s) allele carrier vs non carrier ratio for Bipolar Disorder was 2.21 (Table 
C5T01). This translates into a risk for the (s) allele carriers to be diagnosed with Bipolar Disorder 
twice as high as the one of the non-carriers. Unfortunately, due to the sample size limitation, this 






C05. S03. Summary and Conclusions. Lifetime Prevalence Estimates and their association with 
the (S) carrier allele 
In our sample, the (s) carriers had a statistically significant higher risk of being diagnosed 
with Panic Disorder during their lifetime. This risk was 2.61 higher in those who were carries as 
compared to the non-carriers of the (s) allele.  Carriers for the (s) allele had also twice the risk of 
developing Bipolar Disorder as compared to the non-carriers, but this finding was not statistically 
significant.  Being a carrier of the (s) allele had no association with an increased risk of being 
diagnosed with any other of the examined mental disorders in our study sample. In various 
conditions, namely Agoraphobia, Obsessive Compulsive Disorder, and Dysthymic Disorder, the 
(s) carrier status appears to confer a protective effect (as evidenced by Rate Ratios as low as 
0.64 in GAD) to develop these disorders, although the small number of affected individuals 
precluded from obtaining  statistically significant results. No evidence was found that the (s) allele 
carrier status could have a gender-specific effect.  
 
 
                                                               
C05. S04. Comorbidity between the Lifetime Prevalence of the individual psychiatric disorders 
Table C5T03 summarizes the significant tetrachoric correlations between all the 16 
mental disorders for the whole study sample (N=847). Table C5T04 displays the comorbidity 
odds ratios between the individual mental disorders obtained from logistic regression models for 
the whole study sample. 
We can posit that two patterns of correlations or comorbidities between the individual 




mood disorders and alcohol dependence. In addition, mood disorders had a high degree of 
comorbidity with Alcohol Dependence.  
Agoraphobia, Social Phobia, Obsessive Compulsive Disorder, Generalized Anxiety 
Disorder, and Simple Phobia had a strong correlation with each other and with mood disorders 
(MDD and Bipolar Disorder). As an example, Table C5T04 displays in row(r) 07, column(c) 07, 
the odds of having a lifetime prevalence diagnoses of Panic Disorder is 5.51 times higher in 
subjects that have a lifetime diagnoses of Social Phobia than in those who did not receive this 
diagnosis. In r08, c09, the odds of receiving a diagnosis of OCD during their lifetime was 7.96 
times higher in subjects who have received a diagnosis of Social Phobia than in subjects who 
did not receive this diagnosis.  
Major Depressive Disorder and Bipolar Disorder were highly comorbid with the majority 
of the anxiety disorders. The odds of receiving a diagnosis of GAD during their lifetime was 3.19 
times higher in subjects who have MDD than in subjects without this diagnosis. Bipolar Disorder 
was highly comorbid most anxiety disorders: namely, with Panic Disorder (4.14), Agoraphobia 
(3.76), Social Phobia (2.46), OCD (4.76) and, GAD (3.19). All these comorbidities were robust in 
magnitude and statistically significant despite a relatively low number of subjects affected. The 
odds of receiving a diagnosis of Alcohol Dependence was 1.52 times higher in subjects who 
had a MDD diagnosis, than in those without this diagnosis, and the risk was 2.71 times higher in 
subjects with a lifetime diagnosis of Bipolar Disorder than in those who have not received said 
diagnosis. 
 





Table C5T05 summarizes the significant tetrachoric correlations between all the 16 
mental disorders for the carriers of the (s) allele (N=348). Table C5T06 displays the significant 
tetrachoric correlations between all the 16 mental disorders for the non-carrier subsample 
(N=280). Anxiety disorders accounted for the majority of the significant correlations between 
disorders. Agoraphobia had significant correlations with Panic Disorder (0.4417), and with 
Social Phobia (0.4987) in the (s) carrier subsample (Table C5T05). Major Depressive Disorder 
was highly comorbid with Panic Disorder, as well as other anxiety disorders. 
We examined the association between the (s) allele carrier status and the odds of being 
diagnosed a given comorbidity. When a subject has been diagnosed with two conditions 
(conditions A and B) in his/her lifetime, we describe this phenomenon as the presence of a 
comorbidity pair or dyad. In subjects that have been diagnosed with condition A, we calculated 
both in carriers of the (s) allele, and in non-carriers, the odds of being diagnosed with condition 
B. The ratios of these odds are displayed in Table C5T07. In several cases, the analysis could 
not be done due to insufficient subjects affected. The carrier status was associated with a 
significant increase in the odds for comorbidity in three dyads. For subjects diagnosed with 
Major Depressive Disorder, the carriers of the (s) allele, had a risk for being diagnosed with 
Social Phobia that was 5.13 times higher than the one of the non-carriers (OR: 5.13 (95%CI: 
1.79; 14.74). For subjects diagnosed with Agoraphobia, the carriers of the (s) allele, had a risk 
for being diagnosed with Major Depressive Disorder that was 4.69 times higher than the one of 
the non-carriers (OR: 4.69 (95%CI: 1.11; 19.83). Finally, for subjects diagnosed with Social 
Phobia, the carriers of the (s) allele, had a risk for being diagnosed with Major Depressive 
Disorder that was 4.8 times higher than the one of the non-carriers (Odds Ratio = 4.80 (95%CI: 
1.55; 14.84) 
It is important to underline that the values of the odds ratios of a given comorbidity pair 




carrier with a diagnosis of Major Depressive Disorder had 5.13 times the risk of presenting with 
Social Phobia than the non-carrier subjects affected Major Depressive Disorder. However, if we 
consider the subjects who were carriers and have a diagnosis of Social Phobia, their risk of 




C05. S06. Number of Multiple Diagnoses and Its Association with Gender and Age 
We tallied the number of diagnoses received by individual participants during their 
lifetime. Table C5T11 displays the distribution of the number of lifetime prevalence diagnoses 
for the whole sample (N=847).  
We examined the effect of gender, and age in the distribution of the number of lifetime 
diagnoses in the sample.  Women had a higher burden of comorbidity than men (Table C5T12). 
Individuals over 44 years old had a higher burden of comorbidity as compared to younger 
participants (Table C5T13).  
 
 
C05. S07. Association of SERT carrier status with Number of Diagnosis 
Using Chi Square and Fisher’s Exact Test, we examined the association of the SERT (s) 
allele carrier status with the prevalence of mental disorders.  We examined the effect of the (S) 
allele carrier status in the overall number of lifetime diagnoses in the whole sample (C5T14).  
There were no significant differences in the distribution of the number of lifetime diagnoses 




We subsequently grouped the subjects into dichotomous categories according to the 
number of lifetime diagnoses received in order to perform a logistic regression analysis that 
could allow us to adjust for possible confounding variables. In the first analysis, we divided the 
sample into a first group that included the subjects with one or more diagnoses, and a second 
group that included the subjects with no diagnoses (Table C5T15). For the second analysis, we 
divided the subjects into a first group that included the subjects who had received two or more 
diagnoses, and a second group that included the subjects who had received one or no 
diagnoses (Table C5T16). We performed logistic regression analysis, to determine the risk for 
the carrier subjects to belong to the category that presented with the higher number of 
diagnoses as compared to the risk for the non-carrier subjects. We adjusted the regression 
models for the effect of gender, age, marital status, and ethnicity. We were unable to find an 
association between the SERT (s) allele carrier status and the membership to the groups with a 
higher number of mental disorders (C5T15-16).  
 
 
C05. S08. Summary and Conclusions 
We explored the association of the SERT (s) allele carrier with prevalence and 
comorbidity of mental disorders using several analytical approaches.   
We found a statistically significant association between the (S) allele carrier status and 
an increased risk of receiving a diagnosis of Panic Disorder in our study sample.  
In addition, there was a strong association between the carrier status and the risk of 
being diagnosed with Bipolar Disorder, although the small number of affected individuals 




 Anxiety disorders account for sizeable portion of the comorbidity burden in our sample 
followed by the comorbidity between mood disorders (MDD and Bipolar Disorder) and Alcohol 
Dependence. 
 We found a statistically significant association between the (s) allele carrier state and an 
increased risk for having a comorbidity between Major Depressive Disorder and Social Phobia, 
as well between Agoraphobia and Major Depressive Disorder. 
 We were unable to find any statistical association between the SERT (s) allele carrier 
status and the presence of an increased number of diagnoses, considered globally: namely, the 







                                                                                                                                                                                                                 
CHAPTER 06 COMORBIDITY: MEASUREMENT CHALLENGES  
C06.S01 Introduction 
In this section we will evaluate the diagnostic and comorbidity patterns in our sample. 
Our analysis will be comprehensive and provide a quantitative measure of the degree of 
morbidity present in our study population. Our goal is not to attempt to find any latent factors 
that could explain the observed degree of symptom or diagnostic co-occurrence (C6R01), but to 
measure the diagnostic and comorbidity dynamics of our sample relying only on its observed or 
manifest variables. In order to transcend the mere description of the sample’s characteristics, 
we will develop indicators to measure the overall burden of comorbidity of the individual 
psychiatric disorders and of the whole sample. These developed indicators, based on simple 
statistical principles, will also enable the comparison of the diagnostic and comorbidity patterns 
of the different disorders present within our sample. In addition, they could be used to compare 
diagnostic information between different samples. The overall aim of this investigation is to lay 
the groundwork for the measurement of the burden of comorbidity in different study samples 
that could be used in the future in larger observational studies and clinical trials. 
 
C06.S02. The Effect of Comorbidity on Prevalence Estimates 
Table C6T01A displays the unweighted lifetime prevalence estimates of the 16 selected 
mental disorders examined in our study sample. The column 01 displays the number of subjects 
in the sample diagnosed with each disorder, column 02 shows the unweighted lifetime 
prevalence estimates of each disorder as a percent (Number of Individuals Diagnosed with a 
Disorder/ Total Number of Subjects in the Sample x 100).  Row 17, column 01 displays the Total 




all the affected cases or diagnoses in our cohort. Row 17, column 02 displays the result of the 
quotient between the Total Number of Diagnoses in the sample, and the Total Number of 
Subjects in the sample (868 Diagnoses/ 847 Subjects= 1.0248). This translates into a total 
burden of mental illness in the study sample of 102.48 cases of mental disorders per 100 
individuals in our population.  
The Total Number of Diagnoses yields a tally (N=868) that is greater than the Total 
Number of Individuals in the sample (N=847). This rift between the number of diagnoses and 
the number of individuals becomes even more substantial when we consider that there is a 
large number of individuals in the sample who did not receive any diagnoses (N=355). If we 
exclude these 355 individuals from Total Number of Individuals in the Sample, we are left with a 
smaller group that we can categorize as the Total Number of Individuals Diagnosed (N= 492). 
These 492 are the number of individuals that are the source of the 868 diagnoses in the sample. 
This substantial difference between the number of individuals diagnosed and the number of 
diagnoses clearly indicates a high burden of comorbidity in our study sample. Thus, a more 
comprehensive examination of the extent of the burden of comorbidity becomes a crucial next 
step in order to better understand the distribution of the psychiatric morbidity in our study 
sample. 
 
C06.S03. Methodological Issues  
When an individual is diagnosed with a Condition A and a Condition B in his/her lifetime, 
we have identified a “comorbidity pair” or “comorbidity dyad”. When we estimate the weight of 
the comorbidity phenomenon associated with the individual disorders, we need to count this 
comorbidity dyad once as a comorbidity of the Condition A, and a second time as a comorbidity 




the understanding of the comorbidity phenomenon, as it enables us to evaluate  the proper 
association between the individuals affected, the diagnoses, and the comorbidity burden. 
As an example and to clarify the described concepts above, table C6T01B displays a 
hypothetical sample of 10 individuals. Individuals 01, 02 and 03 received no diagnoses. 
Individuals 04 and 05 have been only diagnosed with Condition A, individual 06 has been only 
diagnosed with Condition B. Individual 07 has been diagnosed with 2 conditions: Condition A, 
and B. Individual 08 has been diagnosed with 2 conditions: Condition A, and C. Individual 09 
was diagnosed with 3 conditions: Conditions A, C, D. Lastly, Individual 10 has been diagnosed 
with 3 conditions: conditions B, C, and D. We can more thoroughly describe this hypothetical 
sample using some of the above described concepts as follows: total Number of Individuals in 
the sample (also known as Sample Size) =10.  The total number of Individuals Diagnosed= 7. 
The Total Number of Diagnoses = 13.  The Total Number of Comorbidities in the sample =16. 
Discriminating the comorbidity count by subjects: Individual 07 accounts for 2 comorbidities, 
Individual 08 accounts for 2 comorbidities, Individual 09 accounts for 6 comorbidities, lastly, 
Individual 10 accounts for 6 comorbidities. Discriminating the comorbidity count by diagnoses: 
Condition A accounts for 4 comorbidities, Condition B accounts for 3 comorbidities, Condition C 
accounts for 5 comorbidities, and finally, condition D accounts for 4 comorbidities.  Figures 01A, 
01B, and 01C display the counting of the comorbidity dyads by individual and by condition, 
according to the number of diagnoses present.   
 
C06.S04. Three Complimentary Approaches for the Examination and Analysis of Comorbidity  
In order to perform a comprehensive analysis of the comorbidity burden in our study 
sample, we will use three complementary approaches. In the first approach, we will examine the 




condition, as well as in the whole sample. In the second approach, we will examine the 
importance or impact of each comorbidity pair or dyad. This impact will be analyzed using three 
different vantage points or perspectives. In the first perspective, we will analyze the importance 
of each comorbidity dyad as measured by their overall sample prevalence. In the second 
vantage point, we will analyze the impact or weight of all comorbidity pairs to each of their 
integrating or member disorders. In the third vantage point of the second approach, we will 
obtain a measure of the strength of each comorbidity pair with respect to both of its integrating 
disorders. Lastly, in the third approach, we will examine the association between each individual 
disorder and the presence of individuals in the sample that received multiple diagnoses. For this 
last approach, we will stratify the individuals in the sample according to the number of 
diagnoses received (0, 1, 2 or more conditions) and we will then examine association of the 
prevalence of the individual conditions in each diagnostic stratum with the number of affected 
individuals in each diagnostic stratum.  
 
 
C06.S05. Graphical Display of the Data:  The Comorbidity Matrix Table 
In order to have a thorough review of comorbidity between mental disorders in our 
sample, we displayed the sample’s complete comorbidity and diagnostic information in Table 
C6T02A. We labeled this table as a Comorbidity Matrix. This table enabled us to calculate the 
number of comorbidities for each disorder and for the whole sample. We plotted in rows and 
columns 1 through 16 the individual mental disorders. The numbers that are displayed in each 
cell are the number of comorbidity pairs or dyads. These represent the number of subjects in 
the sample that were diagnosed in their lifetime with the two conditions that are listed in the 




30 comorbidity pairs representing 30 subjects in the sample that were diagnosed both with 
Alcohol Dependence and Social Phobia (row(r)01, column(c)08; as well as in r08, c01). There 
are 32 comorbidity pairs or dyads that represent 32 subjects diagnosed with Social Phobia and 
Major Depressive Disorder (r03, c08; as well as in r08, c03). The main diagonal represents the 
intersection of the identical disorders (e.g. Alcohol Dependence vs. Alcohol Dependence). 
These cells (r01, c01; r02, c02; … r16, c16) read all “N/A” for “Non- Applicable” as a condition 
cannot be comorbid with itself  The cells of the row 17 from columns 01 through 16, as well as 
the cells of the column 17 from rows 01 through 16 display the total number of comorbidities for 
each individual disorder. Row 17 from c01 through c16 displays the total number of subjects 
diagnosed for each individual mental disorder (identical to the information displayed in row 01 of 
Table C6T01A). As an example, there were a total of 186 comorbidities tallied for those 
diagnosed with Major Depressive Disorder (r17, c03; and r03, c17). There were 152 subjects 
diagnosed with Major Depressive Disorder (r18, c03). Summarizing, we can posit that there 
were 152 individuals diagnosed with Major Depressive Disorder in the sample, and these 152 
individuals were also diagnosed with an additional mental disorder on 186 occasions. The cell in 
row 17 and column 17 display the Total Number of Comorbidities in the sample (N=1146). The 
cell in the intersection of row 18 and column 17 displays the Total Number of Diagnoses in the 
sample (N=868).  
Table C6T02A shows that most of the mental disorders have substantial comorbidity 
with each other. We can posit that comorbidity seems to be more the norm than the exception. 
Most of the individual disorders show a number of comorbidities that exceeds the number of 
subjects diagnosed with the primary condition. There are few empty cells. The only pattern we 
can see in the empty cells is the one that belongs to the identity diagonal (Disorder A vs 
Disorder A), and the cells that belong to the intersection of disorders that the Diagnostic and 




(e.g., Major Depressive Disorder or Dysthymic Disorder should not be diagnosed on a subject 
that has received a diagnosis of Bipolar Disorder).  
 
 
C06.S06. First Approach: Examination of the Comorbidity to Diagnoses Ratio.  
Our goal is to quantify the extent or burden of comorbidity for each individual disorder 
and for the whole sample in a manner that could be less influenced by the differences in 
prevalence of the individual disorders included in the analysis. For that purpose, we calculated a 
ratio between the number of comorbidities and the number of diagnoses for each condition, as 
well as for the total sample. We branded this ratio as the Comorbidity to Diagnosis Inflation 
Ratio (CDIR). We have chosen the term inflation, as it depicts the expansive effect that 
comorbidity can introduce in the diagnostic estimates. We borrowed this term from the field of 
economics as the causes and effects of comorbidity in psychopathology can be seen as 
analogous to the ones of inflation in the economy. Classical monetary theory (C6R03) posits 
that inflation can develop when the monetary authority of a country issues an excess of 
currency into its marketplace. This creates an excess of demand for the same number of goods 
that previously existed. Plainly described, there is more money available to buy the same 
number of goods. This excess of demand creates an increase in the price of goods. The 
practical effect is that the consumer will eventually need more currency bills or notes (plainly 
speaking more paper money) to buy the same number goods that a person was able to buy in 
the past for less. Analogous to this, the complexity of the field of psychopathology, and the 
shortcomings of our modern diagnostic classifications have conspired to create a condition that 
is similar to inflation. In order to increase coverage, our modern psychiatric classifications have 




newly created diagnostic label has an implicit value that can only become explicit when it is 
used to diagnose individuals. The excess in demand created by each new diagnosis lowers the 
value of the already established psychiatric disorders. The “old” or established diagnoses 
continue to be used concurrently with the new ones as they describe conditions that could be 
similar, but not identical, to the conditions covered by the new diagnoses. The end result of this 
diagnostic “excess” creates a new balance, in which there is a need to use a higher number of 
diagnoses than the one used in the past to complete the “purchase” of an individual 
psychopathology (or of the community psychiatric burden if considered at a macro level).  
 
C06.S07. The Comorbidity to Diagnoses Inflation Ratio (CDIR) 
The Comorbidity to Diagnoses Inflation Ratio (CDIR) of the whole sample is the quotient 
between the Total Number of Comorbidities (N=1146) and the Total Number of Diagnoses (or 
Subjects Diagnosed) (N=868). The CDIR for the whole sample yielded a value of 1.32. This 
value indicates that there is a ratio of 132 comorbidities per 100 diagnoses in our sample.  We 
later standardized the CDIR of each disorder using the CDIR of the whole sample as 
denominator. With the standardized CDIR (SCDIR) we were able to clearly identify those 
conditions that exceeded the value of the total sample in their comorbidity burden. By 
standardizing the information, we were more confident in obtaining an instrument that could 
yield results that could be used to compare between conditions. By examining the table 
C6T02A, we can clearly see that the Anxiety Disorders had the highest burden of comorbidity in 
the sample. Obsessive Compulsive Disorder, with a CDIR of 2.5, was the psychiatric condition 
with the highest value. This means that for every 10 diagnoses of Obsessive Compulsive 
Disorder (OCD), there were 25 comorbidities of OCD with other psychiatric disorders. The 
SCDIR for OCD yielded a value of 1.89. This value indicates that OCD had a comorbidity 




decreasing burden, there were three anxiety disorders, Agoraphobia:  CDIR = 2.12 and SCDIR= 
1.61; Social Phobia: CDIR=1.65 and SCDIR=1.25; and, Panic Disorder: CDIR= 1.61 and 
SCDIR= 1.22.  
 
C06.S08. Second Approach: Examination of the Impact of Each Comorbidity Dyad 
As mentioned before, in this second approach we will analyze the importance of each 
comorbidity pair or dyad. The impact of a comorbidity dyad can be analyzed from the three 
different vantage points already described. 
 
C06.S09.Second Approach, First Vantage Point: Examination of the Impact of Each 
Comorbidity Dyad for the Whole Sample  
The goal of the first vantage point is to determine the weight of each comorbidity pair for 
the sample as a whole. If we define a comorbidity dyad as integrated by Condition A and 
Condition B, in this approach we examined the probability or prevalence of the joint probability 
of Condition A and Condition B (PA∩B) in the whole sample. The analysis from this vantage 
point provides us information about the comorbidity dyads that are more frequent in the sample. 
In a prevalence study with careful sampling methodology, this approach might provide 
information about the impact of a particular comorbidity for the population as a whole. Table 
C6T02B displays the prevalence of the comorbidity pairs as a percentage to the total number of 
individuals in the sample (N=847). The comorbidity pair with the highest prevalence (0.0484 or 
4.84%) was composed by the individuals diagnosed with both Major Depressive Disorder and 
Alcohol Dependence (r01, c03 and r03 c01). The second highest pair was the one comprised by 
the individuals diagnosed with both Major Depressive Disorder and Social Phobia (r03, c08 and 




dyads included the mental disorders with the highest prevalence in the sample. We were able to 
detect a pattern in which the absolute prevalence of each comorbidity pair was largely explained 
by the prevalence of the disorders that composed it. This approach might prove useful to detect 
which comorbidity is important from a population perspective.  
 
 
C06.S10.Second Approach: Second Vantage Point. Examination of the Impact of the 
Comorbidity Dyads on Each of Its Integrating Disorders  
The second vantage point examined the impact of the comorbidity pairs on each of their 
member disorders. If we define a comorbidity dyad as composed by Condition A and Condition 
B, our analysis in this approach yielded two different values. The first value can be defined as 
the probability of Condition B, given condition A. It can be estimated by dividing the joint 
probability of Condition A and Condition B (prevalence of the comorbidity) by the probability  of 
Condition A (or prevalence of Condition A) (PA∩B / PA). The second value can be defined as 
the probability of Condition B given Condition A. It can be estimated by dividing the joint 
probability of Condition A and Condition B divided by the probability of Condition B (PA∩B / PB). 
In layman terms, this approach will inform how common it is to suffer from Condition B for a 
patient that is already affected by Condition A (and vice-versa). The two values provided will be 
less influenced by the overall prevalence of the Conditions A and B. In addition, the two values 
can differ greatly. As an example, there are 32 subjects in the sample that presented with Major 
Depressive Disorder and Social Phobia (r03, c08; and r08, c03). This comorbidity dyad was one 
of the most prevalent in the sample (32/ 847= 0.0378), though it only represents 21.05% of the 
total diagnoses for the subjects with Major Depressive Disorder, and the 32.00% of the total of 




between Alcohol Dependence and Bipolar Disorder in the sample (r01, c04; and r04, c01). 
Although this comorbid dyad had a relatively low overall prevalence in relation to the total 
sample (9/847= 0.0106), it represents 40.91% of the diagnoses for Bipolar Disorder. Due to the 
difference in prevalence between the 2 disorders, it only represents 5.08% of the total 
diagnoses of Alcohol Dependence. The high burden that this comorbidity dyad had on Bipolar 
Disorder provided evidence that should be addressed at a research and at a clinical level. The 
information this approach provided is germane to the field of psychopathology. A comorbidity 
that has such a high impact in the prevalence of any given disorder may indicate a common 
etiological mechanism, or a measurement problem (in this example it can bring into 
consideration whether alcohol abuse should be considered a symptom criteria for Bipolar 
Disorder). If this high degree of comorbidity is consistent with other studies, any clinical 
institution dealing with patients affected with Bipolar Disorder should be aware of the increased 
risk of their patients to suffer from Alcohol Dependence as well. In contrast, due to the 
differences in prevalence rates between the two conditions, this comorbidity dyad was not highly 
important for those affected with Alcohol Dependence. Thus, when dealing with a population of 
primary Alcohol Dependence patients, Bipolar Disorder might not be in the main focus when 
considering research and clinical interventions. The unequal impact that a given comorbidity 
pair can have on its integrating disorders should be considered when selecting the source of the 
population in the sampling process. Any sample that derives from a clinical source should be 
controlled for the unequal odds of a second disease that some individuals bring in to the 
sample. 
In order to capture the impact of the comorbidity dyads for each of their integrating 
disorders, we designed Table C6T02C Comorbidity and Diagnosis Composition as Row 
Percentage.  Rows 01 through 16 display the comorbidity composition (as percentages) of the 




how the rest of the mental disorders impact on the comorbidity make-up of Major Depressive 
Disorder. In probability terms, the value in each cell represents the conditional probability of the 
condition that appears in the heading of the column given the condition that appears in the 
heading of the row. As an example, the conditional probability of Social Phobia, given the 
subject has Major Depressive Disorder is 32/152= 0.2105 or 21.05% (r03, c08).  On the other 
hand, the conditional probability that a subject has Major Depressive Disorder given he/she has 
Social Phobia is 32/100= 0.32 or 32% (r08, c03). The table is useful as it can quickly display the 
impact of all comorbidity pairs on each of its member disorders. 
 
 
C06.S11. Second Approach: Third Vantage Point. Examination of the Strength of Each 
Comorbidity Dyad with respect to both of Its Member Disorders  
In this third vantage point, our goal was to obtain a single measure of the strength of the 
association between each comorbidity dyad and its two integrating conditions. In order to obtain 
a quick summary measure, we created a ratio of probabilities. We labeled this indicator as a 
Ratio of Conditional to Marginal Probabilities (RCMP). This ratio holds several statistical 
characteristics and it is relatively easy to compute for all conditions using the Comorbidity Matrix 
Table as a source. 
The results of the RCMP for all comorbidity dyads are displayed in table C6T02D. The 
values in the cells can be described in several ways. As an example, we can state that 
comorbidity dyad is integrated by Condition A and Condition B. The values can be seen as the 
joint probability of Condition A and Condition B divided by the product of Condition A and 
Condition B (P A∩B / PA×PB). This ratio can also be expressed as PA/B / PA the conditional 




In probability terms, the ratio of PA/B /PA is identical to PB/A / PB, the conditional probability of 
Condition B given A divided by the Probability of Condition B, this feature makes the value of 
the indicator the same whether we are considering the impact of the comorbidity pair on 
Condition A or Condition B. In addition, this indicator can also be expressed as the observed 
prevalence of the comorbidity pair divided by its expected prevalence. The observed prevalence 
of the comorbidity dyads is identical to the Joint Probability Prevalence, expressed in Table 
C6T02B as a prevalence proportion. The expected prevalence calculated as computed as 
(Prevalence of Condition A) x (Prevalence of Condition B) / Sample Size).  
The range of values for the RCMP span from 0 to the inverse of the prevalence 
proportion of condition member of the dyad with the highest prevalence. A value of 0 indicates 
that the dyad’s member disorders share no common cases. From 0 through 1 the value 
indicates that the 2 conditions members of the comorbidity dyad have a negative tendency to 
co-occur. A value of 1 indicates that the two conditions have a neutral tendency towards 
comorbidity. In probability terms a value of 1 indicates that the ratio of the conditional probability 
of Condition A given B divided by the marginal probability of the Condition A is identical (PA/B / 
PA =1). In probability terms, this indicates that Condition A and Condition B are independent, 
and all co-occurrence between them is due to chance alone. A value of the RCMP higher than 1 
indicates that the conditional probability of Condition A given B is higher than the marginal 
probability of Condition B. In observed vs expected language, a value over 1 indicates that the 
prevalence of the observed comorbidity of Condition A and Condition B (PA∩B) is higher than 
the prevalence that should be expected if Conditions A and B are fully independent (PA×PB / 
Sample Size). Thus, a value higher than one suggests that there is an association of the two 
conditions that is higher than the one expected by chance alone.  
 In table C6T02D, r01, c03 and r03, c01, we can read the value of 1.29. This can be 




with Alcohol Dependence divided by the probability of a diagnoses of Major Depressive 
Disorder in the whole sample. It can also be described as the probability of a diagnoses of 
Alcohol Dependence in individuals already diagnosed with Major Depressive Disorder divided 
by the probability of Alcohol Dependence in the whole sample. 
Table C6T02E, reports the Odds Ratio (OR) values of all comorbidity pairs (those that 
had common cases). If we compare the OR estimates to the Ratio of Conditional vs Marginal 
Probabilities, we can see that the RCMP values have the same direction that the ORs, being 
somewhat more conservative. The ORs have the added advantage of a significance testing, 
although they are far more time demanding in their execution than the RCMP. The RCMPs are 
easily calculated by row and column operations and can be used in a descriptive initial 
approach to examine the diagnostic patterns of a given sample 
If we examine tables C6T02D and C6T02E we can see that several anxiety disorders, 
including Panic Disorder, Agoraphobia, Social Phobia, Obsessive Compulsive Disorder, and 
Generalized Anxiety Disorder had both the highest number of comorbidities and the highest 
value for both the RCMPs and the ORs. These conditions are comorbid with the disorders s with 
highest prevalence (Major Depressive Disorder, Social Phobia, Alcohol Dependence), in 
addition, these conditions are highly comorbid with each other. The RCMP values for the dyads 
of these conditions are the highest as their upper value of their range is determined by the 
inverse of their prevalence proportion.  As the prevalence proportions of these conditions are 
low, their inverse is high when compared to the ones of more prevalent conditions. 
  
C06.S12.Third Approach: Analysis of the Association between the Prevalence of Each 




In the previous approaches, we have centered our analyses in the prevalence of 
diagnoses and comorbidities without consideration to the affected individuals. As these affected 
individuals are the source of all clinical information, the analysis of the association between 
affected individuals and diagnoses is a crucial step towards a better understanding of 
comorbidity phenomenon. In this third approach, we will analyze the patterns of multiple 
diagnoses in the sample, and attempt to determine the relationship between individuals 
diagnosed, diagnoses, and comorbidities for all the individual disorders as well as for the whole 
sample.  
We stratified the individuals of the whole sample according to the number of mental 
disorders that they have been diagnosed. We divided the subjects into 7 diagnostic groups, as 
the highest number of mental disorders diagnosed in a single individual was 6. The first 
Diagnostic Group (DG0) included 355 individuals that had received no psychiatric diagnosis in 
their lifetime. The second Diagnostic Group (DG1) comprised 255 individuals who had received 
only one mental disorder diagnosis (any of the 16 mental disorders), the third Diagnostic Group 
(DG2) included 143 subjects who had received any 2 mental disorder diagnoses in their lifetime, 
the fourth Diagnostic Group (DG3) comprised 61 subjects who had been diagnosed with 3 
mental disorders, the fifth Diagnostic Group (DG4) included 22 subjects who had each received 
4 mental disorder diagnoses in their lifetime, the Diagnostic Group (DG5) or stratum comprised 
10 subjects who had each received 5 diagnoses, and the final and seventh Diagnostic Group 
(DG6) included only one member, who was diagnosed with 6 disorders.  
Table C6T03A details this grouping or stratification of the 847 individuals in the sample. 
Column 01 displays the individuals that did not receive any psychiatric diagnosis. Columns 02 
through 07, rows 01 through 16 display the number of subjects diagnosed in each diagnostic 
group, the cells of column 08 display the total diagnoses for the individual mental disorders. 




DG1=255, DG2=286, DG3=183, DG4=88, DG5=50, and DG6=6) and by the total sample 
(N=868). Row 18 displays the number of individuals that received a diagnosis in each group 
(DG0=0, DG1=255, DG2=143, DG3=61, DG4=22, DG5=10, and DG6=1) as well as in the total 
sample (N=492). Row 19 displays the number of individuals in each group (as discussed above) 
and in the total sample (N=847). The information in these rows helps in a more comprehensive 
understanding of the dynamics or patterns behind individuals and diagnoses in the sample. 
In order to further understand the dynamics of comorbidity, we presented the diagnostic 
counts on table C6T03A as row percentages in table C6T03B. Considering the cells of rows 17 
through 19, columns 01 through 07, we see that comorbidity entails a pattern of under-
representation of a majority of the individuals of the sample. This under-representation is due to 
the focus placed on the number of diagnoses or clinical data, ignoring the number of individuals 
that these clinical data represent. As an example, DG1 contains 51.83% (r19, c02), of the total 
individuals of the sample that have received a psychiatric diagnosis. Paradoxically, this group 
only represents 29.38% (r17, c02) of the total diagnoses present in the sample. If we combine 
the values of DG0 and DG1, the comparisons become even more striking. By adding the values 
of the cells for row 19 and columns 01 and 02 (41.91 + 30.11 = 72.02%). We can state that 
72.02% of all individuals in the sample have received either one or no diagnoses. This sizable 
part of the sample is providing only 29.38% of all the number of diagnoses in the sample. We 
can state that the sample is ruled by a 70/30 ratio. There is a 70% of the sample that provides 
30% of clinical information, and vice-versa. The importance of the G0 is crucial in this ratio. The 
29.38% (r17, c02) also represents the percentage of all diagnoses originated from individuals 
who do not have any additional mental disorders. These should be considered the “pure cases” 
free of any comorbidity. We can affirm now that these “pure cases” represent only a minority, or 




If we consider the values for DG1 for the psychiatric conditions individually, we can 
appreciate that Alcohol Dependence (38.985), Alcohol Abuse (50%), Major Depressive Disorder 
(32.89%), Bipolar Disorder (36.36%), Dysthymic Disorder (33.33%) Depressive Disorder NOS 
(38.89%), have row percentages that largely exceed the value of the whole DG1 (29.38%). We 
can posit that the individual disorders that appear in DG1 at a rate higher than the average have 
a low propensity to be comorbid. On the opposite end, we can state that the disorders that 
appear at a higher rate than the average in DG3 through DG7 have a tendency towards 
comorbidity. From columns 04 through 07 in table C6T03B we see that that Agoraphobia, Social 
Phobia, Obsessive Compulsive Disorder, and, Generalized Anxiety Disorder are over-
represented in the groups with high number of diagnoses. We can postulate that these mental 
disorders are those with the highest comorbidity propensity in the sample (that is consistent with 
the CDIR results). Thus, we need a proper tool to measure this over-representation in order to 
accurately measure the comorbidity burden in each individual condition included in the sample.  
 
C06.S13.Proposed Method: Adjustment of the Diagnostic Information and Ratio Method                                                                                                                               
Our findings suggest that the burden of comorbidity could be defined as a state of over-
representation of the clinical information from subjects with a high number of diagnoses. We 
propose a two-step method that could measure this over-representation. In the first step, we 
would adjust the clinical information to the individual level, creating a scenario that could act as 
a counterfactual state of this over-representation. In its second step, the method will measure 
the difference between the original diagnostic information with the one obtained by this 
adjustment method.  The adjustment consisted in granting to every individual in the sample only 
one diagnostic allowance. This allowance or quota would have the same weight for every 
individual in the sample, whether they were found to have one mental disorder, or many. If an 




half. The second step would perform a ratio of the original diagnostic information to the one that 
resulted from this adjustment. The working premise was that a condition with a high burden of 
comorbidity would have a higher number of subjects affected in the diagnostic groups that 
allocated individuals with multiple diagnoses. This would translate into a more profound effect of 
the adjustment. Thus, the value of the original over adjusted ratio would be the highest on the 
conditions that had the highest degree of comorbidity. 
Using Major Depressive Disorder as an example, there are 152 subjects that had a 
lifetime prevalence diagnoses for Major Depressive Disorder. This value is the result of the 
addition of 50 diagnoses from individuals in DG1, 48 diagnoses from individuals in DG2, 33 
diagnoses from individuals in DG3, 13 diagnoses from individuals in DG4, 7 diagnoses from 
individuals in DG5, and 1 diagnosis from individuals in DG6. As the individuals in DG2 have 
each provided 2 diagnoses to the analysis, the adjustment method calls for dividing their 
information by 2, reducing the value of each diagnosis originated in the DG2 to ½. This 
reduction will be done in a progressive fashion until we reach the DG with the highest diagnoses 
per individual. In our sample, every diagnosis of the DG6 subjects will be weighted down to 
down to 1/6. The result of this method would adjust the lifetime prevalence count for Major 
Depressive Disorder to 89.82. By calculating the ratio of the cumulative adjusted diagnoses to 
the cumulative or total unadjusted diagnoses of MDD, we can state that the adjustment in Major 
Depressive Disorder deflated 59% of all diagnostic information (89.82 / 152=0.59). The value of 
the ratio of unadjusted diagnostic information over adjusted diagnostic information was 1.69. 
Table C6T03C displays the results of this deflationary adjustment method. Column 01 
displays the unadjusted number of diagnoses. Column 02 displays the same values after the 
adjustment method. Column 03 displays the proportion of the unadjusted estimate that 




the ratio of unadjusted vs adjusted diagnoses. Column 05 presents the previous ratio, adjusted 
by ratio the total sample.  
 
 
C06.S14. The Diagnostic Inflation Ratio (DIR)  
As we can see in table C6T03C, the adjustment had the goal to shrink the Total Number 
of Diagnoses (N=868) (r17, c01), to be identical to the Total Number of Individuals Diagnosed 
(N=492) (r17, c02). The “deflated” diagnostic information proportion left after the adjustment for 
the total sample was 0.57 (r17, c03) (this is analogous to positing that the adjustment or 
deflation for the diagnostic information of the whole sample was 43.32%).  The ratio between 
unadjusted and adjusted for the whole sample, that we will call for consistency purposes, the 
Diagnostic Inflation Ratio (DIR) was 1.76. This value can also be obtained by dividing the Total 
Number of Diagnoses (N=868) by the Total Number of Individuals Diagnosed (N=492). In 
essence, we can state that this value represents the ratio between the Diagnoses and the 
Individuals Diagnosed. In probabilistic terms the DIR is the average or expected number of 
diagnoses that we would find in an individual that has been diagnosed with a mental disorder in 
his/her lifetime, selected at random from the sample. The value of 1.76 for the DIR of the whole 
sample means that we can expect that any individual from the sample selected at random from 
DG1 through DG6 would have an expected number of 1.76 diagnoses. This ratio can provide a 
quantitative indicator of the comorbidity burden of the sample that could be compared with 
values obtained from other samples, as well as between disorders within the sample. It can be 
also used to compare the effect of including or excluding any individual or group of mental 




individual in the sample diagnosed with OCD is selected at random (from DG1 through DG6), 
this individual will be affected, in average, by 2.82 conditions. 
In order to compare the DIR between disorders, we standardized the DIR of each 
disorder, using the DIR of the whole sample as norm (same method we used for the CDIR). The 
standardized ratios in column 05 indicate that the anxiety disorders (Panic Disorders DIR= 2.07, 
SDIR= 1.18, Agoraphobia DIR=2.45, SDIR=1.39, Social Phobia DIR=2.11, SDIR=1.19, 
Obsessive Compulsive Disorder DIR=2.82, SDIR=1.6, and, Generalized Anxiety Disorder 
DIR=1.99, SDIR=1.13 were the conditions that suffered the most extreme adjustments, 
indicating that these are the mental disorders that have the highest propensity towards 
comorbidity. These results are consistent to the results obtained by the Comorbidity to 
Diagnosis Inflation Ratio.   
 
 
C06.S15. A Proposed Measure of Comorbidity: The Comorbidity Inflation Ratio (CIR) 
We wanted to measure the relationship between the adjusted number of diagnoses (that 
was deflated to be identical to the number of individuals diagnosed in the sample) and the 
number of comorbidities. For that purpose we calculated a ratio between the number of 
comorbidities for each disorder and the adjusted number of diagnoses, and the ratio between 
the Total Number of Comorbidities and the Total Number of Individuals Diagnosed for the whole 
sample. For consistency purposes, we called this measure the Comorbidity Inflation Ratio (CIR). 
This crude measure is intended to quantify the average or expected number of comorbidities 
per individual diagnosed. In our sample the CIR was 2.33 (r17, c07). This value indicates that 
any individual selected at random from the sample (from DG1 through DG6) will have an 




different if we make it contingent to a particular condition. As an example, any individual with 
diagnoses of OCD picked up at random will have an expected number of comorbidities of 7.05. 
 We later normalized the CIR of the individual disorders with the CIR of the total sample. 
This enabled us to compare the individual disorders. The results of the Comorbidity Inflation 
Ratio (CIR) and its standardized version (C6T03C column 08) are consistent with the findings 
for the Diagnostic Inflation Ratio. The anxiety disorders are the conditions that have the highest 
values of CIR and SCIR. Specifically, Panic Disorder (CIR: 3.36, SCIR: 1.43), Agoraphobia 
(CIR: 5.20, SCIR: 2.30), Social Phobia (CIR: 3.47, SCIR: 1.49), Obsessive Compulsive Disorder 
(CIR: 7.05, SCIR: 3.02) and Generalized Anxiety Disorder (CIR: 3.50, SCIR: 1.50) are the 
individual conditions whose comorbidity burden largely outweigh both the rest of the disorders 
and the average burden for the whole sample.  
The cells in column 09 display the unadjusted lifetime prevalence estimates for each 
disorder (rows 02 through 17) (identical to the ones of Table C6T01A), and the overall burden 
for whole sample (c06, r18). The cells in column 10 display the corresponding estimates after 
the proposed adjustment. These adjusted lifetime prevalence estimates could serve as a good 
reference of a counterfactual state in which comorbidity would be restricted in the classification. 
 
C06.S16. Significance Test for Individual Disorders 
In the previous section, we proposed the Diagnostic Inflation Ratio (DIR), and 
specifically its standardized version (SDIR), as a measure of the comorbidity burden of each 
individual mental disorder in the sample. We believe that these instruments could be useful in 
describing the comorbidity, although they lack a measure of statistical significance.  
In order to establish this statistical significance, we performed a chi square and exact 




distribution of the individuals diagnosed with Alcohol Dependence across the diagnostic strata. 
We performed Chi Square and Fisher Exact Tests for each disorder, analyzing the diagnostic 
counts of each disorder in the DG1 through DG6 against the rest (obtained by subtracting the 
diagnostic counts of the disorder under examination from the Number of Total Diagnoses in 
each DG). The results are very consistent with the results of the Diagnostic Inflation Ratio. 
Disorders that are under 0.80 or over 1.10 of the standardized DIR have significant results in the 
Fisher’s Exact Test. In Table C6T03E we see that Alcohol Dependence, Agoraphobia, Social 
Phobia, Obsessive Compulsive Disorder, and Generalized Anxiety Disorder have all significant 
results in both the Chi Square and the Fisher’s Exact Tests. These results indicate that the 
diagnostic distribution across the diagnostic groups or strata of these disorders differs 
significantly from the distribution of diagnoses of the sample. In the case of Alcohol Dependence 
(SDIR: 0.89), the results indicate that the individuals diagnosed with this condition tend to have 
less comorbidities (this be less frequent in DG3-DG6). In the case of the other disorders, the 
results indicate that these conditions tend to have relatively more individuals diagnosed in the 




C06.S17.The Dynamics between Diagnoses and Comorbidities in a Sample 
Table C6T04 displays the information on diagnosis and comorbidity by diagnostic groups 
or strata. This table is essentially identically to the Table C6T03A with the addition of the 
information on comorbidities in the strata and in the whole sample to the right of the diagnostic 
information. This table enables visualization of the relationship between individuals, diagnoses, 




  The cells of row 20 display the number of individuals in each diagnostic group. The cells 
of row 19 display the number of individuals diagnosed in each diagnostic group. We see that the 
relationship between the two is simple. The difference between them is that the former counts 
the individuals that have received no diagnosis (DG0). These individuals could have an 
importance for the overall prevalence estimates but have no bearing in this analysis, as they do 
not contribute any diagnostic information. Thus, we should consider the Total Number of 
Individuals Diagnosed (N=492) as the primary or fundamental total count. The cells of row 17 
from columns 01 through 14 display the number of diagnoses for each diagnostic group. In r17, 
c15 we see the Total Number Diagnoses (sometimes called subjects affected, or subjects 
diagnosed) (N= 868). Row 18 from columns 01 through 15, displays the number comorbidities 
for each diagnostic group. In r18, c16 we can see displayed the Total number of Comorbidities 
(N= 1146). Thus, while rows 17 and 18 enables us to see the progressive accumulation of 
diagnoses and comorbidities in the sample, row 19 displays the number of individuals in each 
strata that is the source of this clinical information. FigureC6F02 shows the distribution of the 
number of diagnoses, the number of comorbidities, and, the number of Individuals in the 
sample, stratified by Diagnostic Group or Strata. 
 
 
C06.S18. Dynamics of the Relationship between Total Number of Individuals Diagnosed, Total 
Number of Diagnoses and Total Number of Comorbidities. Random and Fixed Elements  
The relationship between the Total Number of Individuals Diagnosed with the Total 
Number of Diagnoses and the Total Number of Comorbidities can be understood as three 




that pertain to each sample analyzed, and fixed probabilistic elements that are particular to each 
distribution, and are universal to all samples. 
The random elements include: 1) the number of diagnostic groups or strata that in 
probability terms translates as the number of possible outcomes in a random distribution; and,  
2) the number of individuals in each diagnostic strata that in probability terms translates into the 
probability of each outcome (as proportionate to the total number). As we have already 
mentioned, these elements are dependent on the particular sample that we are analyzing and 
are shared by the three distributions.  
The fixed elements correspond to values attached to each outcome. These values are 
specific to each distribution and are permanent, regardless of the samples under study. While 
the number of outcomes is contingent on the sample under examination, the values attached to 
each of these outcomes for these 3 distributions are a function that can be predicted.  
In the distribution of the Total Number of Individuals Diagnosed, the value attached 
would be one for all possible outcomes (as only one diagnosis is allowed for each Diagnostic 
Group). In the distribution concerning the Total Number of Diagnoses, the value of each 
possible outcome is identical to the Modal Diagnoses of the Diagnostic Group or Strata (DG1= 
1, DG2= 2, DG3= 3).  Finally, in the distribution of the Total Number of Comorbidities, the value 
of each possible outcome equals to (Modal Diagnosis x Modal Diagnosis Diagnosis-1).   
In our sample, the distribution of individuals diagnosed has 6 possible outcomes (DG1-
DG6). From Total of Individuals Diagnosed (n=492), the probability of picking an individual that 
has exactly 3 lifetime prevalence diagnoses is 0.12 (61/ 492=0.124). The probability of selecting 
an individual that has exactly 4 diagnoses is 0.04 (22 /492 = 0.045). All these are random 
elements, contingent on the sample. The number of outcomes and probability for each outcome 




element. An individual chosen at random with 3 diagnoses would account for 6 comorbidities. 
This would be true for any sample. Figure C6F03 displays the relationship between the number 
of diagnoses and the number of comorbidities by Diagnostic Group or Stata.  For a 
comprehensive explanation of the mathematical basis of the relationship between diagnoses 
and comorbidities in a sample, see Appendix 01.   
 
 
C06.S19.Summary and Conclusions  
In this section we evaluated the diagnostic and comorbidity patterns of our study cohort.   
Our overall aim was to measure the comorbidity burden of the individual disorders and of the 
whole sample. In order to achieve this goal, we developed indicators based on simple 
probability principles that could enable a quantitative comparison of the diagnostic and 
comorbidity patterns that   the different disorders present within our sample. 
The mean or expected value of diagnoses in our study sample (DIR) was 1.76, the mean 
or expected value for the number of comorbidities for a subject picked up at random was 2.33 
(CIR).  Our findings suggest that anxiety disorders are the psychiatric conditions with the 
highest degree of comorbidity burden in our study sample. 
The indicators presented could have several uses and be useful in different scenarios. 
Table C6T05 lists the proposed measures, with a brief description. These measures can be 
used in the comparison of different samples, or, of subgroups in the same sample, as we have 
done in comparing the carriers of the (s) allele with the non-carriers in our study sample 
(Appendix 02). 
The clinical implications, as well as clinical uses, will be discussed in more detail in the 





CHAPTER 07. PART 1.  
ANALYSIS OF TIME-TO-DIAGNOSIS.  ASSOCIATION WITH THE SEROTONIN 
TRANSPORTER GENE POLYMORPHISM 
 
C07.P01.S01. Aims  
In this section, we will examine the difference in the reported time that the affected 
subjects required to achieve full criteria for selected diagnoses. In particular, we will investigate 
whether the carriers of the Serotonin Transporter Gene (SERT) short (s) allele had any 
significant differences in the time (age) to meet criteria for the selected mental disorders as 
compared to the subjects who were not carriers for this genetic polymorphism in our study 
sample.  
 In order to achieve this goal, we will use several statistical techniques to examine the 
“time to event” variable. In our previous analyses, we examined whether the participants were 
affected by the individual mental disorders using a lifetime prevalence approach. One important 
limitation of this approach, is that it ignores the difference in ages of the participants. Every 
affected subject is equally counted in the numerator, and all subjects are equally included the 
denominator. Thus, the lifetime prevalence estimates disregard the differences in age of the 
participants, disregarding the variations of the time at risk for each individual, to develop the 
disorders under study. By using statistical techniques that focus on the time to event, in this 
case time to diagnosis, we aim at correcting the limitation of the previous analyses. 
 




We used the Kaplan-Meier (Product Limit) Approach. Subjects started to accrue 
exposure time at the moment of their birth. The follow-up time ended at the time the client had 
the “event” or “failure” of interest: namely, the reported age when they met criteria for the 
selected disorder. Subjects who never met criteria for the selected disorder at the moment of 
the study were censored at the age of the interview. We used this technique for each selected 
disorder in which we had information of the age of onset in the sample. By calculating the 
quotient between the number of events and the total person-years accrued by the subjects, we 
were able to obtain an Incidence Rate for each condition.  
We later calculated the events and exposure time both for the carriers of the SERT (S) 
allele and for the non-carrier subjects, and obtained a separate Incidence Rate for both groups 
in each condition. We calculated ratio a between the Incidence Rates of carriers and non-carries 
for each condition with the goal to determine whether there was an association of the carrier 
state with the development of the examined mental disorder.  
We later calculated Log-Rank tests for each condition to estimate whether the survival 
curves (in our case the time to diagnosis) were different between groups: namely, whether the 
carriers had a different time trajectory in attaining each diagnoses under examination 
Finally, we performed a Cox Proportional Hazards Regression Analysis for each 
condition. This approach enabled us to examine the association the SERT (s) allele carrier to 
the survival time (in our case, time to attain diagnosis). The Cox Proportional Hazard 
Regression model also allowed us to adjust the hazard estimates by potential confounding 
variables: namely, gender, ethnicity, and marital status. Thus, using this technique we were able 
to obtain a Hazard Ratio between the carrier and non-carrier participants for each condition 
examined, both unadjusted and adjusted for the aforementioned variables. Lastly, we examined 
whether our analysis for each condition met the proportional-hazards assumption required in the 





C07.P01.S03. Findings Time to Diagnosis  
Table C7T01 summarizes the estimates the total number of failures (Lifetime Prevalence 
Diagnoses), Total Person-Years, and  corresponding Incidence Rate per 1000 person-years for 
each included mental disorder for the whole sample (N=847), the SERT (S) Allele Carrier 
Subjects (LS+ SS) (N=336), and lastly for the SERT (s) Allele Non-Carrier Subjects (LL) 
(N=226).  
Table C7T02 summarizes the estimates of several analyses done comparing the SERT 
(s) allele carrier with the non-carrier subgroups (Incidence Rates Ratios, Long Rank Tests, as 
well as the unadjusted and adjusted Cox Proportional Hazards Regression Analysis results) 
The SERT (s) allele carrier status was associated with a 2.7 times higher risk for 
receiving a diagnosis of Panic Disorder (Incidence Rate Ratio: 2.70 (95% CI: 1.13-7.42).  For 
Panic Disorder subjects, this difference between carriers and non-carriers was also observed in 
the Log-Rank Test, and in the unadjusted Hazard Ratio. The Hazard Ratio, adjusted for gender, 
ethnicity, and marital status, was of borderline significance (Adjusted Hazard Ratio: 2.35 (95% 
CI: 1.00-2.51) (Table C7T02).  
In addition, the SERT (s) allele carrier status was associated with a significant 87% 
decrease in risk for receiving a diagnosis of Obsessive-Compulsive Disorder (Incidence Rate 
Ratio: 0.13 (95%CI: 0.00-0.99).  For Obsessive-Compulsive Disorder, this difference between 
carriers and non-carriers was also significant using the Log-Rank Test, and both the unadjusted 
Hazard Ratio, as well as for the Hazard Ratio adjusted for gender, ethnicity, and marital status 





C07.P01.S04. Conclusions on Time to Diagnosis  
We explored the association of the SERT (s) allele carrier with the time to achieve full 
criteria for the selected diagnoses in our study participants using different survival analysis 
approaches.   
We found a statistically significant increased risk for Panic Disorder in the carrier group 
as compared to the non-carrier. In addition, we found a statistically significant “protective” effect 






CHAPTER 07. PART 02.  
USE OF PSYCHOTROPIC AGENTS. ASSOCIATION WITH THE SEROTONIN 
TRANSPORTER GENE POLYMORPHISM 
 
C07.P02.S01. Aims 
In this section, we will explore the use of medications in our study sample and its 
association with the SERT (s) gene polymorphism.  
At the time of the interview, the subjects were queried about their current use of several 
psychotropic agents. These included antidepressants, anti-anxiety agents, hypnotic agents, 
antipsychotic agents, and anti-manic agents.  
 
C07.P02.S02. Analytical Approach 
Using Pearson’s Chi-Square and Fisher Exact Tests, we explored the association of the 
carrier state for the Serotonin Transporter Gene (SERT) short (s) allele with the use of these 
medications. 
Due to the limited sample size, we created cumulative categories to improve the power 
of the analyses. We combined anti-anxiety and antidepressant agents into one category. Finally, 
we combined all psychotropic agents that were included in the interview into one category to 
explore if there was any association between the use of any psychotropic agent with the SERT 





C07.P02.S03. Use of Psychotropic Agents in the Sample  
Table C7T03 summarizes the findings of our analyses. Antidepressant agents were the 
most widely prescribed for our subjects (8.85 per 100 subjects), followed by anti-anxiety agents 
(4.25 per 100 subjects). The overall use of psychotropic agents in the sample (including all 
types of psychotropic agents) was equal to 10.51 per 100 subjects.  
 
C07.P02.S04. Association of Psychotropic Use with SERT (s) Polymorphism 
The ratio of medication use in the SERT (s) allele carriers versus non-carriers was not 
significant for any of the psychotropic agents included in the study. When examining the overall 
psychotropic use, the SERT carrier status was not associated with an increase use of these 
medications, as compared to non-carriers. 
 
C07.P02.S05. Summary: Use of Medications 
We explored the association of the SERT (s) allele carrier with the use of psychotic 
agents in our study participants using univariate statistical approaches.   
We were unable to find a statistically significant association between the (s) allele carrier 






CHAPTER 08. SUMMARY AND CONCLUSIONS 
 
C08 Part 01 Comorbidity: Summary 
C08.P01.S01 Comorbidity in General Medicine  
Comorbidity has become an important area of study in medicine due to the realization 
that the management of patients with multiple coexisting conditions has become the norm rather 
than the exception in most clinical settings. (C2R01-02).    
Comorbidity can impact the clinical presentation, the prognosis, and clinical 
management of those affected. It has a strong impact on mortality, health-related quality of life, 
and overall daily functioning (C2R03-07). In addition, it is an important factor in the growing 
costs of medical care (C2R08). 
 
C08.P01.S02. Conceptualization and Classification of Comorbidity  
Comorbidity is defined as "any distinct additional clinical entity that has existed or that 
may occur during the clinical course of a patient who has the index disease under study" 
(C2R09). Through the years, several different classifications of the phenomenon of comorbidity 
have been proposed. These classifications focus on the etiological, the temporal, and the 
hierarchical aspects of the co-occurring conditions under study. 
 




The concept of comorbidity in mental disorders has been transformed. The use of the 
term comorbidity in psychiatry has a different implication than in the rest of the medical field. 
The complexities in the nature of mental disorders and their classification play an important 
factor in the distinctive challenge that comorbidity poses in the psychiatric field.  
The term comorbidity in mental health is used in diverse scenarios: 1) when a clinical 
mental disorder (e.g. major depressive disorder, bipolar disorder, schizophrenia) co-occurs with 
a “physical” or “medical disorder”, 2) when a clinical mental disorder co-occurs with a substance 
abuse disorder, 3) when a clinical mental disorder co-occurs with a personality disorder, and, 4) 
when two clinical mental disorders co-occur in an individual.   
Not all these categories should be considered in the same light. The study of the 
comorbidity between mental and “physical” or “medical” disorders is an area of interest in its 
own right. It is the focus of the field of psychosomatics; the study of the relationship between 
body and mind.  
The comorbidity between a clinical disorder and a substance abuse disorder or a 
personality disorder is an indicator of the heterogeneity of the concept of mental illness in our 
current classification. In order to increase coverage, our current classification has included 
different paradigms of mental disorders. These paradigms or concepts act as different 
viewpoints from where to diagnose a subject. An individual can be diagnosed with a substance 
abuse disorder, a personality disorder, and, additionally with a clinical disorder. These three 
diagnoses can be seen as three different mental disorders or complementary perspectives from 
where to label the manifestations of a single condition.  
In contrast, the co-occurrence of two “clinical conditions” can present a challenge to the 
basic tenets of our current classification of mental disorders. The Diagnostic and Statistical 




mental disorders. The categorical model purports that each clinical syndrome should be 
validated by its clear separation from other disorders, a particular clinical course as well as a 
specific genetic aggregation found in family studies. Thus, a high degree of comorbidity 
between mental disorders is contradictory to a paradigm that proposes a clear distinction 
between disorders. 
 
C08.P01.S04. Prevalence of Comorbidity between Mental Disorders in Epidemiologic Studies 
Large-scale epidemiologic surveys have determined a high degree of comorbidity 
between mental and substance use disorders. The Epidemiologic Catchment Area Program 
(ECA) (C2R25, 26, 27, 28) investigators reported that 60% of those diagnosed with a mental 
disorder, had at least one additional condition.  The National Comorbidity Study (NCS) (C2R29), 
showed similar results in a national based sample. The lifetime prevalence for any psychiatric or 
substance abuse disorder for adults was 48%. Stratifying the subjects by the number of lifetime 
prevalence diagnoses received, 21.0% of the sample met criteria for only 1 disorder, 13.0% of 
the sample met criteria for only two disorders, and the remaining 14.0% of the sample met 
criteria for three or more disorders in their lifetime. When examining the total number of 
diagnoses by subject, 20.6% of the disorders were diagnosed in subjects that met criteria for 
only one psychiatric disorder, 25.5% of the disorders originated in subjects that were diagnosed 
with two psychiatric disorders, and, finally 53.9% of the lifetime disorders diagnosed in a sample 
were diagnosed in subjects that met criteria for three or more lifetime disorders.  
 
C08.P01.S05. Comorbidity of Anxiety and Depressive Disorders  
Results from the National Comorbidity Study revealed that only 26% of the subjects with 




74% of all NCS respondents with a lifetime history of MDD had an additional psychiatric 
condition (C2R29). In the National Comorbidity Survey Replication (NCS-R) (C2R40), the 
majority of respondents (72.1%) with lifetime MDD reported at least one other lifetime DSM-IV 
disorder. Of the respondents with lifetime MDD, 59.2% also met criteria for lifetime anxiety 
disorder, 24.0% met criteria for a substance use disorder, and 30.0% met criteria for an impulse 
control disorder (C2R40).   
 
C08. Part 02. Serotonin Transporter Gene: Summary   
C08.P02.S01. Serotonin and Serotonin Transporter  
Serotonin plays a regulatory function in the central nervous system (C3R05). The 
serotoninergic system can reduce or increase anxiety and impulsivity, either directly or by 
altering functions of other neurotransmitter systems (C3R06). In addition, serotonin modulates 
arousal and prevents uncontrolled anxiety or panic through its effect on the locus coeruleus 
(C3R07).  
The serotonin transporter (SERT) is a pre-synaptic plasma membrane transporter. The 
SERT modulates the serotonergic neurotransmission by regulating the magnitude and duration 
of serotonergic responses. It has been established that both the tricyclic antidepressants (TCAs) 
as well as the newest serotonin reuptake inhibitors (SRIs) exert their initial pharmacological 
effect by binding to the SERT. The blockade of the SERT function increases the levels of 
serotonin in the synaptic cleft. This increase in serotonin promotes secondary changes in the 
serotoninergic transmission both at the presynaptic and postsynaptic levels that are posited as 





C08.P02.S02. The Serotonin Transporter Gene Polymorphism and Its Association with 
Psychopathology 
The human serotonin transporter (SERT) is encoded by a single gene (SLC6A4) located 
on the long arm of chromosome 17 (17q111-17q12). The most investigated area of the SLC6A4 
is the serotonin transporter gene promoter region (5-HTTLPR). The 5-HTTLPR has been the 
object of great attention due to a functioning polymorphism. This polymorphism is constituted by 
a 44 base pair deletion /insertion in the 5’ regulatory region. The polymorphic variant that 
includes this 44 base pair is referred as the long (L) allele, the variant without the 44 base pair is 
also called the short (S) allele (C3R14, C3R15).   
The decreased level of transcriptional efficacy of the SERT by the short (S) allele has 
been associated with several psychiatric conditions (C3R16, C3R17), in particular depression, 
as well as suicidal behavior, and response to antidepressant treatment. There is a copious body 
of literature on the SERT polymorphism and its potential association with diverse psychiatric 
conditions. The results of these investigations, have been, so far, inconclusive.  
 
 
Chapter 08 Part 03: SERT Polymorphism and Psychopathology. Highlights of Study Findings  
C08.P03.S01. Aims and Participant Selection 
We examined the lifetime prevalence (LP) of Alcohol Dependence, Alcohol Abuse, Opioid 
Dependence, Schizophrenia and other Psychotic Disorders, Major Depressive Disorders (MDD), 
Bipolar Disorder, Panic Disorder, Agoraphobia, Social Phobia, Obsessive Compulsive Disorder 




Disorder Not Otherwise Specified, Depressive Disorder Not Otherwise Specified, and Adjustment 
Disorder with Depressed Mood in a community-based sample.  
Our study sample was the result of a three-phase selection process. The first phase 
involved the development of the original cohort for the Baltimore site of the Epidemiological 
Catchment Area (ECA) in the early 1980’s (C4R01). The second phase consisted of the follow-
up or re-assessment of the sample obtained in the first phase in the Baltimore Epidemiologic 
Catchment Area Follow up (EFU) in the early 1990’s (C4R02- C4R04). The third phase entailed 
the development of a sub-sample of the EFU. This third re-assessment was the source of our 
study sample (C4R06- C4R07).  
Our study participants were assessed by a psychiatrist using the Schedule for Clinical 
Assessment in Neuropsychiatry (SCAN) (C4R08-09) (N=847). In addition, the majority of 
participants provided a sample for genetic testing (N=628).  
 
C08.P03.S12. Lifetime Prevalence and Comorbidity in the Whole Sample  
The disorders with the highest lifetime prevalence were Alcohol Dependence (20.90 (95% 
CI: 18.32; 23.82), followed by Major Depressive Disorder (MDD) (17.95 (95% CI: 15.54; 20.73), 
Simple Phobia (12.51 (95% CI: 10.47; 14.95)), and Social Phobia (11.81 (95% CI: 9.82; 14.91), 
respectively.  
 There was a significant and extensive comorbidity between anxiety disorders, mood 
disorders, and Alcohol Dependence.  Agoraphobia, Social Phobia, Obsessive Compulsive 
Disorder (OCD), Generalized Anxiety Disorder (GAD), and Simple Phobia were highly comorbid 
with each other and with mood disorders. The odds of having a lifetime prevalence diagnoses of 
Panic Disorder is 5.51 times higher in subjects that have a lifetime diagnoses of Social Phobia 




during their lifetime is 7.96 times higher in subjects who have received a diagnosis of Social 
Phobia than in subjects who did not receive this diagnosis. MDD was significantly comorbid with 
the majority of the anxiety disorders: namely with Panic Disorder (OR: 3.20), Agoraphobia (OR: 
2.79), Social Phobia (OR: 2.46), and, OCD (OR: 4.74). Bipolar Disorder was highly comorbid 
most anxiety disorders: namely, with Panic Disorder (OR: 4.14), Agoraphobia (OR: 3.76), Social 
Phobia (OR: 2.46), OCD (OR: 4.76) and, GAD (OR: 3.19).  Finally Alcohol Dependence was 
highly comorbid with MDD (OR: 1.52), and Bipolar Disorder (OR: 2.71) 
 
C08.P03.S03. Lifetime Prevalence of Selected Disorders and its Association with SERT 
Polymorphism 
 We examined the association of the lifetime prevalence of the 16 disorders included in 
this investigation and the SERT polymorphism using Poisson Regression models. Panic 
Disorder was the only condition in which the carriers of the short (S) allele of the SERT 
polymorphism had an increased risk for receiving a lifetime prevalence diagnoses (2.61 (95% 
CI: 1.20; 5.69), p=0.02). No evidence of a gender-specific effect was detected when the analysis 
was stratified by sex. This association of the SERT polymorphism and Panic Disorder was 
significant adjusted for ethnicity.  
 
C08.P03.S04. Comorbidity between Selected Disorders and its Association with SERT 
Polymorphism 
Using logistic regression models, we examined the odds of comorbidity between all the 
included psychiatric conditions. We can posit that two patterns of correlations or comorbidities 
between the individual mental disorders emerge.  Anxiety Disorders are highly comorbid with 




addition, Major Depressive Disorder and Bipolar Disorder had a high degree of comorbidity with 
Alcohol Dependence. These findings were in agreement with previous reports of large scale 
epidemiologic studies above mentioned.  
 We examined the association between the (s) allele carrier status and the odds of being 
diagnosed a given comorbidity. The SERT (s) allele carrier status was associated with a 
significant increase in the odds for comorbidity in three dyads. For subjects diagnosed with 
Major Depressive Disorder, the carriers of the (s) allele, had a risk for being diagnosed with 
Social Phobia that was 5.13 times higher than the one of the non-carriers (OR: 5.13 (95%CI: 
1.79; 14.74)). For subjects diagnosed with Agoraphobia, the carriers of the (s) allele, had a risk 
for being diagnosed with Major Depressive Disorder that was 4.69 times higher than the one of 
the non-carriers (OR: 4.69 (95%CI: 1.11; 19.83). Finally, for subjects diagnosed with Social 
Phobia, the carriers of the (s) allele, had a risk for being diagnosed with Major Depressive 
Disorder that was 4.8 times higher than the one of the non-carriers (Odds Ratio = 4.80 (95%CI: 
1.55; 14.84)). 
 
C08.P03.S05. SERT Polymorphism and Overall Burden for Psychopathology 
We later examined the association of the SERT (s) allele carrier status with the 
prevalence of mental disorders, considered globally.  We examined the effect of the (S) allele 
carrier status in the overall number of lifetime diagnoses.  There were no significant differences 
in the distribution of the number of lifetime diagnoses between the (s) allele carrier and the non-
carriers. In addition, the carrier status was not associated with an increase in the odds of being 
diagnosed with one, or two or more mental disorders as compared to the non-carrier status: 








Chapter 08 Part 04: Summary on Methodological Issues in the Measurement of Comorbidity 
Methodological   
 
C08.P04.S01. Aims and Rationale  
In Chapter 06 we evaluated the diagnostic and comorbidity patterns of our study sample.  
Our goal was to measure the comorbidity burden of the individual mental disorders and the 
cumulative effect of all diagnoses in the whole sample. In order to achieve a quantitative 
analysis and not a mere description of the phenomenon, we developed indicators based on 
simple statistical principles. These simple indicators helped us to measure the comorbidity 
burden relying solely on the observed variables of the sample.  
 
C08.P04.S02. Methodological Approaches  
We used three complementary approaches in our analyses of the comorbidity burden of 
the sample. In the first approach, we measured the weight of the comorbidity of each individual 
disorder by calculating the ration between tally of the comorbidities and the tally of diagnoses for 
each diagnoses and for the whole sample. In the second approach, we investigated the impact 
of different comorbidity pairs or dyads on the whole sample as well as on each of its member 
disorders. In the third approach, we examined the association between the prevalence of each 
individual mental disorder and the presence of multiple diagnoses among individuals in the 





C08.P04.S03. First Approach: Comorbidity to Diagnosis Inflation Ratio (CDIR)  
In the first analytic approach, we crafted a number of tables for purposes of describing 
the number of diagnoses and comorbidities in our study population. We calculated a simple ratio 
between the total number of comorbidities and the total number of diagnoses for each disorder, 
as well as for the total sample. We named this crude measure the Comorbidity to Diagnosis 
Inflation Ratio (CDIR). By standardizing the DCIR with the total value, we were able to detect 
the differential comorbidity burden of each disorder. The CDIR of the whole sample represents 
the quotient between the Total Number of Comorbidities (n=1,146) and the Total Number of 
Diagnoses (or Subjects Diagnosed) (n=868) which yielded a value of 1.32 in our population. 
This means that, in our sample, there was an average of 132 comorbidities per 100 diagnoses. 
This measure allowed us to detect those conditions with the highest comorbidity burden in the 
sample. OCD was the psychiatric condition with the highest comorbidity burden which had a 
CDIR of 2.5. This translates into the presence of 2.5 comorbidities for each OCD diagnosis. The 
SCDIR for OCD yielded a value of 1.89. This estimate indicates that OCD has a comorbidity 
burden that is 89% higher than the one observed in the overall sample. Following OCD, in order 
of decreasing burden, there are three anxiety disorders, Agoraphobia:  CDIR = 2.12 and 
SCDIR= 1.61; Social Phobia: CDIR=1.65 and SCDIR=1.25; and Panic Disorder: CDIR= 1.61 
and SCDIR= 1.22.  
 
 
C08.P04.S04. Second Approach: Impact of the Comorbidity Dyads 
In the second analytic approach, we examined the impact of each comorbidity pair or 




obtain a quick summary measure of the impact of every comorbidity dyad on both its integrating 
condition, we calculated a ratio of probabilities. We labeled this indicator as the Ratio of 
Conditional to Marginal Probabilities (RCMP). This ratio has several appealing statistical 
characteristics and it is relatively easy to compute for all conditions. This ratio can also be 
expressed as the conditional probability of Condition A given Condition B divided by the 
probability of Condition A (PA/B / PA or PB/A /PB). In addition, this indicator can also be 
expressed as the observed prevalence of the comorbidity pair divided by its expected 
prevalence. A value of 1.0 indicates that Conditions A and B are independent. A value of less 
than one indicates a negative tendency towards comorbidity whereas a value of greater than 1 
indicates that the observed comorbidity exceeds the expected frequency.  Panic Disorder, 
Agoraphobia, Social Phobia, Obsessive Compulsive Disorder, and Generalized Anxiety 
Disorder were the conditions that have both the highest number of comorbidities and the highest 
value for both the RCMPs and the Odds Ratios (Table C6T02). These conditions were comorbid 
with each other as well as with other disorders with a high prevalence (e.g., Major Depressive 
Disorder, Social Phobia, and Alcohol Dependence). 
 
 
C08.P04.S05. Third Approach: Stratification, Adjustment and Diagnostic Inflation Ratio 
In the last analytic approach, we stratified individuals in the study sample according to 
the number of diagnoses received (0, 1, 2 or more conditions). Tables C6T03A and C6T03B 
displayed the frequency of each diagnostic strata and the prevalence of each condition within 
each diagnostic strata. The stratification of diagnoses by diagnostic group or strata, helped us to 
understand that comorbidity creates a scenario of over-representation of individuals with 




70% of the individuals in the sample contributed only with 30% of the diagnostic information. In 
order to measure this over-representation of individuals with multiple diagnoses, we adjusted all 
diagnostic and comorbidity information to be identical to the number of individuals diagnosed.  
(Table C6T03C).  We called this indicator the Diagnostic Inflation Ratio (DIR). In the entire study 
sample, the DIR corresponds to the quotient of the Total Number of Diagnoses (N=868) with the 
Total Number of Individuals Diagnosed (N=492). In probability terms, the DIR is the expected 
value of diagnoses that we will find in a subject from the sample picked at random. For the 
whole sample the DIR yielded a value of 1.76. The DIR can provide a quantitative indicator of 
the comorbidity burden of the sample that could be compared with values obtained from other 
samples, as well as between disorders within the sample. The DIR of OCD indicates that we 
can expect to find 2.82 diagnoses from any individual of the sample affected with OCD, picked 
up at random. In addition, we also analyzed the ratio of the Total Number of Comorbidities 
(N=1,146) to the Total Number of Individuals Diagnosed (N=492). For consistency reasons, we 
labeled this measure as the Comorbidity Inflation Ratio (CIR). The CIR for the whole sample 
was 2.33 which means that we can expect to find 2.3 comorbidities in an individual of the 
sample picked at random (of the individuals that have received one diagnosis at least). We later 
normalized the DIR and CIR of the individual disorders with the DIR and CIR of the total sample 
to be able to compare the individual disorders ( Table C6T03C). These findings were consistent 
with previous measures. The anxiety disorders were the conditions with the highest values for 
all indicators. Specifically, Panic Disorder (DIR: 2.07, SDIR: 1.18, CIR: 3.36, SCIR: 1.43), 
Agoraphobia (DIR: 2.45, SDIR: 1.39, CIR: 5.20, SCIR: 2.30), Social Phobia (DIR: 2.11, SDIR: 
1.19, DIR: 3.47, SCIR: 1.49), Obsessive Compulsive Disorder (DIR: 2.82, SDIR: 1.60, CIR: 
7.05, SCIR: 3.02) and Generalized Anxiety Disorder (DIR: 1.99, SDIR: 1.128, CIR: 3.50, SCIR: 
1.50) were the individual conditions whose comorbidity burden largely outweighed both the rest 





C08.P04.S06. Relationship between Individuals, Diagnoses, and Comorbidities in a Sample  
Finally, we analyzed the association between the Total Number of Individuals 
Diagnosed, the Total Number of Diagnoses, and the Total Number of Comorbidities in the 
sample. We concluded that these can be seen as 3 related random probability distributions that 
share random elements, but have unique fixed features.     The random 
elements depend exclusively on the sample to be analyzed and include: 1) the number of 
diagnostic groups or strata (that can be seen in probability terms as the number of possible 
outcomes), and 2) the number of individuals in each diagnostic strata, that in probability terms 
translates into the probability of each outcome (as a proportion in relation to the total number).  
    
The fixed elements were the value attached to each outcome were unique to each 
distribution, and did not change when different samples were analyzed. The value attached for 
each outcome for the distribution of Total Number of Individuals was 1 for all outcomes. The 
value for each outcome for the distribution of the Total Number of Diagnoses was the modal 
diagnoses (MD) of each diagnostic group or strata. Finally,  the value attached to each outcome 
for the Total Number of Comorbidities was equal to the product of the modal diagnoses of the 
diagnostic strata multiplied by itself minus one (MD x MD-1).  We could see that the value of the 
mean or expected value of the distribution of the Total Number of Diagnoses was the DIR, the 
mean or expected value of the Total Number of Comorbidities was the CIR, and the ratio 
between the CIR and DIR was the CDIR.  
 
Chapter 08 Part 05: Summary on Analysis of Time Achieve Criteria for Full Diagnosis and Its 





C08.P05.S01. Time to Diagnosis, Aims and Introduction  
We examined the differences in the recorded time that the affected subjects required to 
achieve full criteria for the selected diagnoses, and the association of this time to diagnosis with 
the Serotonin Transporter Gene (SERT) Polymorphism 
In order to achieve this goal, we used several statistical techniques to examine the “time 
to event” variable.  By using these statistical techniques that focus on the time to event, in this 
case time to diagnosis, we aimed at correcting the limitation of the previous analyses that 
ignored the differences in the time at risk of the participants. . 
 
 
C08.P05.S02. Findings: Time to Diagnoses and SERT Gene Polymorphism 
The SERT (s) allele carrier state was associated with nearly three times higher risk for 
receiving a diagnosis of Panic Disorder (Incidence Rate Ratio=2.70 (95% CI: 1.13-7.42).  For 
Panic Disorder subjects, this difference between carriers and non-carriers was also observed in 
the Log-Rank Test, and in the unadjusted Hazard Ratio. The Hazard Ratio, adjusted for gender, 
ethnicity, and marital status, was of borderline significance (Adjusted Hazard Ratio: 2.35 (95% 
CI: 1.00-2.51).  
Lastly, the SERT (s) allele carrier state was associated with a significant 77% decrease in 
risk for receiving a diagnosis of Obsessive Compulsive Disorder (Incidence Rate Ratio=0.13 
(95%CI: 0.00-0.99).  For Obsessive Compulsive Disorder, this difference between carriers and 




as well as for the Hazard Ratio adjusted for gender, ethnicity, and marital status (Adjusted 




Chapter 08 Part 06: Summary: Use of Psychotropic Agents and Its Association with the 
Serotonin Transporter Gene Polymorphism 
 
C08.P06.S01. Aims and Rationale for the Analysis of Use of Medications 
We examined the use of psychotropic medications in our study participants and its 
association with the SERT Gene Polymorphism. 
Several studies (C3R48-50) have reported that subjects who were homozygotes for the 
(L) SERT polymorphism, had significantly better antidepressant responses than subjects who 
were carriers of the (S) allele.  
 
C08.P06.S02. Analysis of Use of Medications Findings 
 Antidepressant agents were the most widely prescribed for our subjects (8.85 per 100 
subjects), followed by anti-anxiety agents (4.25 per 100 subjects). The overall use of 
psychotropic agents in the sample (including all types of psychotropic agents) was equal to 
10.51 per 100 subjects. The use of psychotropic agents was similar for both the SERT (s) allele 







Chapter 08 Part 07: Concluding Remarks 
 
C08.Part 07.S01. Introduction  
We can divide our work into three interrelated goals. The first goal was to examine the 
lifetime prevalence and comorbidity of selected mental disorders in a community-based sample. 
The second goal was to examine the association of the SERT gene polymorphism with and the 
prevalence, comorbidity burden, and, treatment patterns of the most frequently diagnosed 
mental disorders in a group of 847subjects that were sampled from the Epidemiologic 
Catchment Area (ECA) in Baltimore, Maryland: namely, whether the subjects who were carriers 
of the short (s) allele of the SERT gene had an increase rate of morbidity and comorbidity for 
mental disorders. The final and third goal, born out of the need to fulfill the first two goals, was to 
develop instruments to quantitatively and comprehensively measure the comorbidity burden in a 
sample. 
 
C08.Part 07.S01. Lifetime Prevalence and Comorbidity of Selected Mental Disorders in a 
Community Based Sample.  
Our findings on the prevalence and comorbidity are consistent to the cited literature. We 
found extensive comorbidity between the major mental disorders. In particular between anxiety 
disorders, mood disorders, and Alcohol Dependence.  Agoraphobia, Social Phobia, Obsessive 
Compulsive Disorder (OCD), Generalized Anxiety Disorder (GAD) were highly comorbid. This is 




significant between most of the anxiety disorders: namely with Panic Disorder (OR: 3.20), 
Agoraphobia (OR: 2.79), Social Phobia (OR: 2.46), and, OCD (OR: 4.74). These findings are 
consistent with the previously cited results of large community based studies as the National 
Comorbidity Survey.  Our proposed instruments can prove to be useful in this area, as they can 
provide a quantitative indicator of the comorbidity burden of each individual disorder. The DIR 
and CIR can be used as a single measure of the comorbidity of each condition. This widespread 
and significant comorbidity burden between could be an indicator of the limitations in the validity 
of the categorical psychiatric classification. Categorical diagnoses can be great tools for 
communication in clinical settings, and be useful in research.  Thus, a high degree of 
comorbidity between categorical diagnoses can create communication barriers between 
providers and patients, and unwanted bias for research, due to misclassification of individuals  
Considering the relationship between diagnoses and individuals diagnosed, our findings 
indicate that comorbidity entails a pattern of under-representation of a majority of the individuals 
in the sample. The participants that have been diagnosed with only one condition is equivalent 
to 51.83% of the total individuals of the sample that have received a psychiatric diagnosis. 
Paradoxically, this group only represents 29.38 % of the total diagnoses present in the sample: 
namely, over 70% of the diagnoses in the sample originated from individuals with more than one 
diagnoses. Thus, our findings are nearly identical to those reported by the NCS investigators. 
Kessler et al. reported that 56.25% of all the NCS participants that received a DSM diagnoses 
met criteria for more than one disorder, and, in addition 79.4% of the lifetime diagnoses of 
psychiatric and substance abuse disorders diagnosed in the NCS sample were comorbid 
conditions (C2R29).  
In summary, in our relatively small sample of participants interviewed by psychiatrists 




disorders similar to the large scale epidemiologic studies that relied on non-psychiatrists or 
diagnostic purposes.  
 
C08.Part 07.S02. Findings SERT Gene Polymorphism and Psychopathology  
We found an increased lifetime prevalence of Panic Disorder in the study participants 
who were carriers of the (s) alleles. Our findings are in agreement with previous literature that 
reports an increase in anxiety-related traits in the carriers of the (s) allele of the SERT promoter 
region polymorphism (C3R15, C3R24). However, the findings on the association between the 5-
HTTLPR and Panic Disorder have been inconsistent. In our Poisson models, the lifetime 
prevalence remained significant after adjustment for gender and race. In the time- to –event 
analysis, the controlling for gender and race, the association was only of borderline significance.    
We found a significant association between SERT (s) allele carrier status and a 
decreased risk to be diagnosed with Obsessive-Compulsive Disorder in the time-to-event 
analysis. After controlling for gender and race, this association remained significant. This finding 
is consistent with previous studies (C3R63, C3R54), that reported an association between the 
long (l) allele of the SERT promoter region with OCD. Thus, the (s) carrier status could have a 
“protective” effect for OCD.  
In addition, the carriers of the (s) allele had a significant increased risk for two 
comorbidity pairs, MDD and Social Phobia, and Agoraphobia and MDD in logistic regression 
models. Due to the limited number of affected individuals in each comorbidity dyad, we were 
unable to adjust for gender and race. 
When comparing the overall number of diagnoses, there was no sign of increase in the 




In summary, our findings suggest a limited effect of the SERT promoter gene 
polymorphism in the overall psychopathology burden. It is important to highlight the limitation of 
our small sample size. We have also considered the SERT promoter region polymorphism in a 
bi-allelic approach. We were unable to explore a more novel tri-allelic approach for the 5-
HTTLPR, as well as additional single nucleotide polymorphisms present in the SERT gene, due 
to availability and limited sample size.  
In addition, we should acknowledge the limitation of a sample that originates in only one 
geographical region, and has a multi-ethnic composition. This could have introduced population 
stratification bias in our findings.  
Nevertheless, considering the role of serotonin transmission in the central nervous 
system, and the role of the SERT in the regulation of serotonin transmission, the existence of a 
polymorphism in the gene that codes the SERT should continue to be an area of active interest 
in research. Especially if this polymorphism impacts on the SERT function, and therefore, on the 
serotonin transmission. Future work should combine large population based cohorts, nation-
wide sampled. This future cohorts could be comprehensively screened for psychopathology 
using standardized instruments, and genotyped for all possible functional variants of the SERT 
gene 
 
C08.Part 07.S03. Utility of Instruments and Adjustment Methods 
We believe that the proposed measures might be helpful instruments in the 
measurement and characterization of the diagnostic and comorbidity patterns in a sample. They 
are easy to instrument, and can provide a comprehensive and novel analysis of the relationship 




At present, we believe that the medical field is struggling with the phenomenon of 
comorbidity or multi-morbidity. There is a growing awareness of the increased cost and clinical 
effects that comorbidity can have on the diagnosis and treatment of the population. Thus, simple 
methods to quantify this phenomenon can provide some help in this endeavor.  
These methods can be used to compare the different samples, or different subgroups in 
the single sample as we have done in comparing the carriers of the SERT (s) allele with the 
non-carriers in our study sample in the Appendix 02.  
In addition, the proposed instruments can be useful in the quantification and 
characterization of the different diagnoses contained in the sample, as they are able to quantify 
and compare the comorbidity burden of each individual diagnosis contained in the sample  
These indicators are based on simple mathematical principles, rely on counting subjects 
characteristics. They can therefore be used for other purposes such as pharmaco-epidemiology. 
In this case, we will be counting number of pharmaceutical prescribed and measuring the 
burden or degree of polypharmacy use in a cohort or service dataset.   
In addition, these indicators could provide an individual measure of comorbidity for a 
single individual in a cohort, and can be combined with univariate and multivariate methods.  
They could be used in clinical settings, research, and health-services research.  
Comorbidity in mental health has the added effect of a challenge to the validity of the 
diagnostic classification of mental disorders. We hope that our proposed instruments can be 
useful in the complex enterprise of refining our nosology.  
In summary, these indicators are quick to implement. They are based on clear 
mathematical principles. They can provide a descriptive and analytic measure of the diagnostic 
and comorbidity pattern in a sample. 
 
 











Mean (95% CI) 48.29  (47.35;49.23) 47.19(46.18; 48.20) 51.37 (49.23; 53.52) <0.001.
Gender N (%) Females 522 (63.97%) 381 (63.29%) 141 (65.89%) 0.5
Males 294 (36.03%) 221 (36.71%) 73 (34.11%)
Race 
N (%)
White 489 (59.93%) 362 (60.13%) 127 (59.35%) 0.84






No High School 289 (49.15%) 210 (48.39%) 79 (51.30%) 0.83
High School 255 (43.47%) 191 (44.01%) 64 (41.56%)
GED 44 (7.48%) 33 (7.60%) 11 (7.14%)
Highest Educational 
Level Achieved
N (%)  
HS Incomplete 317 (38.85%) 231 (38.37%) 86 (40.19%) 0.92
HS Complete 271 (33.21%) 203 (33.72%) 68 (31.78%)
College Incomplete 143 (17.52%) 104 (17.28%) 39 (18.22%)
College Complete  85 (10.42%) 64 (10.63%): 21 (9.81%)
Marital Status N (%) Married 340 (41.67%) 261 (43.36%) 79 (36.92%) 0.10
Table C4AT01 displays the demographic characteristics of both genotyped (N=816 that had available demographic information out of the whole sample of
N=847), and non-genotyped subjects (N=628). 
 
 
Table C4AT02. Genotypes Distribution of Serotonin Transporter Gene 
Frequency Whole Sample (%) Genotyped Sample (%)
1=L/L 280 33.1 44.6
2=L/S 274 32.3 43.6
3=S/S 74 8.7 11.8
Total Genotyped 628 74.1 100.0
Non-Genotyped 219 25.9
Total Sample 847 100.0























01 Alcohol Dependence 20.90 (18.32; 23.82) 20.22 (17.3; 23.622) 20.98 (17.11; 25.72) 19.29 (15.18; 24.51) 1.09 (0.79; 1.49) 0.60
02 Alcohol Abuse 5.67 (4.31; 7.46) 6.37(4.72; 8.60) 6.61 (4.45; 9.81) 6.07(3.83; 9.62) 1.09 (0.59; 2.00) 0.78
03 Major Depressive Disorder 17.95 (15.54; 20.73) 18.79 (15.97;22.11) 18.39 (14.74;22.95) 19.29 (15.18; 24.51) 0.95 (0.69;1.32) 0.78
04 Bipolar Disorder 2.6 (1.72; 3.92) 2.39 (1.45; 3.94) 3.16 (1.77; 5.65) 1.43 (0.54; 3.78) 2.21 (0.71; 6.87) 0.17
05 Psychotic Disorders 1.42 (0.81; 2.48) 0.96 (0.43; 2.12) 0.86 (0.28; 2.66) 1.07 (0.035; 3.30) 0.80 (0.16;3.96) 0.79
06 Panic Disorder 5.43 (4.10; 7.19) 5.41 (3.90; 7.51) 7.47 (5.16; 10.81) 2.86 (1.44; 5.66) 2.61 (1.20; 5.69) 0.02*
07 Agoraphobia 5.90 (4.51; 7.72) 5.94 (3.50; 10.06) 5.17(3.30; 8.11) 6.79 (4.40; 10.47) 0.76 (0.41; 1.42) 0.40
08 Social Phobia 11.81 (9.82; 14.19) 11.62 (9.37; 14.42) 12.64 (9.59; 16.67) 10.36 (7.34; 14.62) 1.22 (0.78; 1.90) 0.38
09 Obsessive Compulsive Disorder 1.65   (0.98; 2.78) 1.27 (0.64; 2.54) 1.15 (0.43; 3.05) 1.43 (0.54; 3.78) 0.80 (0.20; 3.24) 0.76
10 Generalized Anxiety Disorder 2.95 (2.01; 4.34) 2.87 (1.82; 4.52) 2.30 (1.16; 4.56) 3.57 (1.94; 6.56) 0.64 (0.26; 1.61) 0.35
11 Anxiety Disorder NOS 2.48 (1.63; 3.78) 2.07 (1.21; 3.54) 2.01 (0.97; 4.19) 2.14 (0.97; 4.73) 0.94 (0.32; 2.76) 0.91
12 Dysthymic Disorder 1.06 (0.55; 2.04) 1.27 (0.64; 2.54) 1.15 (0.43; 3.05) 1.43 (0.54; 3.78) 0.80 (0.20; 3.24) 0.76
13 Depressive Disorder NOS 2.13 (1.35; 3.36) 2.23 (1.33; 3.74) 2.01 (0.97; 4.19) 2.50 (1.20; 5.20) 0.80 (0.29; 2.27) 0.68
14 Simple Phobia Disorder 12.51 (10.47; 14.95) 14.17 (11.69; 17.18) 12.64 (9.59; 16.67) 16.07 (12.30; 21.00) 0.79 (0.54; 1.16) 0.22
15 Adjust DO Depressed Mood 3.78 (2.69; 5.31) 3.98 (2.71;5.85) 4.02 (2.41;6.72) 3.93 (2.20;7.01) 1.02 (0.47;2.22) 0.95
16 Opioid Dependence 4.25 (3.09; 5.85) 3.98 (2.71;5.85) 4.02 (2.41;6.72) 3.93 (2.20;7.01) 1.02 (0.47;2.22) 0.95
Column 01 02 03 04 05 06
Table C5T01 displays the un-weighted LP prevalence estimates as percentages with 95% confidence intervals (CI) of the 16 Axis I disorders examined in a subsample. Column 
01 summarizes the un-weighted LP estimates for the whole sample (N=847). Column 02 displays the un-weighted LP estimates for the genotyped sub-sample (N=628). Column 03 
displays the un-weighted LP estimates for the SERT (s) allele carrier sub-sample (N=348). Column 04 displays the un-weighted LP estimates for the SERT (s) allele non-carrier 
sub-sample (N=280). Column 05 displays the prevalence ratio estimates between the carrier and the non-carrier subsamples with 95% Confidence Intervals. Column 06 
summarizes the p-values for the prevalence ratio estimates of column 05. SERT (s) allele carrier status was associated with an increase in risk for Panic Disorder. Carriers of the 
SERT (s) allele had a 2.61 higher risk for a LP diagnosis of Panic Disorder (Prevalence Rate Ratio: 2.61 (95% CI: 1.20; 5.69) p: 0.02) 
 
 















Disorder   
Females 11.17 (7.60; 16.41) 4.00  (1.95; 8.27) 2.79 (1.23; 6.36) 0.01
02 Males 23.08 (0.75; 7.06) 10.99 (0.16; 7.72) 2.1 (0.22; 19.87) 0.52
Column 01 02 03 04 05
  
Table C5T02 displays the un-weighted LP prevalence estimates with 95% confidence intervals (CI) for Panic Disorder, stratified by gender. Column 02 displays the un-weighted 
LP estimates for Panic Disorder in males and females who are SERT (s) allele carriers (N=348). Column 03 displays the un-weighted LP estimates for Panic Disorder in males and 
females who are non-carriers (N=280). Column 04 displays the prevalence ratio estimates between the carrier and the non-carrier subsamples with 95% Confidence Intervals for 
each gender. Column 04 summarizes the p-values for the prevalence ratio estimates of column 04.
 
 
















































































































01 Alcohol Dependence 1.0000 
02 Alcohol Abuse 1.0000 
03 Major Depressive Disorder 0.1378 1.0000 
04 Bipolar Disorder 0.2526 -1.0000 1.0000 
05 Psychotic Disorders 1.0000 
06 Panic Disorder 0.3228 0.3174 1.0000 
07 Agoraphobia 0.3097 0.2872 0.2973 0.3744 1.0000 
08 Social Phobia 0.1745 0.2777 0.2575 0.2436 0.4564 1.0000 
09 Obsessive Compulsive 
Disorder
0.3686 0.3805 0.4192 0.4763 1.0000 
10 Generalized Anxiety Disorder 0.2965 0.3252 1.0000 
11 Anxiety Disorder NOS 1.0000 
12 Dysthymic Disorder 0.4531 1.0000 
13 Depressive Disorder NOS 1.0000 
14 Simple Phobia Disorder 0.2640 0.2989 0.3572 1.0000 
15 Adjust DO Depressed Mood -0.3783 0.3135 1.0000 
16 Opioid Dependence 0.2852 0.4263 1.0000
Column 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16
Table C5T03 summarizes the significant (p-value: < 0.05) tetrachoric correlations between all the 16 mental disorders for the whole study sample (N=847).
 
 
















































































































01 Alcohol Dependence N/A 0.52 1.52* 2.71* 0.34 0.92 2.98* 1.75* 1.53 1.20 0.62 0.47 1.47 1.12 1.27 2.86*
02 Alcohol Abuse 0.52 N/A 0.91 1.52 2.15 1.07 1.80 2.85 0.98 0.80 0.98
03 Major Depressive Disorder 1.52* 0.91 N/A 1.53 3.20* 2.78* 2.46* 4.74* 3.19* 1.86 2.31 0.57 1.59 0.14 2.09*
04 Bipolar Disorder 2.71* N/A 4.14* 3.76* 2.92* 6.78* 0.33
05 Psychotic Disorders 0.34 1.52 1.53 N/A 3.28 1.50 3.70 4.37 2.37
06 Panic Disorder 0.92 2.15 3.20* 4.14* N/A 4.51* 2.51* 2.99 1.54 1.02 1.27 1.17 2.29
07 Agoraphobia 2.98* 1.07 2.78* 3.76* 3.28 4.51* N/A 5.42* 6.84* 3.21* 2.76 2.01 0.94 2.66* 0.50 1.48
08 Social Phobia 1.75* 1.80 2.46* 2.92* 1.50 2.51* 5.42* N/A 7.96* 3.73* 1.25 2.16 1.51 2.74* 1.07 0.93
09 Obsessive Compulsive Disorder 1.53 2.85 4.74* 6.78* 2.99 6.84* 7.96* N/A 5.87* 7.93 2.87
10 Generalized Anxiety Disorder 1.20 3.19* 1.54 3.21* 3.73* 5.87* N/A 10.12* 4.20* 1.06
11 Anxiety Disorder NOS 0.62 1.86 3.70 2.76 1.25 N/A 2.38 1.17 2.79 1.13
12 Dysthymic Disorder 0.47 2.31 2.01 2.16 7.93 10.12* N/A A 2.02
13 Depressive Disorder NOS 1.47 0.98 0.57 4.37 1.02 0.94 1.51 2.38 N/A 0.87 7.12*
14 Simple Phobia Disorder 1.12 0.80 1.59 0.33 2.37 1.27 2.66* 2.74* 2.87 4.20* 1.17 2.02 0.87 N/A 3.40* 0.87
15 Adjust DO Depressed Mood 1.27 0.14 1.17 0.50 1.07 1.06 2.79 3.40* N/A
16 Opioid Dependence 2.86* 0.98 2.09* 2.29 1.48 0.93 1.13 7.12* 0.87 N/A
Column 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16
Table C5T04 displays all the comorbidity odds ratios between the individual mental disorders obtained from logistic regression models for the whole study sample. Empty cells 





















































































































01 Alcohol Dependence 1.0000 
02 Alcohol Abuse 1.0000 
03 Major Depressive Disorder 1.0000 
04 Bipolar Disorder 1.0000 
05 Psychotic Disorders 1.0000 
06 Panic Disorder 0.3810 1.0000 
07 Agoraphobia 0.4565 0.5009 0.4417 1.0000 
08 Social Phobia 0.5511 0.3541 0.4987 1.0000 
09 Obsessive Compulsive Disorder 1.0000 1.0000 
10 Generalized Anxiety Disorder 0.3804 0.4832 1.0000 
11 Anxiety Disorder NOS 1.0000 
12 Dysthymic Disorder 1.0000 
13 Depressive Disorder NOS 1.0000 
14 Simple Phobia Disorder 0.3015 1.0000 
15 Adjust DO Depressed Mood 1.0000 
16 Opioid Dependence 0.5192 1.0000
Column 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16
Table C5T05 summarizes the significant (p-value: < 0.05) tetrachoric correlations between all the 16 mental disorders for the SERT (s) Allele Carriers (SS+ SL) (N = 348)
 
 
















































































































01 Alcohol Dependence 1.0000 
02 Alcohol Abuse 1.0000 
03 Major Depressive Disorder 0.3205 1.0000 
04 Bipolar Disorder 1.0000 
05 Psychotic Disorders 1.0000 
06 Panic Disorder 0.5028 1.0000 
07 Agoraphobia 0.5879 1.0000 
08 Social Phobia 0.5669 1.0000 
09 Obsessive Compulsive Disorder 0.6243 0.6677 1.0000 
10 Generalized Anxiety Disorder 0.3947 1.0000 
11 Anxiety Disorder NOS 1.0000 
12 Dysthymic Disorder 0.7113 1.0000 
13 Depressive Disorder NOS 1.0000 
14 Simple Phobia Disorder 0.2965 1.0000 
15 Adjust DO Depressed Mood 0.5854 1.0000 
16 Opioid Dependence 1.0000
Column 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16
Table C5T06 summarizes the significant (p-value: < 0.05) tetrachoric correlations between all the 16 mental disorders for the SERT (s) Allele Non-Carriers (LL) (N = 280)
 
 
















































































































01 Alcohol Dependence N/A 1.58 0.72 1.71 3.50 1.04 0.21 0.83 0.22 0.72 2.73 1.48
02 Alcohol Abuse 1.51 N/A 0.48 1.27 1.35 0.24 0.77
03 Major Depressive Disorder 0.61 0.36 N/A 0.44 4.69* 4.80* 1.00 1.00 0.33 3.0 1.30 1.48
04 Bipolar Disorder 3.07 N/A 0.50 0.64
05 Psychotic Disorders N/A 0.65
06 Panic Disorder 3.37 2.03 N/A 3.2 6.22 5.00 0.77 1.67
07 Agoraphobia 1.56 2.31 0.10 0.71 N/A 0.58 0.65 0.77
08 Social Phobia 1.19 1.58 5.13* 0.22 1.00 3.11 1.10 N/A 0.50 4.00 1.00 1.33 1.67 2.73
09 Obsessive Compulsive DO 0.26 0.28 0.15 N/A *
10 Generalized Anxiety Disorder 0.17 0.65 1.35 N/A 1.02
11 Anxiety Disorder NOS 0.74 0.41 N/A 2.10
12 Dysthymic Disorder 1.71 N/A 1.02
13 Depressive Disorder NOS 0.24 0.65 N/A 1.67
14 Simple Phobia Disorder 0.50 0.15 1.00 0.62 0.74 1.40 2.00 1.00 N/A 0.70 1.67
15 Adjust DO Depressed Mood 2.27 0.28 1.33 1.03 N/A
16 Opioid Dependence 1.25 0.73 1.44 0.58 1.06 2.05 2.40 2.10 N/A
Column 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16
Table C5T07 Summarizes the ratio of the odds of the SERT (S) allele carriers to the odds of the non-carriers, of the comorbidity for the conditions listed in the row headings, 
on those subjects who have been diagnosed with the condition listed in the column headings. As an example, for subjects diagnosed with Major Depressive Disorder, the 
odds of the carriers of the (s) allele for being diagnosed with Social Phobia was 5.13 times higher than the odds of the non-carriers (OR: 5.13 (95%CI: 1.79; 14.74). For subjects 
diagnosed with Agoraphobia, the carriers of the (s) allele, had a risk for being diagnosed with Major Depressive Disorder that was 4.69 times higher than the one of the non-
carriers (OR: 4.69 (95%CI: 1.11; 19.83). For subjects diagnosed with Social Phobia, the carriers of the (s) allele, had a risk for being diagnosed with Major Depressive Disorder 
that was 4.8 times higher than the one of the non-carriers (Odds Ratio = 4.80 (95%CI: 1.55; 14.84). Please note that order of the conditions matter in the analysis of comorbidity 
pairs by SERT carrier status (For more information see Tables C5T08 and C5t09)
 
 
Table C5T08.Odds Ratio Comorbidity for Social Phobia in SERT S Allele Carriers/ Non-Carriers for Subjects with Major Depressive Disorder
Rows Grouping SERT 













01 Comorbid Cases MDD-Social Phobia 22 5 27 0.8148
02 Non- Comorbid Cases MDD 42 49 91 0.4615
03 Totals 64 54 118 0.5424
Columns 01 02 03 03
Odds Ratio = 5.13 (95%CI: 1.79; 14.74) 
Table C5T08 displays the two by two table and analysis for the Odds Ratio for the comorbidity for Social Phobia in subjects with Major Depressive Disorder, in SERT (s) allele 
carriers vs. non-carriers for in subjects
 
 
Table C5T09.Odds Ratio Comorbidity for Major Depressive Disorder in SERT S Allele Carriers/ Non-Carriers for Subjects with Social Phobia














01 Comorbid Cases Social Phobia- MDD 22 5 27 0.8148
02 Non- Comorbid Cases  Social Phobia 22 24 46 0.4783
03 Totals 44 29 73 0.6027
Columns 01 02 03 03
Odds Ratio = 4.80 (95%CI: 1.55; 14.84) 
Table C5T09 displays the two by two table and analysis for the Odds Ratio for the comorbidity for Major Depressive Disorder in subjects with Social Phobia, in SERT (s) allele 
carriers vs. non-carriers for in subjects
 
 
Table C5T10.Odds Ratio Comorbidity for Major Depressive Disorder in SERT S Allele Carriers/ Non-Carriers for Subjects with Agoraphobia
Rows Grouping SERT 













01 Comorbid Cases Agoraphobia- MDD 10 4 14 0.7143
02 Non- Comorbid Cases Agoraphobia 8 15 23 0.3478
03 Totals 18 19 37 0.4865
Columns 01 02 03 03
Odds Ratio = 4.69 (95%CI: 1.11; 19.83) 
Table C5T10 displays the two by two table and analysis for the Odds Ratio for the comorbidity for Major Depressive Disorder in subjects with Agoraphobia, in SERT (s) allele 
carriers vs. non-carriers for in subjects
 
 
Table C5T11. Number of Lifetime Prevalence Diagnoses Whole Sample (N=847)








01 0 355 41.91 41.91
02 1 255 30.11 72.02
03 2 143 16.88 88.90
04 3 61 7.20 96.10
05 4 22 2.60 98.70
06 5 10 1.18 99.88
07 6 1 0.12 100.00
08 Totals 847 100.00
Columns 01 02 03
Table C5T11 Displays the subject distribution (individuals affected in each diagnostic group) for the number of lifetime prevalence diagnoses for the whole sample (N=847). 
 
 
Table C5T12. Number of Lifetime Prevalence Diagnoses Stratified by Gender (N=816) 












01 0 106 218 324
02 1 113 142 255
03 2 49 94 143
04 3 15 46 61
05 4 7 15 22
06 5 4 6 10
07 6 0 1 1
08 Totals 294 522 816
Columns 01 02 03




Table C5T12 Displays the subject distribution and significance testing for the number of lifetime prevalence diagnoses stratified by gender (N=816). 
 
 
Table C5T13. Number of Lifetime Prevalence Diagnoses Stratified by Median Age (44 y/o) (N=847)















01 0 146 209 355
02 1 130 125 255
03 2 80 63 143
04 3 42 19 61
05 4 14 8 22
06 5 7 3 10
07 6 0 1 1
08 Totals 419 428 847
Columns 01 02 03




Table C5T13 Summarizes the subject distribution and significance testing for the number of lifetime prevalence diagnoses stratified by median age (44 y/o) (N=847). 
 
 
Table C5T14. Number of Lifetime Prevalence Diagnoses Stratified by SERT (S) Carrier Status, Genotyped Sample (N=628)















01 0 120 147 267
02 1 82 100 182
03 2 46 60 106
04 3 21 27 48
05 4 5 9 14
06 5 5 5 10
07 6 1 0 1
08 Totals 280 348 628
Columns 01 02 03




Table C5T14 Summarizes the subject distribution and significance testing for the number of lifetime prevalence diagnoses 
stratified by SERT (s) allele carrier status  (N=628).
 
 
Table C5T15. Association of SERT Carrier Status with Prevalence of One or More LP Diagnosis (N=628)












01 No Diagnosis LP 120 147 267
02 One or More Diagnosis LP 160 201 361
03 Totals 280 348 628
Columns 01 02 03
Significance Tests SERT Carrier Status with Prevalence of One or More LP Diagnosis (N=628)
Test OR (95% CI) P Value
Odds Ratio Unadjusted 1.05 (0.76- 1.50) 0.75
Odds Ratio Adjusted 1.07 (0.75-1.55) 0.70
Table C5T15 displays the subject distribution into diagnostic categories stratified by SERT (s) allele carrier status (N=628).
Odds Ratio (95% CI) obtained from Logistic Regression models, display the risk for the carrier subgroup to be member of the category with the higher number of LP 




Table C5T16. Association of SERT Carrier Status with Prevalence of Two or More LP Diagnosis (N=628)












01 One or Less Diagnosis LP 202 247 449
02 Two or More Diagnosis LP 78 101 179
03 Totals 280 348 628
Columns 01 02 03
Significance Tests SERT Carrier Status with Prevalence of Two or More LP Diagnosis (N=628)
Test OR (95% CI) P Value
Odds Ratio Unadjusted 1.04 (0.63-1.69) 0.90
Odds Ratio Adjusted 1.12 (0.67-1.88) 0.66
Table C5T16 displays the subject distribution into diagnostic categories stratified by SERT (s) allele carrier status (N=628).
Odds Ratio (95% CI) obtained from Logistic Regression models, display the risk for the carrier subgroup to be member of the category with the higher number of LP 
diagnoses. ORs were adjusted for gender, age, ethnicity, and marital status.
 
 
TABLES FOR CHAPTER 06







01 Alcohol Dependence 177 20.90
02 Alcohol Abuse 48 5.67
03 Major Depressive Disorder 152 17.95
04 Bipolar Disorder 22 2.60
05 Psychotic Disorders 12 1.42
06 Panic Disorder 46 5.43
07 Agoraphobia 50 5.90
08 Social Phobia 100 11.81
09 Obsessive Compulsive Disorder 14 1.65
10 Generalized Anxiety Disorder 25 2.95
11 Anxiety Disorder NOS 21 2.48
12 Dysthymic Disorder 9 1.06
13 Depressive Disorder NOS 18 2.13
14 Simple Phobia Disorder 106 12.51
15 Adjust DO Depressed Mood 32 3.78
16 Opioid Dependence 36 4.25
17 Total Affected by LP Psychiatric Disorders Total # Diagnoses 
Sample
868
Total Burden Mental  





Table C6T01A displays the unweighted lifetime prevalence estimates of the 16 selected mental disorders examined in our study sample. The column 01 
displays the number of subjects in the sample diagnosed with each disorder, column 02 shows the unweighted lifetime prevalence estimates of each disorder 
per 100 subjects (Number of Individuals Diagnosed with a Disorder/ Total Number of Subjects in the Sample x 100).  In row 17, column 01 displays the Total 
Number of Diagnoses in the sample (N=868). This number is the result of the simple addition of all the affected cases or diagnoses in our cohort. Row 17, 
column 02 displays the result of the quotient between the Total Number of Diagnoses in the sample, and the Total Number of Subjects in the sample (868 
Diagnoses/ 847 Subjects= 1.028). This translates into a total lifetime prevalence burden of mental illness in the study sample of 102.48 cases of mental 
disorder per 100 subjects in the sample.
 
 



















Table C6T01B depicts a small hypothetical sample of 10 Individuals. Individuals 01, 02 and 03 received no diagnoses. Individuals 04 and 05 have been 
diagnosed only with Condition A. Individual 06 has been diagnosed only with Condition B.  Individual 07 has been diagnosed with 2 conditions: Condition A, 
and B. Individual 08 has been diagnosed with 2 conditions: Condition A, and C. Individual 09 was diagnosed with 3 conditions: Conditions A, C, D.  
Total Number of Individuals in the sample =10 
Total number of Individuals Diagnosed = 7 
Total Number of Diagnoses = 13.  
Total Number of Comorbidities in the sample =16. 
Comorbidity count by Individuals: Individuals 07 and 08 = 2 comorbidities each. Individuals 09 and 10 = 6 comorbidities each 
Comorbidity count by diagnoses: Conditions A and D = 4 comorbidities each, Condition B= 3 comorbidities, Condition C = 5 comorbidities 
 
 























































































































01 Alcohol Dependence N/A 6 41 9 1 9 21 30 4 6 3 1 5 24 8 15 183
02 Alcohol Abuse 6 N/A 8 0 1 5 3 9 2 0 0 0 1 5 0 2 42
03 Major Depressive Disorder 41 8 N/A 0 3 18 18 32 7 10 6 3 2 26 1 11 186
04 Bipolar Disorder 9 0 0 N/A 0 4 4 6 2 0 0 0 0 1 0 0 26
05 Psychotic Disorders 1 1 3 0 N/A 0 2 2 0 0 1 0 1 3 0 0 14
06 Panic Disorder 9 5 18 4 0 N/A 9 11 2 2 0 0 1 7 2 4 74
07 Agoraphobia 21 3 18 4 2 9 N/A 19 4 4 3 1 1 13 1 3 106
08 Social Phobia 30 9 32 6 2 11 19 N/A 7 8 3 2 3 25 4 4 165
09 Obsessive Compulsive Disorder 4 2 7 2 0 2 4 7 N/A 2 0 1 0 4 0 0 35
10 Generalized Anxiety Disorder 6 0 10 0 0 2 4 8 2 N/A 0 2 0 9 1 0 44
11 Anxiety Disorder NOS 3 0 6 0 1 0 3 3 0 0 N/A 0 1 3 2 1 23
12 Dysthymic Disorder 1 0 3 0 0 0 1 2 1 2 0 N/A 0 2 0 0 12
13 Depressive Disorder NOS 5 1 2 0 1 1 1 3 0 0 1 0 N/A 2 0 4 21
14 Simple Phobia Disorder 24 5 26 1 3 7 13 25 4 9 3 2 2 N/A 10 4 138
15 Adjust DO Depressed Mood 8 0 1 0 0 2 1 4 0 1 2 0 0 10 N/A 0 29
16 Opioid Dependence 15 2 11 0 0 4 3 4 0 0 1 0 4 4 0 N/A 48
17 Total #  Comorbidities 183 42 186 26 14 74 106 165 35 44 23 12 21 138 29 48 1146
18 # Axis I Diagnoses 177 48 152 22 12 46 50 100 14 25 21 9 18 106 32 36 868
19 Comorbidity/ Diagnosis 
Inflation Ratio
1.03 0.88 1.22 1.18 1.17 1.61 2.12 1.65 2.50 1.76 1.10 1.33 1.17 1.30 0.91 1.33 1.32
20 Standardized Comorbidity to Diagnosis 
Inflation Ratio
0.78 0.66 0.93 0.90 0.88 1.22 1.61 1.25 1.89 1.33 0.83 1.01 0.88 0.99 0.69 1.01 1.00
Column 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17
 
 
Table C6T02A. Rows 01 through 16 and Columns 01 through 16 display in each cell the tally of the number of comorbidity pairs or dyads. These represent the 
number of subjects in the sample that were diagnosed in their lifetime with the two conditions that are listed in the heading of the row and column that 
intersect in the selected cell. Row(r)01, column(c)08; as well as in r08, c01 displays 30 comorbidity pairs representing 30 subjects in the sample that were 
diagnosed both with Alcohol Dependence and Social Phobia in the sample. The cells of the row 17 from columns 01 through 16, as well as the cells of the 
column 17 form rows 01 through 16 display the total number of comorbidities for each individual disorder. The row 18, c01 through c16 displays the total 
number of subjects diagnosed for each individual Axis I mental disorder (identical to information presented in row 01 of Table 01).  The cell in row 17 and 
column 17 displays the Total Number of Comorbidities in the sample (N=1146). The cell in the intersection of row 18 and column 17 displays the Total Number 
of Diagnoses in the sample (N=868). The cells in row 19, c01 through c16, represent the ratio of the number of Comorbidities to Number of Diagnoses in each 
disorder that we labeled with Comorbidity to Diagnosis Inflation Ratio (CDIR). The cell r19, c17, represents the CDIR of the whole sample. The row 20, c01 
through c16, displays the standardized CDIR, of each disorder. These are the result of the CDIR of each disorder divided by the CDIR of the whole sample.
 
 
















































































































01 Alcohol Dependence N/A 0.71 4.84 1.06 0.12 1.06 2.48 3.54 0.47 0.71 0.35 0.12 0.59 2.83 0.95 1.77
02 Alcohol Abuse 0.71 N/A 0.95 0.00 0.12 0.59 0.35 1.06 0.24 0.00 0.00 0.00 0.12 0.59 0.00 0.24
03 Major Depressive Disorder 4.84 0.95 N/A 0.00 0.35 2.13 2.13 3.78 0.83 1.18 0.71 0.35 0.24 3.07 0.12 1.30
04 Bipolar Disorder 1.06 0.00 0.00 N/A 0.00 0.47 0.47 0.71 0.24 0.00 0.00 0.00 0.00 0.12 0.00 0.00
05 Psychotic Disorders 0.12 0.12 0.35 0.00 N/A 0.00 0.24 0.24 0.00 0.00 0.12 0.00 0.12 0.35 0.00 0.00
06 Panic Disorder 1.06 0.59 2.13 0.47 0.00 N/A 1.06 1.30 0.24 0.24 0.00 0.00 0.12 0.83 0.24 0.47
07 Agoraphobia 2.48 0.35 2.13 0.47 0.24 1.06 N/A 2.24 0.47 0.47 0.35 0.12 0.12 1.54 0.12 0.35
08 Social Phobia 3.54 1.06 3.78 0.71 0.24 1.30 2.24 N/A 0.83 0.95 0.35 0.24 0.35 2.95 0.47 0.47
09 Obsessive Comp Dis 0.47 0.24 0.83 0.24 0.00 0.24 0.47 0.83 N/A 0.24 0.00 0.12 0.00 0.47 0.00 0.00
10 Generalized Anx Dis 0.71 0.00 1.18 0.00 0.00 0.24 0.47 0.95 0.24 N/A 0.00 0.24 0.00 1.06 0.12 0.00
11 Anxiety Disorder NOS 0.35 0.00 0.71 0.00 0.12 0.00 0.35 0.35 0.00 0.00 N/A 0.00 0.12 0.35 0.24 0.12
12 Dysthymic Disorder 0.12 0.00 0.35 0.00 0.00 0.00 0.12 0.24 0.12 0.24 0.00 N/A 0.00 0.24 0.00 0.00
13 Depressive Dis NOS 0.59 0.12 0.24 0.00 0.12 0.12 0.12 0.35 0.00 0.00 0.12 0.00 N/A 0.24 0.00 0.47
14 Simple Phobia 2.83 0.59 3.07 0.12 0.35 0.83 1.54 2.95 0.47 1.06 0.35 0.24 0.24 N/A 1.18 0.47
15 Adjust DO Depr Mood 0.95 0.00 0.12 0.00 0.00 0.24 0.12 0.47 0.00 0.12 0.24 0.00 0.00 1.18 N/A 0.00
16 Opioid Dependence 1.77 0.24 1.30 0.00 0.00 0.47 0.35 0.47 0.00 0.00 0.12 0.00 0.47 0.47 0.00 N/A
Column 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16
 
 
Table C6T02B displays the prevalence of the comorbidity pairs per 100 individuals in the sample (N=847). The cells display the weight of each comorbidity pair 
(joint probability) for the sample as a whole.  The comorbidity pair with the highest prevalence (0.0484 or 4.84%) was the one formed by those diagnosed with 
Major Depressive Disorder and Alcohol Dependence (r01, c03 and r03 c01). The second highest pair was the one comprised by those diagnosed with Major 
Depressive Disorder and Social Phobia (r03, c08 and r08, c03) presenting with a prevalence in the sample of 0.0378 or 3.78%. 
 
 
















































































































01 Alcohol Dependence N/A 3.39 23.16 5.08 0.56 5.08 11.86 16.95 2.26 3.39 1.69 0.56 2.82 13.56 4.52 8.47
02 Alcohol Abuse 12.50 N/A 16.67 0.00 2.08 10.42 6.25 18.75 4.17 0.00 0.00 0.00 2.08 10.42 0.00 4.17
03 Major Depressive Disorder 26.97 5.26 N/A 0.00 1.97 11.84 11.84 21.05 4.61 6.58 3.95 1.97 1.32 17.11 0.66 7.24
04 Bipolar Disorder 40.91 0.00 0.00 N/A 0.00 18.18 18.18 27.27 9.09 0.00 0.00 0.00 0.00 4.55 0.00 0.00
05 Psychotic Disorders 8.33 8.33 25.00 0.00 N/A 0.00 16.67 16.67 0.00 0.00 8.33 0.00 8.33 25.00 0.00 0.00
06 Panic Disorder 19.57 10.87 39.13 8.70 0.00 N/A 19.57 23.91 4.35 4.35 0.00 0.00 2.17 15.22 4.35 8.70
07 Agoraphobia 42.00 6.00 36.00 8.00 4.00 18.00 N/A 38.00 8.00 8.00 6.00 2.00 2.00 26.00 2.00 6.00
08 Social Phobia 30.00 9.00 32.00 6.00 2.00 11.00 19.00 N/A 7.00 8.00 3.00 2.00 3.00 25.00 4.00 4.00
09 Obsessive Comp Dis 28.57 14.29 50.00 14.29 0.00 14.29 28.57 50.00 N/A 14.29 0.00 7.14 0.00 28.57 0.00 0.00
10 Generalized Anx Dis 24.00 0.00 40.00 0.00 0.00 8.00 16.00 32.00 8.00 N/A 0.00 8.00 0.00 36.00 4.00 0.00
11 Anxiety Disorder NOS 14.29 0.00 28.57 0.00 4.76 0.00 14.29 14.29 0.00 0.00 N/A 0.00 4.76 14.29 9.52 4.76
12 Dysthymic Disorder 11.11 0.00 33.33 0.00 0.00 0.00 11.11 22.22 11.11 22.22 0.00 N/A 0.00 22.22 0.00 0.00
13 Depressive Dis NOS 27.78 5.56 11.11 0.00 5.56 5.56 5.56 16.67 0.00 0.00 5.56 0.00 N/A 11.11 0.00 22.22
14 Simple Phobia 22.64 4.72 24.53 0.94 2.83 6.60 12.26 23.58 3.77 8.49 2.83 1.89 1.89 N/A 9.43 3.77
15 Adjust DO Depr Mood 25.00 0.00 3.13 0.00 0.00 6.25 3.13 12.50 0.00 3.13 6.25 0.00 0.00 31.25 N/A 0.00
16 Opioid Dependence 41.67 5.56 30.56 0.00 0.00 11.11 8.33 11.11 0.00 0.00 2.78 0.00 11.11 11.11 0.00 N/A 
Column 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16
 
 
Table C6T02C Comorbidity and Diagnosis Composition as Row Percentage. Rows 01 through 16 display the comorbidity composition (as percentages) of the 
Axis I disorders that appear in the heading of each row. Row 03 displays how the rest of the Axis I disorders impact on the comorbidity makeup of Major 
Depressive Disorder. In probability terms, the value in each cell represents the conditional probability of the condition that appears in the heading of the 
column given the condition that appears in the heading of the row. As an example, the condition probability of Social Phobia, given the subject has Major 
Depressive Disorder is 32/152= 0.2105 or 21.05% (r03, c08).  On the other hand, the conditional probability that a subject has Major Depressive Disorder given 
he/she has Social Phobia is 32/100= 0.32 or 32% (r08, c03). 
 
 
















































































































01 Alcohol Dependence N/A 0.60 1.29 1.96 0.40 0.94 2.01 1.44 1.37 1.15 0.68 0.53 1.33 1.08 1.20 1.99
02 Alcohol Abuse 0.60 N/A 0.93 0.00 1.47 1.92 1.06 1.59 2.52 0.00 0.00 0.00 0.98 0.83 0.00 0.98
03 Major Depressive Disorder 1.29 0.93 N/A 0.00 1.39 2.18 2.01 1.78 2.79 2.23 1.59 1.86 0.62 1.37 0.17 1.70
04 Bipolar Disorder 1.96 0.00 0.00 N/A 0.00 3.35 3.08 2.31 5.50 0.00 0.00 0.00 0.00 0.36 0.00 0.00
05 Psychotic Disorders 0.40 1.47 1.39 0.00 N/A 0.00 2.82 1.41 0.00 0.00 3.36 0.00 3.92 2.00 0.00 0.00
06 Panic Disorder 0.94 1.92 2.18 3.35 0.00 N/A 3.31 2.03 2.63 1.47 0.00 0.00 1.02 1.22 1.15 2.05
07 Agoraphobia 2.01 1.06 2.01 3.08 2.82 3.31 N/A 3.22 4.84 2.71 2.42 1.88 0.94 2.08 0.53 1.41
08 Social Phobia 1.44 1.59 1.78 2.31 1.41 2.03 3.22 N/A 4.23 2.71 1.21 1.88 1.41 2.00 1.06 0.94
09 Obsessive Comp Dis 1.37 2.52 2.79 5.50 0.00 2.63 4.84 4.24 N/A 4.84 0.00 6.72 0.00 2.28 0.00 0.00
10 Generalized Anx Dis 1.15 0.00 2.23 0.00 0.00 1.47 2.71 2.71 4.84 N/A 0.00 7.53 0.00 2.88 1.06 0.00
11 Anxiety Disorder NOS 0.68 0.00 1.59 0.00 3.36 0.00 2.42 1.21 0.00 0.00 N/A 0.00 2.24 1.14 2.52 1.12
12 Dysthymic Disorder 0.53 0.00 1.86 0.00 0.00 0.00 1.88 1.88 6.72 7.53 0.00 N/A 0.00 1.78 0.00 0.00
13 Depressive Dis NOS 1.33 0.98 0.62 0.00 3.92 1.02 0.94 1.41 0.00 0.00 2.24 0.00 N/A 0.89 0.00 5.23
14 Simple Phobia 1.08 0.83 1.37 0.36 2.00 1.22 2.08 2.00 2.28 2.88 1.14 1.78 0.89 N/A 2.50 0.89
15 Adjust DO Depr Mood 1.20 0.00 0.17 0.00 0.00 1.15 0.53 1.06 0.00 1.06 2.52 0.00 0.00 2.50 N/A 0.00
16 Opioid Dependence 1.99 0.98 1.70 0.00 0.00 2.05 1.41 0.94 0.00 0.00 1.12 0.00 5.23 0.89 0.00 N/A 
Column 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16
 
 
Table C6T02D displays the values of the Ratio of Conditional to Marginal Probabilities (RCMP) for all comorbidity dyads in the sample. If we define that a 
comorbidity dyad is integrated by Condition A and Condition B. The values displayed in the cells con be defined as PA/B / PA, the conditional probability of 
the Condition A given the Condition B divided by the probability of the Condition A. In probability terms, the ratio of PA/B /PA is identical to PB/A / PB, the 
conditional probability of Condition B given A divided by the Probability of Condition B.  In r01, c03 and r03, c01 we can read the value of 1.29. This can be 
described as the probability of a diagnoses of Major Depressive Disorder in subjects diagnosed with Alcohol Dependence divided by the probability of a 
diagnoses of Major Depressive Disorder in the whole sample. It can also be described as the probability of a diagnoses of Alcohol Dependence in individuals 
already diagnosed with Major Depressive Disorder divided by the probability of Alcohol Dependence in the whole sample. 
 
 
















































































































01 Alcohol Dependence N/A 0.52 1.52* 2.71* 0.34 0.92 2.98* 1.75* 1.53 1.20 0.62 0.47 1.47 1.12 1.27 2.86*
02 Alcohol Abuse 0.52 N/A 0.91 1.52 2.15 1.07 1.80 2.85 0.98 0.80 0.98
03 Major Depressive Disorder 1.52* 0.91 N/A 1.53 3.20* 2.78* 2.46* 4.74* 3.19* 1.86 2.31 0.57 1.59 0.14 2.09*
04 Bipolar Disorder 2.71* N/A 4.14* 3.76* 2.92* 6.78* 0.33
05 Psychotic Disorders 0.34 1.52 1.53 N/A 3.28 1.50 3.70 4.37 2.37
06 Panic Disorder 0.92 2.15 3.20* 4.14* N/A 4.51* 2.51* 2.99 1.54 1.02 1.27 1.17 2.29
07 Agoraphobia 2.98* 1.07 2.78* 3.76* 3.28 4.51* N/A 5.42* 6.84* 3.21* 2.76 2.01 0.94 2.66* 0.50 1.48
08 Social Phobia 1.75* 1.80 2.46* 2.92* 1.50 2.51* 5.42* N/A 7.96* 3.73* 1.25 2.16 1.51 2.74* 1.07 0.93
09 Obsessive Compulsive Disorder 1.53 2.85 4.74* 6.78* 2.99 6.84* 7.96* N/A 5.87* 7.93 2.87
10 Generalized Anxiety Disorder 1.20 3.19* 1.54 3.21* 3.73* 5.87* N/A 10.12* 4.20* 1.06
11 Anxiety Disorder NOS 0.62 1.86 3.70 2.76 1.25 N/A 2.38 1.17 2.79 1.13
12 Dysthymic Disorder 0.47 2.31 2.01 2.16 7.93 10.12* N/A A 2.02
13 Depressive Disorder NOS 1.47 0.98 0.57 4.37 1.02 0.94 1.51 2.38 N/A 0.87 7.12*
14 Simple Phobia Disorder 1.12 0.80 1.59 0.33 2.37 1.27 2.66* 2.74* 2.87 4.20* 1.17 2.02 0.87 N/A 3.40* 0.87
15 Adjust DO Depressed Mood 1.27 0.14 1.17 0.50 1.07 1.06 2.79 3.40* N/A
16 Opioid Dependence 2.86* 0.98 2.09* 2.29 1.48 0.93 1.13 7.12* 0.87 N/A
Column 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16
 
 
Table C6T02E displays the Odds Ratio (OR) of the lifetime prevalence comorbidity pairs for all 16 Axis I disorders. We can see that the RCMP values have the 
same direction that the ORs, being somewhat more conservative. The ORs have the added advantage of a significance testing, although they are far more time 
demanding in their execution than the RCMP. 
 
 























01 Alcohol Dependence 0 69 60 28 14 5 1 177
02 Alcohol Abuse 0 24 12 8 2 2 0 48
03 Major Depressive Disorder 0 50 48 33 13 7 1 152
04 Bipolar Disorder 0 8 7 3 3 1 0 22
05 Psychotic Disorders 0 2 6 4 0 0 0 12
06 Panic Disorder 0 8 15 13 7 3 0 46
07 Agoraphobia 0 6 11 13 12 7 1 50
08 Social Phobia 0 15 40 22 12 10 1 100
09 Obsessive Compulsive DO 0 1 3 2 4 4 0 14
10 Generalized Anxiety Disorder 0 7 2 8 6 2 0 25
11 Anxiety Disorder NOS 0 6 10 4 0 0 1 21
12 Dysthymic Disorder 0 3 3 1 1 1 0 9
13 Depressive Disorder NOS 0 7 6 2 2 0 1 18
14 Simple Phobia Disorder 0 28 39 26 5 8 0 106
15 Adjust DO Depressed Mood 0 10 16 5 1 0 0 32
16 Opioid Dependence 0 11 8 11 6 0 0 36
17 #Diagnoses Per Group DG 0 255 286 183 88 50 6 868
18 # Individuals Diagnosed 0 255 143 61 22 10 1 492
19 # Individuals 355 255 143 61 22 10 1 847
Column 01 02 03 04 05 06 07 08
 
 
Table C6T03A details the data of the grouping or stratification of the 847 individuals in the sample. Column 01 displays the individuals that did not receive any 
Axis I diagnosis. Columns 02 through 07, rows 01 through 16 display the number of subjects diagnosed with a mental disorder in each diagnostic group. The 
cells of column 08 display the total number of diagnoses for the individual Axis I disorders. Row 17 contains the number of diagnoses accrued by each 
diagnostic group (DG0=0, DG1=255, DG2=286, DG3=183, DG4=88, DG5=50, and DG6=6) and by the total sample (N=868). Row 18 displays the number of 
individuals that received a diagnosis in each group (DG0=0, DG1=255, DG2=143, DG3=61, DG4=22, DG5=10, and DG6=1) as well as in the total sample (N=492). 
Row 19 displays the number of individuals in each group (in columns 01 through 07) and in the total sample (in column 08). 
 
 























01 Alcohol Dependence 0.00 38.98 33.90 15.82 7.91 2.82 0.56 100
02 Alcohol Abuse 0.00 50.00 25.00 16.67 4.17 4.17 0.00 100 
03 Major Depressive Disorder 0.00 32.89 31.58 21.71 8.55 4.61 0.66 100 
04 Bipolar Disorder 0.00 36.36 31.82 13.64 13.64 4.55 0.00 100 
05 Psychotic Disorders 0.00 16.67 50.00 33.33 0.00 0.00 0.00 100 
06 Panic Disorder 0.00 17.39 32.61 28.26 15.22 6.52 0.00 100 
07 Agoraphobia 0.00 12.00 22.00 26.00 24.00 14.00 2.00 100 
08 Social Phobia 0.00 15.00 40.00 22.00 12.00 10.00 1.00 100 
09 Obsessive Compulsive DO 0.00 7.14 21.43 14.29 28.57 28.57 0.00 100 
10 Generalized Anxiety Disorder 0.00 28.00 8.00 32.00 24.00 8.00 0.00 100 
11 Anxiety Disorder NOS 0.00 28.57 47.62 19.05 0.00 0.00 4.76 100 
12 Dysthymic Disorder 0.00 33.33 33.33 11.11 11.11 11.11 0.00 100 
13 Depressive Disorder NOS 0.00 38.89 33.33 11.11 11.11 0.00 5.56 100 
14 Simple Phobia Disorder 0.00 26.42 36.79 24.53 4.72 7.55 0.00 100 
15 Adjust DO Depressed Mood 0.00 31.25 50.00 15.63 3.13 0.00 0.00 100 
16 Opioid Dependence 0.00 30.56 22.22 30.56 16.67 0.00 0.00 100 
17 #Diagnoses Per Group DG (as percentages of N=868) 0.00 29.38 32.95 21.08 10.14 5.76 0.69 100 
18 # Individuals Diagnosed (as percentages of N=492) 0.00 51.83 29.07 12.40 4.47 2.03 0.20 100 
19 # Individuals (as percentages of N=847) 41.91 30.11 16.88 7.20 2.60 1.18 0.12 100 
Column 01 02 03 04 05 06 07 08
 
 
Table C6T03B displays the information of table 03A as percentages of the total row counts contained in Column 08. Column 01 displays the individuals that did 
not receive any Axis I diagnosis. Columns 02 through 07, rows 01 through 16 display the percentage of subjects diagnosed in each diagnostic group with all
the individual Axis I disorders. Row 17 contains the number of diagnoses accrued by each diagnostic group as percentages of the total number of diagnoses 
in the sample (n=868) (DG0=0%, DG1=29.38%, DG2=32.95%, DG3=21.08%, DG4=10.14%, DG5=5.76%, DG6=0.69%). Row 18 displays the number of individuals 
that received a diagnosis in each group as percentages of the total number of individuals diagnosed (N=492) (DG0=0%, DG1=51.83%, DG2=29.07%, 
DG3=12.40%, DG4=4.47%, DG5=2.03%, DG6=0.20%). Row 19 displays the number of individuals in each group as percentages of the total number of 
Individuals in the Sample (N=847).
 
 










































01 Alcohol Dependence 177 113.00 0.64 1.57 0.89 183 1.62 0.70 20.90 13.34
02 Alcohol Abuse 48 33.57 0.70 1.43 0.81 42 1.25 0.54 5.67 3.96
03 Major Depressive Disorder 152 89.82 0.59 1.69 0.96 186 2.07 0.89 17.95 10.60
04 Bipolar Disorder 22 13.45 0.61 1.64 0.93 26 1.93 0.83 2.60 1.59
05 Psychotic Disorders 12 6.33 0.53 1.89 1.07 14 2.21 0.95 1.42 0.75
06 Panic Disorder 46 22.18 0.48 2.07 1.18 74 3.34 1.43 5.43 2.62
07 Agoraphobia 50 20.40 0.41 2.45 1.39 106 5.20 2.23 5.90 2.41
08 Social Phobia 100 47.50 0.48 2.11 1.19 165 3.47 1.49 11.81 5.61
09 Obsessive Comp DO 14 4.97 0.35 2.82 1.60 35 7.05 3.02 1.65 0.59
10 Generalized Anxiety DO 25 12.57 0.50 1.99 1.13 44 3.50 1.50 2.95 1.48
11 Anxiety Disorder NOS 21 12.50 0.60 1.68 0.95 23 1.84 0.79 2.48 1.48
12 Dysthymic Disorder 9 5.28 0.59 1.70 0.97 12 2.27 0.97 1.06 0.62
13 Depressive Disorder NOS 18 11.33 0.63 1.59 0.90 21 1.85 0.80 2.13 1.34
14 Simple Phobia Disorder 106 59.02 0.56 1.80 1.02 138 2.34 1.00 12.51 6.97
15 Adjust DO Depressed Mood 32 19.92 0.62 1.61 0.91 29 1.46 0.63 3.78 2.35
16 Opioid Dependence 36 20.17 0.56 1.79 1.01 48 2.38 1.02 4.25 2.38






























Column 01 02 03 04 05 06 07 08 09 10
 
 
Table C6T03C displays the result of the adjustment and ratios. Column 01, row 01 through row 16 displays the number of unadjusted diagnoses for each disorder. Column 01, 
row 17, the total number of diagnoses in the sample (N=868). Column 02, rows 01 through 16, displays the number of adjusted diagnoses. Column 02, row 17, the total number 
of adjusted diagnoses in the sample (N=492). Column 03, rows 01 through 16, displays proportion of diagnostic information after adjustment for each disorder. Column 03, row 
17, displays proportion of total diagnostic proportion after adjustment. This is a measure of the extent of the adjustment. Column 04, rows 01 through 16, displays the 
Diagnostic Inflation Ratio (DIR) (Unadjusted # Diagnoses/ Adjusted # Diagnoses) for each disorder. Column 04, row 17, displays the DIR for the whole sample. Column 05, 
rows 01 through 16, displays the Standardized Diagnostic Inflation Ratio (SDIR) for each disorder (DIR of each disorder/ DIR whole sample). Column 06, row 01 through row 16 
displays the number of comorbidities for each disorder. Column 07, row 17, the total number of comorbidities in the sample (N=1146).  Column 07, rows 01 through 16, 
displays the Comorbidity Inflation Ratio (CIR) (Unadjusted # Comorbidities/ Adjusted # Diagnoses) for each disorder. Column 07, row 17, displays the CIR for the whole 
sample. Column 08, rows 01 through 16, displays the Standardized Comorbidity Inflation Ratio (SCIR) for each disorder (CIR of each disorder/ CIR whole sample). Column 09, 
rows 01 through 16, displays the Unadjusted Lifetime Prevalence Estimates per 100 subjects for the Whole Sample. Column 09, row 17, displays the unadjusted burden of 
mental disorders per 100 subjects for the whole sample (102.48). Column 10, rows 01 through 16, displays the Adjusted Lifetime Prevalence Estimates per 100 subjects for the 
Whole Sample (Adjusted Number of Diagnoses/ Sample Size). Column 10, row 17, displays the adjusted burden of mental disorders per 100 subjects for the whole sample 
(58.09).  
Column 01
Unadjusted Number of Diagnoses for Individual Disorders (rows 01-16), and for total number of disorders per diagnostic group (row17) =
= # Diagnoses in DG1 + # Diagnoses in DG2 + # Diagnoses in DG3 + # Diagnoses in DG4 + # Diagnoses in DG5 + # Diagnoses in DG6  
Column 02
Adjusted Number of Diagnoses for Individual Disorders (rows 01-16), and for total number of disorders per diagnostic group (row17) =
= # Diagnoses in DG1 /1 + # Diagnoses in DG2 /2 + # Diagnoses in DG3 /3 + # Diagnoses in DG4 /4 + # Diagnoses in DG5 / 5 + # Diagnoses in DG6 /6
Column 03
Diagnostic Proportion Post Adjustment for Individual Disorders= Adjusted Number of Diagnoses Disorder A / Unadjusted Number of Diagnoses Disorder A
Diagnostic Proportion Post Adjustment for Total # Disorders= Adjusted Total Number of Diagnoses / Unadjusted Total Number of Diagnoses 
Column 04
Diagnostic Inflation Ratio (DIR) for Individual Disorders= Unadjusted Number of Diagnoses Disorder A / Adjusted Number of Diagnoses Disorder A
Diagnostic Inflation Ratio (DIR) for Total # Disorders = Unadjusted Total Number of Diagnoses / Adjusted Total Number of Diagnoses
Column 05




Unadjusted number of Comorbidites = Can be Obtained from Row 17, Table C6T02A or can be calculated as 
= # Diagnoses in DG1 x 0 + # Diagnoses in DG2 x 2 + # Diagnoses in DG3 x 6 + # Diagnoses in DG4 x 12 + # Diagnoses in DG5 x 20 + # Diagnoses in DG6 x 30
Column 07
Comorbidity Inflation Ratio (CIR) for Individual Disorders= Number of Comorbidities Disorder A / Adjusted Number of Diagnoses Disorder A
Comorbidity Inflation Ratio (CIR) for Total # Disorders= Total Number of Comorbidities / Adjusted Total Number of Diagnoses
Column 08
Standardized Comorbidity Inflation Ratio = CIR of Individual Disorder /CIR Total # Disorders  
Column 09
Unadjusted Lifetime Prevalence x 100 Subjects for Individual Disorders = Unadjusted Number of Diagnoses Disorder A x 100 / Sample Size (847)
Unadjusted Burden for Total # Mental Disorders in Whole Sample x 100 Subjects = Unadjusted Total Number of Diagnoses x 100/ Sample Size (847)
Column 10
Adjusted Lifetime Prevalence x 100 Subjects for Individual Disorders = Adjusted Number of Diagnoses Disorder A x 100 / Sample Size (847)
Adjusted Burden for Total # Mental Disorders in Whole Sample x 100 Subjects = Adjusted Total Number of Diagnoses x 100/ Sample Size (847)
 
 
Table C6T03D. Example on the Table for Chi Square and Fisher’s Exact Test Calculation
DG1 DG2 DG3 DG4 DG5 DG6 Totals
# Diagnoses Alcohol Dependence 69 60 28 14 5 1 177 
# Rest of Diagnoses 186 226 155 74 45 5 691 
Total of Diagnoses In each DG 255 286 183 88 50 6 868 
Table C6T03D Display the diagnostic distribution of the individuals diagnosed with Alcohol Dependence across the diagnostic strata
 
 
Table C6T03E. Results for the Chi Square and Fisher’s Exact Test Significance Test on all 16 Axis I Conditions 
Inference on Total Number of Diagnoses
Row Axis I Condition Chi2  p values Exact Test  p values
01 Alcohol Dependence 0.013* 0.013*
02 Alcohol Abuse 0.048* 0.082
03 Major Depressive Disorder 0.876 0.887
04 Bipolar Disorder 0.917 0.875
05 Psychotic Disorders 0.463 0.496
06 Panic Disorder 0.394 0.335
07 Agoraphobia 0.000* 0.000*
08 Social Phobia 0.017* 0.007*
09 Obsessive Compulsive DO 0.001* 0.004*
10 Generalized Anxiety Disorder 0.040* 0.019*
11 Anxiety Disorder NOS 0.074 0.123
12 Dysthymic Disorder 0.962 0.795
13 Depressive Disorder NOS 0.117 0.232
14 Simple Phobia Disorder 0.253 0.251
15 Adjust DO Depressed Mood 0.206 0.268
16 Opioid Dependence 0.226 0.217
Column 01 02
 
Table C6T03E displays the results of the Chi Square and Fisher Exact Tests done for each of the Axis I conditions. The p<0.05 are marked with an asterisk. The 
results show that Alcohol Dependence, Agoraphobia, Social Phobia, Obsessive Compulsive Disorder, and Generalized Anxiety Disorder have a distribution of 
individuals diagnosed across the Diagnostic Strata that differs significantly from the one of the total sample. 
 
 























Diag Com Diag Com Diag Com Diag Com Diag Com Diag Com Diag Com Diag Com
01 Alcohol Dependence 0 0 69 0 60 60 28 56 14 42 5 20 1 5 177 183
02 Alcohol Abuse 0 0 24 0 12 12 8 16 2 6 2 8 0 0 48 42
03 Major Depressive Disorder 0 0 50 0 48 48 33 66 13 39 7 28 1 5 152 186
04 Bipolar Disorder 0 0 8 0 7 7 3 6 3 9 1 4 0 0 22 26
05 Psychotic Disorders 0 0 2 0 6 6 4 8 0 0 0 0 0 0 12 14
06 Panic Disorder 0 0 8 0 15 15 13 26 7 21 3 12 0 0 46 74
07 Agoraphobia 0 0 6 0 11 11 13 26 12 36 7 28 1 5 50 106
08 Social Phobia 0 0 15 0 40 40 22 44 12 36 10 40 1 5 100 165
09 Obsessive Compulsive Disorder 0 0 1 0 3 3 2 4 4 12 4 16 0 0 14 35
10 Generalized Anxiety Disorder 0 0 7 0 2 2 8 16 6 18 2 8 0 0 25 44
11 Anxiety Disorder NOS 0 0 6 0 10 10 4 8 0 0 0 0 1 5 21 23
12 Dysthymic Disorder 0 0 3 0 3 3 1 2 1 3 1 4 0 0 9 12
13 Depressive Disorder NOS 0 0 7 0 6 6 2 4 2 6 0 0 1 5 18 21
14 Simple Phobia Disorder 0 0 28 0 39 39 26 52 5 15 8 32 0 0 106 138
15 Adjust DO Depressed Mood 0 0 10 0 16 16 5 10 1 3 0 0 0 0 32 29
16 Opioid Dependence 0 0 11 0 8 8 11 22 6 18 0 0 0 0 36 48
17 #Diagnoses 0 255 286 183 88 50 6 868
18 # Comorbidities 0 0 286 366 264 200 30 1146
19 #Individuals  Diagnosed 0 255 143 61 22 10 1 492
20 #Individuals  355 255 143 61 22 10 1 847
Columns 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16
 
 
Table C6T04 details the data of the grouping or stratification of the 847 individuals in the sample. Columns 01 through 14, rows 01 through 16 display the 
number of diagnoses and comorbidities in each diagnostic group. Column 15, rows 01 through 16 display the total diagnoses for the individual Axis I 
disorders. Column 16, rows 01 through 16 display the total comorbidities for the individual Axis I disorders. Row 17 contains the number of diagnoses accrued 
by each diagnostic group (DG0=0, DG1=255, DG2=286, DG3=183, DG4=88, DG5=50, and DG6=6) and by the total sample (N=868). Row 18 contains the number 
of comorbidities accrued by each diagnostic group (DG0=0, DG1=0, DG2=286, DG3=366, DG4=264, DG5=200, and DG6=30) and by the total sample (N=1146).  
Row 19 displays the number of individuals that received a diagnosis in each group (DG0=0, DG1=255, DG2=143, DG3=61, DG4=22, DG5=10, and DG6=1) as well 
as in the total sample (N=492). Row 20 displays the number of individuals in each group (in columns 01 through 07) and in the total sample (in column 08).
 
 
Table C6T05 List of Developed Measures, Description, Potential Uses
Instrument Description Use 
Diagnostic Proportion 
Post Adjustment
Ratio = Adjusted Number of Diagnoses 
Unadjusted Number of Diagnoses 
Both for the Total Number of Diagnoses as well as the Individual Disorders
It is a measure of the diagnostic information remaining after the adjustment 
process. The higher the comorbidity burden of a total sample or an individual 
diagnosis, the lower the proportion will remain.  
Provides a measure of the significance of the 
comorbidity burden for the individual disorders and 
for the whole sample (using proportion testing) 
Diagnostic Inflation 
Ratio (DIR)
Ratio = Unadjusted Number of Diagnoses 
Adjusted Number of Diagnoses 
Both for the Total Number of Diagnoses as well as for the Individual Disorders
It is the expected or mean number of diagnoses for 
any diagnosed participant selected at random. The 
DIR of the whole sample can characterize the 




Ratio = Diagnostic Inflation Ratio for Individual Disorder
Diagnostic Inflation Ratio for the Whole Sample 
For Individual Disorders
It is a measure of the difference in the expected 
diagnosis for each disorder, compared to the DIR 




Ratio = Unadjusted Number of Comorbidities  
Adjusted Number of Diagnoses 
Both for the Total Number of Comorbidities as well as the Individual Disorders
It is the expected or mean number of comorbidities 
for any diagnosed participant selected at random. 





Ratio = Comorbidity Inflation Ratio for Individual Disorder
Comorbidity Inflation Ratio for the Whole Sample 
For Individual Disorders
It is a measure of the difference in expected 
comorbidities for each disorder, compared to the 




Ratio = Unadjusted Number of Comorbidities  
Unadjusted Number of Diagnoses 
Can also be calculated by = CIR / DIR
Both for the Total Number of Comorbidities as well as the Individual Disorders
The CDIR is the ratio of comorbidities to diagnoses 





Ratio = CDIR for Individual Disorder  
CIDR for the Whole Sample  
For Individual Disorders
It is a measure of the difference in expected ratio of 
comorbidity to diagnosis for each disorder, 
compared to the CDIR for the whole sample




Table C7T01. Number of Events (Lifetime Prevalence Diagnoses), Number of Person-Years, and Incidence Rate x 1000 patients for Whole Sample (N=847), 
SERT (s) Allele Carriers (N=336) and Non-Carriers (N=266)
Whole  Sample N=847 SERT (S) Allele Carrier (LS+ SS) 
N=336























01 Alcohol Dep 200 36408 5.49 85 14931 5.69 60 11422 5.25
02 Major Depr DO 143 37836 3.78 61 15310 3.98 50 11858 4.22
03 Bipolar DO 14 39185 0.36 5 15883 0.31 4 12352 0.33
04 Psychotic Dos 10 39187 0.26 2 15934 0.13 2 12384 0.16
05 Panic Disorder 42 38998 1.08 24 15727 1.52 7 12377 0.57
06 Agoraphobia 46 38466 1.20 17 15596 1.09 17 12092 1.41
07 Social Phobia 93 36685 2.54 41 14740 2.78 25 11718 2.13
08 Obs Comp DO 12 39175 0.31 1 15954 0.06 6 12285 0.49
09 Gen Anx DO 22 39068 0.56 8 15851 0.50 8 12267 0.65
10 Simple Phobia 92 36106 2.55 37 14612 2.53 39 11094 3.52
11 Opioid Dep 10 38291 0.26 3 15566 0.19 4 12095 0.33
Column 01 02 03 04 05 06 07 08 09
Table C7P1T01 summarizes the number of events (Lifetime Prevalence Diagnoses), the Total Person-Years for each disorder, and, the corresponding 
Incidence Rate per 1000 person-years, for the Whole Sample (N=847), SERT (s) Allele Carrier (N=336), and Non-Carriers (N=266)
 
 




















01 Alcohol Dependence 1.08 (0.77-1.53) 0.64 0.72 1.06 (0.76-1.48) 0.72 1.05 (0.75-1.48) 0.78
02 Major Depr DO 0.94 (0.64-1.40) 0.76 0.76 0.94 (0.65-1.37) 0.76 0.93 (0.63-1.36) 0.69
03 Bipolar DO 0.97 (0.21-4.90) 0.96 0.98 0.99 (0.26-3.67) 0.98 0.82 (0.22-3.09) 0.76
04 Psychotic Dos 0.78 (0.06-10.72) 0.81 0.82 0.79 (0.11-5.63) 0.82 0.85 (0.11-6.46) 0.88
05 Panic Disorder 2.70 (1.13-7.42) 0.01 0.02 2.63 (1.13-6.10) 0.03 2.35 (1.00-5.51) 0.05
06 Agoraphobia 0.78 (0.37-1.62) 0.46 0.45 0.77 (0.39-1.51) 0.45 0.77 (0.39-1.53) 0.46
07 Social Phobia 1.30 (0.77-2.24) 0.30 0.21 1.37 (0.83-2.25) 0.22 1.35 (0.81-2.27) 0.25
08 Obs Comp DO 0.13 (0.00-0.99) 0.03 0.03 0.13 (0.16-1.09) 0.06 0.11 (0.01-0.95) 0.04
09 Gen Anxiety DO 0.77 (0.25-2.37) 0.61 0.63 0.78 (0.29-2.09) 0.63 0.81 (0.30-2.19) 0.68
10 Simple Phobia 0.72 (0.45-1.16) 0.15 0.19 0.74 (0.47-1.16) 0.19 0.86 (0.54-1.36) 0.51
11 Opioid Dependence 0.58 (0.09-3.44) 0.50 0.49 0.59 (0.13-2.64) 0.49 1.05 (0.23-4.69) 0.95
Column 01 02 03 04 05 06 07
Table C7P1T02 summarizes the estimates of several survival analyses techniques comparing the SERT (s) allele carrier with the non-carrier subgroups. 
Column 01 included the estimated the Ratio between the Incidence Rates of the two groups. Column 03 includes the results of the Log Rank tests comparing 
the survival curves of the two groups. Column 04 displays the results of the unadjusted Hazard Ratios for each disorder obtained from the Cox Proportional 
Hazards Regression Analyses. Column 06 summarizes the estimates of the Hazard Ratios, adjusted by gender, ethnicity, and marital status.
 
 


















01 Any Psychotropic Medication Use 10.51 10.19 9.48 11.07 0.86 0.51
02 Anti-depressant or Anti-anxiety Medication Use 8.85 8.44 8.05 8.93 0.90 0.69
03 Anti-depressant Medication Use 6.14 5.73 5.46 6.07 0.90 0.74
04 Anti-Anxiety Medication Use 4.25 4.62 4.60 4.64 0.99 0.98
05 Hypnotic Medication Use 1.77 2.07 1.72 2.05 0.69 0.50
06 Anti-psychotic Medication Use 1.42 1.11 0.86 1.43 0.60 0.51
07 Anti-manic Medication Use 1.06 1.27 0.86 1.78 0.48 0.32
Column 01 02 03 04 05 06
Table C7T03 summarizes the findings of our analyses on the use of psychotropic agents. Antidepressant agents were the most widely prescribed for our 
subjects (8.85 per 100 subjects), followed by anti-anxiety agents (4.25 per 100 subjects). The overall use of psychotropic agents in the sample (including all 
types of psychotropic medications) was equal to 10.51 per 100 subjects. No statistical significant association was found on the SERT (s) allele carrier status 
and the use of any psychotropic medications, considered individually or as a cumulative use.
 
 
TABLES FOR APPENDIX 02.

























01 Alcohol Dependence 0 27 26 13 5 2 0 73
02 Alcohol Abuse 0 12 5 4 1 1 0 23
03 Major Depressive DO 0 14 24 15 6 5 0 64
04 Bipolar Disorder 0 6 3 0 2 0 0 11
05 Psychotic Disorders 0 1 1 1 0 0 0 3
06 Panic Disorder 0 4 10 5 4 3 0 26
07 Agoraphobia 0 2 4 3 5 4 0 18
08 Social Phobia 0 5 14 13 7 5 0 44
09 Obsessive Comp DO 0 0 1 0 0 1 0 2
10 Generalized Anxiety DO 0 2 1 3 1 1 0 8
11 Anxiety Disorder NOS 0 3 3 1 0 0 0 7
12 Dysthymic Disorder 0 2 1 1 0 0 0 4
13 Depressive Disorder NOS 0 3 2 1 1 0 0 7
14 Simple Phobia 0 10 17 13 1 3 0 44
15 Adjust DO Dep Mood 0 6 5 3 0 0 0 14
16 Opioid Dependence 0 3 3 5 3 0 0 14
17 #Diagnoses Per Group DG 0 100 120 81 36 25 0 362
18 # Individuals Diagnosed 0 100 60 27 9 5 0 201
19 # Individuals per Group 147 100 60 27 9 5 0 348
Column 01 02 03 04 05 06 07 08
 
 
Table AP02T01 details the diagnostic counts of the stratification of the 348 SERT (s) allele carrier subjects in the sample. Rows 01 through 15 display the 
number of diagnoses of each individual mental disorder. Column 01 displays the individuals that did not receive any psychiatric diagnosis. Columns 02 
through 07, rows 01 through 16 display the number of subjects diagnosed with a mental disorder in each diagnostic group. The cells of column 08, rows 01 
through 16 display the total number of diagnoses for the individual mental disorders. Row 17 contains the number of diagnoses accrued by each diagnostic 
group (DG0=0, DG1=100, DG2=120, DG3=81, DG4=36, DG5=25, and DG6=0) and by all carrier sub-sample (N=362). Row 18 displays the number of individuals 
that received a diagnosis in each group (DG0=0, DG1=100, DG2=60, DG3=27, DG4=9, DG5=5, and DG6=0) as well as in the SERT (s) allele carrier sub- sample 
(N=201). In columns 01 through 07, row 19 displays the number of individuals in each group (DG0=147, DG1=100, DG2=60, DG3=27, DG4=9, DG5=5, and 






























01 Alcohol Dependence 0 17 21 9 3 3 1 54
02 Alcohol Abuse 0 7 4 4 1 1 0 17
03 Major Depressive Disorder 0 17 19 13 2 2 1 54
04 Bipolar Disorder 0 1 1 1 0 1 0 4
05 Psychotic Disorders 0 0 1 2 0 0 0 3
06 Panic Disorder 0 1 2 5 0 0 0 8
07 Agoraphobia 0 3 4 6 2 3 1 19
08 Social Phobia 0 7 10 4 2 5 1 29
09 Obsessive Compulsive DO 0 0 0 1 2 3 0 6
10 Generalized Anxiety DO 0 3 1 2 3 1 0 10
11 Anxiety Disorder NOS 0 1 3 1 0 0 1 6
12 Dysthymic Disorder 0 0 2 0 1 1 0 4
13 Depressive Disorder NOS 0 2 3 1 0 0 1 7
14 Simple Phobia Disorder 0 15 14 9 2 5 0 45
15 Adjust DO Dep Mood 0 3 6 1 1 0 0 11
16 Opioid Dependence 0 5 1 4 1 0 0 11
17 #Diagnoses Per Group DG 0 82 92 63 20 25 6 288
18 # Individuals Diagnosed 0 82 46 21 5 5 1 160
19 # Individuals 120 82 46 21 5 5 1 280





Table AP02T02 details the diagnostic counts of the stratification of the 280 SERT (s) allele non-carrier subjects in the sample. Rows 01 through 15 display the 
number of diagnoses of each individual mental disorder. Column 01 displays the individuals that did not receive any psychiatric diagnosis. Columns 02 
through 07, rows 01 through 16 display the number of subjects diagnosed with a mental disorder in each diagnostic group. The cells of column 08, rows 01 
through 16, display the total number of diagnoses for the individual mental disorders in the whole non-carrier sub-sample. Row 17 contains the number of 
diagnoses accrued by each diagnostic group (DG0=0, DG1=82, DG2=92, DG3=63, DG4=20, DG5=25, and DG6=6) and by all non-carrier sub-sample (N=288). 
Row 18 displays the number of individuals that received a diagnosis in each group (DG0=0, DG1=82, DG2=46, DG3=21, DG4=5, DG5=5, and DG6=2) as well as 
in the non-carrier sub- sample (N=160). In columns 01 through 07, row 19 displays the number of individuals in each group ((DG0=120, DG1=82, DG2=46, 
DG3=21, DG4=5, DG5=5, and DG6=1). In column 08, row 19 displays the individuals diagnosed in the total sample (N=280).
 
 





























01 Alcohol Dependence 45.98 73 1.59 0.88 32.02 54 1.69 0.94 0.94
02 Alcohol Abuse 16.28 23 1.41 0.78 10.78 17 1.58 0.88 0.90
03 Major Dep DO 33.50 64 1.91 1.06 31.90 54 1.69 0.94 1.13
04 Bipolar Disorder 8.00 11 1.38 0.76 2.03 4 1.97 1.09 0.70
05 Psychotic DOs 1.83 3 1.64 0.91 1.17 3 2.57 1.43 0.64
06 Panic Disorder 12.27 26 2.12 1.18 3.67 8 2.18 1.21 0.97
07 Agoraphobia 7.05 18 2.55 1.42 8.27 19 2.30 1.28 1.11
08 Social Phobia 19.08 44 2.31 1.28 15.00 29 1.93 1.07 1.19
09 Obs Comp DO 0.70 2 2.86 1.59 1.43 6 4.19 2.33 0.68
10 Gen Anxiety DO 3.95 8 2.03 1.12 5.12 10 1.95 1.09 1.04
11 Anxiety DO NOS 4.83 7 1.45 0.80 3.00 6 2.00 1.11 0.72
12 Dysthymic DO 2.83 4 1.41 0.78 1.45 4 2.76 1.53 0.51
13 Dep  DO NOS 4.58 7 1.53 0.85 4.00 7 1.75 0.97 0.87
14 Simple Phobia 23.68 44 1.86 1.03 26.50 45 1.70 0.94 1.09
15 Adj  DO Dep Mood 9.50 14 1.47 0.82 6.58 11 1.67 0.93 0.88



















































Table AP02T03. Unadjusted and Adjusted Diagnostic Counts, and Ratios for Carriers of the SERT (s) Allele (N=348) and Non-Carriers (N=280). This table 
displays the result of the adjustment process and the resulting ratios. Column 01, row 01 through row 16 displays the number of adjusted diagnoses for each 
disorder for the carrier sample (N=348). Column 01, row 17, the total number of adjusted diagnoses in the carrier sample (201). Column 02, rows 01 through 16, 
displays the number of unadjusted diagnoses for each disorder in the carrier sub-sample. Column 02, row 17, the total number of unadjusted diagnoses in the 
carrier sub-sample (362). Column 03, rows 01 through 16, displays the Diagnostic Inflation Ratio (DIR) (Unadjusted # Diagnoses/ Adjusted # Diagnoses) for 
each disorder in the carrier sub-sample. Column 04, row 17, displays the DIR for the whole carrier sub-sample (1.80). Column 04, rows 01 through 16, displays 
the Standardized Diagnostic Inflation Ratio (SDIR) for each disorder (DIR of each disorder/ DIR whole carrier sub-sample). Column 05, row 01 through row 16 
displays the number of adjusted diagnoses for each disorder for the non-carrier sub-sample (N=280). Column 05, row 17, the total number of adjusted 
diagnoses in the non-carrier sample (160). Column 06, rows 01 through 16, displays the number of unadjusted diagnoses for each disorder in the non-carrier 
sub-sample. Column 06, row 17, the total number of unadjusted diagnoses in the non-carrier sample (288). Column 07, rows 01 through 16, displays the 
Diagnostic Inflation Ratio (DIR) (Unadjusted # Diagnoses/ Adjusted # Diagnoses) for each disorder in the non-carrier sub-sample. Column 07, row 17, displays 
the DIR for the whole non-carrier sub-sample (1.80). Column 08, rows 01 through 16, displays the Standardized Diagnostic Inflation Ratio (SDIR) for each 
disorder in the non-carrier sub-sample (DIR of each disorder/ DIR whole non-carrier sub-sample). Column 09, rows 01 through 16 displays the ratio of the DIR 
of the carrier vs. the non-carrier sub-samples for each disorder. Column 09, row 17displays the ratio of the DIR of the whole carrier sub-sample versus the DIR 
of the whole non-carrier sub-sample.
 
 

















01 Alcohol Dep 0.63 0.59 0.67
02 Alcohol Abuse 0.71 0.63 0.62
03 Major Dep DO 0.52 0.59 0.46
04 Bipolar Disorder 0.73 0.51 0.43
05 Psychotic DOs 0.61 0.39 0.59
06 Panic Disorder 0.47 0.46 0.95
07 Agoraphobia 0.39 0.44 0.79
08 Social Phobia 0.43 0.52 0.48
09 Obs Comp DO 0.35 0.24 0.76
10 Gen Anxiety DO 0.49 0.51 0.94
11 Anxiety DO NOS 0.69 0.50 0.48
12 Dysthymic DO 0.71 0.36 0.33
13 Dep  DO NOS 0.65 0.57 0.75
14 Simple Phobia 0.54 0.59 0.63
15 Adj  DO Dep Mood 0.68 0.60 0.68
16 Opioid Dep 0.49 0.64 0.45
17 # Total 0.56 0.56 0.99
Column 01 07 10
 
Table AP02T04 displays the proportion testing between the carrier sub-sample (N=348) and non-carrier sub-sample (N=280). Column 01 Rows 01 through 16 
displays the proportion of the diagnostic information remaining after the adjustment process for each disorder in the carrier sub-sample (Remainder 
Proportion After adjustment process) Column 01 Row 17 the proportion of the diagnostic remaining after the adjustment for the whole carrier sub-sample. 
Column 02 displays diagnostic information remaining after the adjustment process for the non-carrier sub-sample. Column 03 displays the results of the two 
sample test for proportions between the carrier and non-carrier sub-samples.
 
 
CHAPTER 06: FIGURES 
Figure C6F01A. Example of Comorbidity Count on Individuals with Two Diagnoses
Condition A Condition B
Total Number of Comorbidity Dyads or Pairs per Subject= 2
Total Number of Comorbidity Dyads or Pairs per Condition = 1
 
 
Figure C6F01B Example of Comorbidity Count on Individuals with Three Diagnoses.
Condition A Condition B
Condition C
Total Number of Comorbidity Dyads or Pairs per Subject = 6 
Total Number of Comorbidity Dyads or Pairs per Condition = 2
 
 
Figure C6F01C. Example of Comorbidity Count on Individuals with Four Diagnoses. 
Condition A Condition B
Condition C Condition D
Total Number of Comorbidity Dyads or Pairs per Subject = 12   
Total Number of Comorbidity Dyads or Pairs per Condition = 3 
 
 
Figure C6F02 Number of Diagnoses, Comorbidities and Individuals in Whole Sample by Diagnostic Group or Strata
Figure C6F02 Shows the Distribution of the Number of Diagnoses (in blue), the number of comorbidities (in orange), and the number of Individuals (in grey) in 
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Figure C6F03 Displays the Relationship between the number of diagnoses and the number of comorbidities by Diagnostic Group or Stata
An  Individual in the DG3 will have the following characteristics
# Diagnoses= Modal Number of Diagnoses in the Diagnostic Group  (MDDG ) = 3
#  Comorbidities = (MDDG ) (MDDG-1) =3 x 2 = 6
An individual in the DG5 will have the following characteristics
# Diagnoses = Modal Number of Diagnoses in the Diagnostic Group  (MDDG ) = 5









Figure C4AF01: Flow Diagram Study Participants Selection Process displays the three phase subject selection process. 
In 1981, a probabilistic sample of N=3481 Easter Baltimore residents was done for the original Epidemiologic 
Catchment Area (ECA). In 1993-4, a sample of N=1920 of the ECA participants was selected for ECA Baltimore Follow-
up (EFU). In 1999, a sample of N=847 subjects of the original ECA and EFU was obtained for our study. These 


























































































































































07 Body Mass Index (kg/m2) Mean (SE) 30.04 (0.43)
08 Body Mass Index 
09 Normal: 18.5 - 24.9 kg/m2 0.2
10 Overweight: 25 - 29.9 kg/m2 0.3
11 Obese: >= 30 kg/m2 0.4




AP3T02. Laboratory Values Sample (N= 224) 
Col
SERUM CHOLESTEROL AND LIPOPROTEINS
01 Total Cholesterol mg/dl 178.48 (2.5)
02 > 240 mg/dl 8.79%
03 LDL Cholesterol mg/dl 102.59 (2.14)
04 Less than 100 mg/dl 76.62%
05 Above Optimal 100-129 mg/dl 16.88%
06 Borderline High 130-159 mf/dl 4.55%
07 Very High: >190 mg/dl 1.95%
08 HDL Cholesterol mg/dl 44.7 (0.98)
09 < 40 mg/dl Males/ < 50 mg/dl Females 48.15%
10 SERUM GLUCOSE AND HGBA1C
11 Fasting Plasma Glucose mg/dl 100.25(2.16)
12 Fasting Plasma Glucose > 100 mg/dl 29.36%
13 Fasting Plasma Glucose > 126 mg/dl 11.01%
14 Fasting Plasma Glucose > 200 mg/dl 4.46%
15 Hemoglobin A1C % 5.66 (0.06)
16 Hemoglobin A1C <= 5.7 77.32%
17 Hemoglobin A1C 5.7-6.4%  15.46%
18 Hemoglobin A1C >=6.5% 7.22%
19 LIVER FUNCTION TESTS
20 ALT- Alanine Aminotransferase U/L 24.98 (1.41)
21 ALT > 29 U/L 24.77%
22 AST- Aspartate Aminotransferase U/L 22.69 (1.22)




AP3T03. Prevalence of Different Psychiatric Disorders (N= 224)





01 Schizophrenia and Other Psychotic Disorders 162 0.72 0.03
02 Bipolar Disorders 22 0.10 0.02
03 Depressive Disorders 25 0.11 0.02
04 Anxiety and Somatoform Disorders 7 0.03 0.01
05 Substance Abuse Disorders 100 0.45 0.03
06 Personality Disorders 28 0.13 0.02
07 Dementia and Organic Mental DOs 20 0.09 0.02
08 Total # Diagnosed/ Total # Diagnoses 3.64 X X
09 Burden Psychiatric Disorders in Sample X 1.63 X
Row 1 2 3
 
 
AP3T04. Comorbidities Schizophrenia (N=162)
Col Schizophrenia and Depression 
1 Schizophrenia w/o Depression 93.83 %
2 Schizophrenia w/ Depression 6.17%
3
4 Schizophrenia and Substance Abuse
5 Schizophrenia w/o Substance Abuse  56.79%








































































01 Schizophrenia and Other Psychotic Disorders N/A 0 10 3 70 11 10 104
02 Bipolar Disorders 0 N/A 0 1 15 6 3 25
03 Depressive Disorders 10 0 N/A 1 10 5 3 29
04 Anxiety and Somatoform DO 3 1 1 N/A 3 2 0 10
05 Substance Abuse Disorders 70 15 10 3 N/A 12 5 115
06 Personality Disorders 11 6 5 2 12 N/A 1 37
07 Dementia and Org Mental DO 10 3 3 0 5 1 N/A 22
08 Total #  Comorbidities 104 25 29 10 115 37 22 342
09 Total # Diagnoses 162 22 25 7 100 28 20 364
10 Comorbidity/ Diagnosis Inflation Ratio (CDIR) 0.64 1.14 1.16 1.43 1.15 1.32 1.10 0.94
11 Standardized CDIR 0.68 1.21 1.23 1.52 1.22 1.41 1.17 1.00
Column 01 02 03 04 05 06 07 08
 
 



















01 Schizophrenia and Other Psychotic Dos 0 69 82 11 0 162
02 Bipolar Disorders 0 3 14 4 1 22
03 Depressive Disorders 0 5 11 9 0 25
04 Anxiety Disorders 0 1 3 2 1 7
05 Substance Abuse Disorders 0 5 76 18 1 100
06 Personality Disorders 0 3 14 10 1 28
07 Dementia and Other Organic Dos 0 4 10 6 0 20
08 # Diagnoses in Each Diagnostic Group 0 90 210 60 4 364
09 # Individuals in Each Diagnostic Group 0 90 105 20 1 216
10 # Individuals  in Each DG 8 90 105 20 1 224
Columns 01 02 03 04 05 06
 
 



















01 Schizophrenia and Other Psychotic Dos 0.000 0.426 0.506 0.068 0.000 1.000
02 Bipolar Disorders 0.000 0.136 0.636 0.182 0.045 1.000
03 Depressive Disorders 0.000 0.200 0.440 0.360 0.000 1.000
04 Anxiety Disorders 0.000 0.143 0.429 0.286 0.143 1.000
05 Substance Abuse Disorders 0.000 0.050 0.760 0.180 0.010 1.000
06 Personality Disorders 0.000 0.107 0.500 0.357 0.036 1.000
07 Dementia and Other Organic Dos 0.000 0.200 0.500 0.300 0.000 1.000
08 # Diagnoses in Each Diagnostic Group 0.000 0.247 0.577 0.165 0.011 1.000
09 # Individuals Diagnosed in Each DG 0.000 0.417 0.486 0.093 0.005 1.000
10 # Individuals in Each Diagnostic Group 0.036 0.402 0.469 0.089 0.004 1.000
Columns 01 02 03 04 05 06
 
 



















































01 Psychotic Disorders 162 113.67 0.70 1.43 0.85 266 2.34 0.72
02 Bipolar Disorders 22 11.58 0.53 1.90 1.13 47 4.06 1.24
03 Depressive Disorders 25 13.50 0.54 1.85 1.10 54 4.00 1.22
04 Anxiety Disorders 7 3.42 0.49 2.05 1.22 17 4.98 1.52
05 Substance Abuse Disorders 100 49.25 0.49 2.03 1.20 215 4.37 1.34
06 Personality Disorders 28 13.58 0.49 2.06 1.22 65 4.79 1.46
07 Dementia and Other Organic DO 20 11.00 0.55 1.82 1.08 42 3.82 1.17


























Columns 01 02 03 04 05 06 07 08
 
 






01 Schizophrenia and Other Psychotic Dos 0.000* 0.000*
02 Bipolar Disorders 0.373 0.271
03 Depressive Disorders 0.099 0.129
04 Anxiety Disorders 0.018* 0.088
05 Substance Abuse Disorders 0.000* 0.000*
06 Personality Disorders 0.029* 0.023*















1 Amitriptyline 1 50 50 N/A.
2 Bupropion 12 300 281.25 34.15
3 Citalopram 18 25 36.94 11.3
4 Clomipramine N/A N/A N/A N/A
5 Doxepin 1 50 50 N/A
6 Duloxetine 3 90 80 26.46
7 Fluoxetine 15 20 26.67 2.87
8 Fluvoxamine 2 100 100 N/A 
9 Mirtazapine 16 22.5 27.19 3.68
10 Paroxetine 4 20 20 N/A 
11 Sertraline 15 150 135 14.39
12 Trazodone 45 100 168.33 38.44
13 Venlafaxine 13 225 195.19 13.17
Row 01 02 03 05
 
 











1 Carbamazapine 4 700 675 110.87
2 Gabapentin 15 1200 1366.67 196.56
3 Lamotrigine 13 200 238.46 51.08
4 Lithium 23 900 963.04 90.14
5 Oxcarbazepine 6 1050 1083.33 235.82
6 Topiramate 14 175 162.5 17.53
7 Valproate 49 1250 1351.02 96.39
8 Zonisamide 2 200 200 100
Row 01 02 03 04
 
 











1 Aripiprazole 17 10 13.77 2.19
2 Chlorpromazine 8 175 193.75 31.96
3 Clozapine 37 350 313.18 26.00
4 Fluphenazine 11 15 23.18 4.59
5 Haloperidol 35 12 15.57 2.83
6 Haloperidol Decanoate 17 150 145.7 15.34
7 Loxapine 4 50.5 81.75 53.15
8 Lusaridone 1 80 80 .
9 Olanzapine 52 20 19.57 1.46
10 Perphenazine 5 28 27.6 9.30
11 Quetiapine 41 400 418.90 37.83
12 Risperidone 47 4 4.88 0.40
13 Risperidone Depot 6 100 95.83 4.17
14 Risperidone 47 4 4.88 0.40
15 Thiothixene 2 20 20 10
16 Ziprasodone 1 160 160 .
Row 01 02 03 05
Note: Haloperidol Used by 47 patients / Risperidone Used by 50 patients 
 
 
























































































01 Aripiprazole N/A 0 1 0 1 0 0 2 0 0 2 1 0 0 7
02 Chlorpromazine 0 N/A 1 2 1 0 1 2 0 0 1 1 0 0 9
03 Clozapine 1 1 N/A 2 6 0 0 3 0 0 5 2 0 0 20
04 Fluphenazine 0 2 2 N/A 0 0 0 2 0 0 3 2 0 0 11
05 Haloperidol 1 1 6 0 N/A 1 0 10 0 0 6 6 1 0 32
06 Loxapine 0 0 0 0 1 N/A 0 2 0 1 0 1 0 0 5
07 Lusaridone 0 1 0 0 0 0 N/A 0 0 0 0 0 0 0 1
08 Olanzapine 2 2 3 2 10 2 0 N/A 0 1 7 8 1 0 38
09 Paliperidone 0 0 0 0 0 0 0 0 N/A 0 0 0 0 0 0
10 Perphenazine 0 0 0 0 0 1 0 1 0 N/A 0 0 0 0 2
11 Quetiapine 2 1 5 3 6 0 0 7 0 0 N/A 7 0 0 31
12 Risperidone 1 1 2 2 6 1 0 8 0 0 7 N/A 0 0 28
13 Thiothixene 0 0 0 0 1 0 0 1 0 0 0 0 N/A 0 2
14 Ziprasodone 0 0 0 0 0 0 0 0 0 0 0 0 0 N/A 0
15 # Total Concomitant Rx 7 9 20 11 32 5 1 38 0 2 31 28 2 0 186
16 # Primary Rx 17 8 37 11 47 4 1 52 0 5 41 50 2 1 276
17 Conc/ Primary Rx Ratio 0.41 1.13 0.54 1.00 0.68 1.25 1.00 0.73 0 0.40 0.76 0.56 1.00 0.00 0.67
18 Standardized CPR 0.61 1.67 0.80 1.48 1.01 1.85 1.48 1.08 0 0.59 1.12 0.83 1.48 0.00 1.00
Column 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15
 
 
AP3T13. Indicators of Antipsychotic Use (N= 224)
Ro
w Use Indicator # Pts Prop
Pts
1 Total # of Antipsychotics Orders 276 N/A
2 Total # Typical Antipsychotic Orders 77 N/A
3 Total # Atypical Antipsychotic Orders 199 N/A
4 Total # Depot Antipsychotic Orders 23 N/A 
5 Patients Prescribed at Least One AP 194 0.87
6 Patients Prescribed at Least Two AP 72 0.32
7 Patients Prescribed Atypical AP 164 0.73




AP3T14. Indicators of Mood Stabilizer and Antidepressant Use (N= 224) 
Ro
w
Use Indicator # Pts Prop
Pts
1 Total # of Mood Stabilizer Orders 126 N/A 
2 Patients Prescribed Mood Stabilizers 106 0.47
3 Total # of Antidepressant Orders 100 N/A 




AP3T15. Indicators of Medication Combinations Use (N= 224)
Ro
w Use Indicator # Pts Prop
Pts
1 Antipsychotic Agent + Mood Stabilizer 82 0.36




AP3T16. Indicators of Metabolic Syndrome and Prediabetes in the Sample 
Plasma Triglyceride Level  >150 mg/dl
Plasma High Density lipoprotein (HDL) Level: <40 mg/dl in Males              
                                                                       <50 mg/dl in Females
Fasting Serum Glucose Level >100 mg/dl
Body Mass Index (BMI) >30 kg/m2
Hemoglobin A1C > 5.7%
 
 
AP3T17. Number of Prescriptions Stratified by Prescription Group and Totals (N=224)
Ro
w
Medication PG0 PG1 PG2 PG3 PG4 Totals
01 Aripiprazole 0 12 4 0 1 17
02 Chlorpromazine 0 2 3 3 0 8
03 Clozapine 0 17 20 0 0 37
04 Fluphenazine 0 2 7 2 0 11
05 Haloperidol 0 20 22 5 0 47
06 Loxapine 0 1 1 2 0 4
07 Lusaridone 0 0 1 0 0 1
08 Olanzapine 0 22 23 6 1 52
09 Paliperidone 0 0 0 0 0 0
10 Perphenazine 0 4 0 1 0 5
11 Quetiapine 0 16 20 4 1 41
12 Risperidone 0 25 23 1 1 50
13 Thiothixene 0 0 2 0 0 2
14 Ziprasodone 0 1 0 0 0 1
15 Total # Prescriptions 0 122 126 24 4 276
16 Total # Individuals Prescribed 0 122 63 8 1 194
17 Total #  Individuals 30 122 63 8 1 224
Column 01 02 03 04 05 06
 
 
AP3T18. Prescriptions Stratified by Prescription Group by Row Percentage (N=224)
Ro
w
Medication PG0 PG1 PG2 PG3 PG4 Totals
01 Aripiprazole 0.00 70.59 23.53 0.00 5.88 100.00
02 Chlorpromazine 0.00 25.00 37.50 37.50 0.00 100.00
03 Clozapine 0.00 45.95 54.05 0.00 0.00 100.00
04 Fluphenazine 0.00 18.18 63.64 18.18 0.00 100.00
05 Haloperidol 0.00 42.55 46.81 10.64 0.00 100.00
06 Loxapine 0.00 25.00 25.00 50.00 0.00 100.00
07 Lusaridone 0.00 0.00 100.00 0.00 0.00 100.00
08 Olanzapine 0.00 42.31 44.23 11.54 1.92 100.00
09 Paliperidone N/A N/A N/A N/A N/A N/A
10 Perphenazine 0.00 80.00 0.00 20.00 0.00 100.00
11 Quetiapine 0.00 39.02 48.78 9.76 2.44 100.00
12 Risperidone 0.00 50.00 46.00 2.00 2.00 100.00
13 Thiothixene 0.00 0.00 100.00 0.00 0.00 100.00
14 Ziprasodone 0.00 100.00 0.00 0.00 0.00 100.00
15 Total # Prescriptions 0.00 44.20 45.65 8.70 1.45 100.00
16 Total # Individuals Prescribed 0.00 62.89 32.47 4.12 0.52 100.00
17 Total #  Individuals 13.39 54.46 28.13 3.57 0.45 100.00
Column 01 02 03 04 05 06
 
 














01 Aripiprazole 17.00 14.25 0.84 1.19 0.84
02 Chlorpromazine 8.00 4.50 0.56 1.78 1.25
03 Clozapine 37.00 27.00 0.73 1.37 0.96
04 Fluphenazine 11.00 6.17 0.56 1.78 1.25
05 Haloperidol 47.00 32.67 0.70 1.44 1.01
06 Loxapine 4.00 2.17 0.54 1.85 1.30
07 Lusaridone 1.00 0.50 0.50 2.00 1.41
08 Olanzapine 52.00 35.75 0.69 1.45 1.02
09 Paliperidone N/A N/A N/A N/A N/A
10 Perphenazine 5.00 4.33 0.87 1.15 0.81
11 Quetiapine 41.00 27.58 0.67 1.49 1.04
12 Risperidone 50.00 37.08 0.74 1.35 0.95
13 Thiothixene 2.00 1.00 0.50 2.00 1.41
14 Ziprasodone 1.00 1.00 1.00 1.00 0.70













Column 01 02 03 04 05
 
 







with Sub  Abuse
(N =70) (%)
P-Value 
01 Triglyceride Level  >150 mg/dl 59.78 44.29 0.058
02 High Density lipoprotein (HDL) Level: M <40 mg/dl/ F:  <50 mg/dl 45.98 56.72 0.186
03 Fasting Serum Glucose Level >100 mg/dl 28.41 32.35 0.594
04 Body Mass Index (BMI) >30 kg/m2 43.48 44.29 0.918
05 Hemoglobin A1C > 5.7% 34.15 20.00 0.064
06 Metabolic Score (Mean (SE)) 2.30(0.15) 1.93(0.17) 0.119
07 Metabolic Score Higher than Median 48.91 55.71 0.391
Column 01 02 03
 
 




< 1 AP Agent
(N =152) (%)
Pts Receiving
> 2 AP Agents
(N=72) (%)
P-Value 
01 Triglyceride Level  >150 mg/dl 46.71 51.39 0.513
02 High Density lipoprotein (HDL) Level: M <40 mg/dl/ F:  <50 mg/dl 49.32 45.59 0.610
03 Fasting Serum Glucose Level >100 mg/dl 32.21 23.19 0.173
04 Body Mass Index (BMI) >30 kg/m2 51.39) 44.64 0.162
05 Hemoglobin A1C > 5.7% 28.68 16.92 0.073
06 Metabolic Score (Mean (SE)) 2.12 (0.12) 1.88 (0.16) 0.244
07 Metabolic Score Higher than Median 48.68 62.50 0.053
Column 01 02 03
 
 







with Sub  Abuse
(N =70) (%)
P-Value 
01 Receiving One or More AP Agent 90.22 100.00 0.007*
02 Receiving Two or More AP Agents 33.70 42.86 0.233
03 Use of Atypical AP Agents 76.09 80.00 0.553
04 Receiving Only Typical AP Agents 14.13 20.00 0.321
05 Receiving Long Term IM AP Agents 10.87 14.29 0.513
06 Receiving Antidepressant Agents 34.78 24.29 0.150
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